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Abstract 
 
Fibroblast Growth Factors (FGFs) play critical roles during development, 
tissue homeostasis and repair and in controlling cell proliferation, survival, 
migration and differentiation. Of the 22 mammalian FGFs, FGF22, a member of 
the FGF7/10/22 subfamily, is relatively understudied.  
 
I have investigated the in vivo functions of FGF22 in mice engineered to 
lack Fgf22. Fgf22 null animals were viable, fertile and did not display any obvious 
abnormalities. No differences in skin histology and pelage hair were observed, 
demonstrating that FGF22 is dispensable during embryogenesis and in 
unchallenged adult skin. Mice lacking FGF22 were able to heal acute wounds just 
as efficiently as wild type mice. However, classical two-step skin carcinogenesis 
challenge revealed that Fgf22 null mice developed considerably less papillomas 
than wild type mice.  
 
Interestingly, Fgf22 knockout mice displayed a significant reduction in body 
weight and I identified several novel sites of Fgf22 expression in the 
gastrointestinal tract. However, the morphology and function of various tested 
tissues of the digestive system were not affected by Fgf22 deletion and the 
mechanism underlying metabolic differences between Fgf22 wild type and 
knockout mice remains unknown.  
 
FGF22 signals through FGFR2b, a receptor tyrosine kinase that we 
recently have shown plays a tumour-suppressive role in the mouse skin. Another 
aspect of my project was to verify whether FGFR2 plays a similar role in human 
skin, by investigating squamous cell carcinoma (SCC) sections and cell lines 
isolated from patient SCCs. I observed differences in the pattern of anti-FGFR2 
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immunostaining of normal skin and tumours. Also, since it is well documented that 
mutations in FGFR2 arise in patients with different types of cancer, I screened 
DNA isolated from the cell lines and identified eleven different mutations in 
FGFR2. 
 
This study contributes towards a better understanding of the wide 
spectrum of FGF/FGFR activities and distinct regulatory functions in the biology of 
physiological and pathological processes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
All truths are easy to understand 
once they are discovered; 
the point is to discover them. 
 
Galileo Galilei 
 
 
Science never solves a problem 
without creating ten more. 
 
George Bernard Shaw 
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CHAPTER 1: Introduction 
 
1.1.1 The fibroblast growth factor family  
 
Fibroblast growth factors (FGFs) comprise a large family of widely 
expressed intercellular signalling molecules (Fig 1.1). The name ‘fibroblast growth 
factors’, nonetheless, is a limiting description for this group of cytokines, as FGF 
functions are not restricted to cell growth. FGFs are responsible for regulating a 
range of processes, including cell proliferation, survival, migration, differentiation 
and response to injury (Ornitz and Itoh, 2001). Many are essential for patterning 
during embryogenesis, controlling complex processes of organ formation and limb 
development, maintenance of tissue homeostasis in adulthood (Coumoul and 
Deng, 2003) and management of metabolism (Berndt et al., 2007). The first FGF - 
FGF1 or acidic FGF - was discovered in 1974 by Gospodarowicz, in cow pituitary 
gland and brain extract, as a growth factor for fibroblasts (Gospodarowicz, 1974). 
The FGF family has been growing ever since (the mammalian FGF family now 
numbers 22 members) just as the range of processes in which they have been 
described to be engaged has grown. For instance, FGFs play a major role during 
wound healing stimulating proliferation of endothelial cells, fibroblasts and 
keratinocytes (with particular focus on FGF1, FGF2 and FGF7 signalling) (Ornitz 
and Itoh, 2001). FGFs are important for the adult vasculature, as they can promote 
angiogenesis (FGF1 and FGF2), but their inappropriate signalling may play a role 
in tumour formation (Grose and Dickson, 2005). They are responsible for 
formation of the central nervous system and emerging evidence links the FGFs to 
psychiatric disorders (Riva and Molteni 2005).  
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FGFs can be grouped into seven subfamilies (Fig 1.1), each containing two 
to four members, based on their sequence similarities, functional properties and 
evolutionary relatedness. Members of each subfamily share increased similarities 
in sequence, as well as in biochemical and developmental properties (Ornitz and 
Itoh, 2001). There is a certain inconsistency concerning one of the subfamilies – 
the FGF11 subfamily, members of which are FGF11-FGF14 (Fig 1.1). Called 
fibroblast homologous factors, they have high sequence and structural homology 
with FGFs, they bind heparin with high affinity, but lack signal peptides, remain 
intracellular and function within cells in a receptor-independent manner (Itoh and 
Ornitz, 2004). Therefore there is some hesitation whether they should be included 
into the FGF family structure. 
 
 
 
 
 
Figure 1.1 Fibroblast growth factor family. Highlighted in blue are FGF homologous 
factors, which have high sequence identity with the FGF family but do not activate its 
receptors. Highlighted in purple is the FGF7 subfamily of particular interest to my studies 
(adapted from Ornitz and Itoh, 2004). 
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Most human FGF genes are scattered throughout the genome, indicating 
that they were generated by gene duplications and translocations during evolution 
(Itoh and Ornitz, 2004). They encode a family of proteins ranging in molecular 
weight from 17 to 34 kDa and sharing a 13 – 71% amino acid homology. 
 
1.1.2 FGF7 subfamily 
 
The main research interests of our lab lie in members of the FGF7 
subfamily, consisting of four members: FGF3, FGF7, FGF10 and FGF22, and their 
cognate receptors. Phylogenetic analyses of the gene loci of the FGF7 subfamily 
members in the human genome show that FGFs 7, 10 and 22, but not FGF3, are 
closely linked to the hyperpolarisation-activated, cyclic nucleotide-gated potassium 
channel genes (HCNs4, 1 and 2), indicating that those three FGFs might have 
arisen from a common ancestral gene by two successive genome duplications. 
The FGF3 genomic locus indicates that it might have arisen from FGF4 by local 
gene duplication followed by divergent evolution or, alternatively, it could have 
derived from an ancestor of the FGF7 subfamily by gene duplication and chance 
insertion near FGF4 (Itoh and Ornitz, 2004).  
 
When comparing sequence similarities, FGFs 7, 10 and 22 are more 
closely related to each other by sequence than to any other FGFs, with FGF22 
sharing ~46% amino acid similarity with FGF10 and ~40% with FGF7 (Nakatake et 
al., 2001). FGF7 was discovered as a lung fibroblast derived mitogen for murine 
keratinocytes (Rubin et al., 1989). Unlike other FGFs that act on a wide spectrum 
of cell types, FGF7 is a secreted glycoprotein acting as a specific mitogen for 
epithelial cells. It is produced by various types of mesenchymal cells in vitro and in 
vivo as well as by ??T cells in inflamed tissues (Werner, 1998) and it serves as a 
paracrine mediator of mesenchymal-epithelial cross-talk. A very similar expression 
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pattern of FGF7 and FGF10 was observed in adult mouse tissues, with both 
growth factors expressed at particularly high levels in mesenchymal cells of the 
lung and the skin. FGF7, FGF10 and FGF22 act predominately on cells of 
epithelial origin but, notably, FGF22 is expressed by epithelial cells themselves 
(Beyer et al., 2003). The biological activities of FGFs are mediated by cell-surface 
high affinity receptors that belong to the receptor tyrosine kinase family. FGF7 
subfamily members activate two receptors: FGFR2b and FGFR1b, although they 
signal preferentially via FGFR2b (Ornitz et al., 1996, Zhang et al., 2006). FGF7 
and FGF10 bind FGFR2b with similar high affinity and compete with each other for 
this binding (Igarashi and Finch 1998; Lu and Luo 1999). However, striking 
phenotypic similarities between Fgf10 and Fgfr2b knockout mice have established 
FGF10 as the predominant ligand for this receptor in development and 
organogenesis (described in more detail later) (Min et al., 1998). Although 
FGFR2b remains the only receptor for FGF7, FGF10 and FGF22 can signal 
through both FGFR2b and FGFR1b (Zhang et al., 2006). 
 
1.2 Fibroblast growth factor receptors – structure and specificity 
 
The FGFs mediate their cellular responses by binding to and activating 
fibroblast growth factor receptors (FGFRs). The FGFRs share a number of 
common structural features. They all have an extracellular region composed of 
three immunoglobulin (Ig)-like domains (D1-D3), a transmembrane sequence, a 
juxtamembrane domain containing an FRS2 docking site and an intracellular split 
tyrosine kinase domain (Fig 1.3) (Schlessinger, 2000). The D1 and the linker 
region between the D1 and D2 sections have much sequence variability, and 
multiple splice variants, but are considered not necessary for ligand binding – FGF 
can bind to its receptor even in the absence of domain D1. A hallmark of FGFRs is 
the presence of an acidic, serine-rich sequence in the D1-D2 linker region, termed 
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the acid box (Fig 1.3). This region of the protein is thought to have a role in 
receptor autoinhibition (Olsen et al., 2004), as it can mimic the negative surface 
potential of acidic glycosaminoglycans and heparan sulphate proteoglycan 
(HSPG) and thus, bind at the heparin-binding sites located on the surface of the 
D2 region of the FGFR without initiating a biological response. The D2–D3 
fragment of the FGFR ectodomain is necessary and sufficient for ligand binding 
and specificity.  
 
There are four major tyrosine kinase FGFRs designated as FGFR1, 
FGFR2, FGFR3 and FGFR4, but a range of splice variants adds to the complexity 
of the ligand-receptor binding repertoire. Multiple FGFR isoforms are generated by 
alternative mRNA splicing, so that seven signalling FGFR proteins (FGFRs 1b, 1c, 
2b, 2c, 3b, 3c, and 4) with different ligand-binding specificities are created from 
four FGFR genes (Ornitz et al., 1996). Alternative splicing is especially frequent in 
the D3 domain of the receptors or Ig-loop III. Ig-loop III is encoded by three 
potential exons: IIIa, IIIb, and IIIc, and gene splicing events lead to the mature 
mRNA sequence encoding the D3 domain being formed from the invariant IIIa 
exon followed by either IIIb or IIIc (Fig 1.2). Alternative splicing events are 
regulated in a tissue-specific manner, in general with exon IIIb expressed in 
epithelial lineages and exon IIIc in mesenchymal lineages (De Moerlooze et al., 
2000). The IIIa splice isoform encodes a secreted extracellular FGF-binding 
protein with no known signalling capability (Duan et al., 1992). 
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Figure 1.2 Schematic structure of FGFR2IIIb and FGFR2IIIc. The third Ig like loop is 
involved in alternative FGFR2IIIb or FGFR2IIIc splicing incorporating, exon 8 or exon 9, 
respectively, in the mature receptor mRNA. 
 
A split intracellular domain containing tyrosine kinase activity is typical of 
FGF receptors. This kinase region is split in two by a short non-catalytic insert of 
approximately 15 amino acids (Feng et al., 1997) and contains two 
phosphorylatable tyrosine residues in FGFR1 and R2, one in FGFR3, and none in 
FGFR4 (Szebenyi and Fallon, 1999) . 
 
For the most part, there is no one-to-one correspondence between FGF 
ligands and receptors - for example FGF1 (acidic FGF) is a universal ligand, 
recognised by all FGF receptors (Ornitz et al., 1996) and FGF5 signals through 
FGFR1c, FGFR2c, FGFR3c and FGFR4.  
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Figure 1.3 Schematic structure of the FGF – FGFR complex, comprising two receptor 
molecules, two FGFs and two heparan sulphate proteoglycan (HSPG). FGFs (purple) bind 
with low affinity to cell surface heparan sulphate proteoglycans (HSPG; blue) and, with 
high affinity, to specific FGFRs. The FGF receptors consist of three extracellular 
immunoglobulin-like domains (D1-D3), a single transmembrane helix, and an intracellular 
split tyrosine kinase domain (navy blue).  
 
1.3 FGF signalling 
 
In the presence of heparan sulphate proteoglycans (HSPGs), upon ligand 
binding, FGF receptor dimers are formed leading to the arrangement of 2:2:2 
FGF-FGFR-HSPG complex (Fig 1.3) (Mohammadi et al., 2005), or possibly 2:2:1 
complex (Pellegrini et al., 2000). FGF-HSPG interactions stabilise FGFs against 
thermal denaturation and proteolysis (Gospodarowicz and Cheng, 1986), limit the 
diffusion and release of FGFs into interstitial spaces and increase the affinity and 
half-life of the FGF-FGFR dimer (Saksela and Rifkin, 1990). Receptor dimerisation 
enables the cytoplasmic kinase domains to transphosphorylate on A loop 
tyrosines and become activated. A loop phosphorylation is followed by 
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phosphorylation of tyrosines in the C terminal tail, kinase insert and 
juxtamembrane regions (Mohammadi et al., 1996). Activated multiple tyrosine 
residues then serve as docking sites for the recruitment of adaptors, docking 
proteins or signalling enzymes. FGF binding to the FGFRs activates multiple 
signal transduction pathways that are often inter-dependent (Fig 1.4). When 
signalling complexes are assembled and recruited to the active receptors, a 
cascade of phosphorylation events commences. The two main intracellular 
substrates of FGFR are phospholipase C (PLC)gamma1 (also known as FRS1) 
and FGFR substrate 2 (FRS2). Phosphorylation of FRS2 is essential for activation 
of the Ras-mitogen-activated protein kinase (MAPK) and phosphoinositide 3-
kinase-Akt signalling pathways (PI3K). The third signalling pathway activated by 
FGF - PLC? pathway, is FRS2 independent (Fig 1.4). FGFs are also known to 
function in the cytosol and nucleus of cells, both through endocytosis of activated 
FGF-FGFR complexes and through endogenous sources of ligand (Beenken and 
Mohammadi, 2009). 
 
 
 
 
Figure 1.4 Schematic representation of the three principal pathways of FGFR intracellular 
signalling. Upon FGF binding, activated MAP kinase, PI3 kinase and PLC? signalling 
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pathways cause changes in nuclear gene expression profile and/or rearrangement of cell 
cytoskeleton. 
 
The best understood FGF signalling pathway is the RAS-MAP kinase 
pathway. It includes ERK1/2, p38, and JNK kinases and activation of the first two, 
in response to FGF, has been seen in all cell types (Dailey et al., 2005). FRS2 is a 
very important element in transducing the signal downstream upon FGF activation. 
It acts as an essential core upon which a signalling complex, consisting of the 
tyrosine phosphatase Shp2, the adaptor Grb2, and the docking protein Gab1, is 
formed, leading to the activation of the RAS-MAP kinase and PI3 kinase pathways 
(Eswarakumar et al., 2005). The FRS2 signalling complex recruits the guanine 
nucleotide exchange factor Sos, via binding through Grb2, which activates Ras 
and the downstream effectors of MAP kinase (Fig 1.4). The MAP kinases are a 
family of proteins that regulate the activity of downstream kinases or transcription 
factors. FGF signals also activate phosphatidyl inositol hydrolysis, release of 
intracellular calcium and activation of PKC via recruitment of the SH2 domain of 
PLC? to the FGFR. Activated PLC? hydrolyses PIP2 to form diacylglygerol (Tekin 
et al., 2007) and IP3 which stimulates calcium release and activation of 
calcium/calmodulin dependent protein kinases (Dailey et al., 2005).  
 
 FGF signalling plays a major role during early vertebrate development. 
Induction and patterning of mesoderm is one of the earliest events during 
vertebrate body axis formation and FGF involvement is critical for regulation of 
target genes [e.g. brachyury (Smith et al., 1991)]. Moreover, control of 
morphogenetic movements (Nutt et al., 2001) and neural patterning (Holowacz 
and Sokol, 1999) are processes FGF dependent. The wide spectrum of FGF roles 
in developmental processes is well documented in model organisms, such as 
Drosophila melanogaster and Caenorhabditis elegans (described in more detail in 
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Chapter 5, p.222). FGF signalling regulates expression of target genes, such as 
Tbx2, Erm, Pea3, and Pax3 (Firnberg and Neubuser, 2002).  
 
 FGF signalling itself can be regulated at many levels in the extracellular 
space and within the cell. Regulation of the extracellular environment is modulated 
by the presence of HSPGs, as well as by Sef (a negative regulator so named due 
to Similar Expression Pattern to FGF) considered to regulate FGF signalling at the 
transmembrane region (Tsang et al., 2002) by either inhibiting FGFR or binding to 
activated forms of MEK and inhibiting the dissociation of the MEK-ERK 
complexes. By this means, nuclear translocation of ERK is blocked without 
inhibiting its activity in the cytoplasm (Torii et al., 2004). At the intracellular level 
FGF signalling is regulated by PTP MAPK phosphatase 3 (MKP3, also called 
Pyst1), which antagonises the MAPK pathway via ERK1/2 inactivation. Sprouty 
proteins (Spry1–4 in mammals) also interfere with FGF signalling through several 
mechanisms exhibiting different activities and having different interaction partners, 
including Grb2 and Raf1 (Bottcher and Niehrs, 2005). 
 
1.4 FGF mutations in human birth defects  
 
The fibroblast growth factor family constitutes one of the most critical 
groups of paracrine factors that act during development. The importance of the 
proper spatial and temporal regulation of FGF signals is evident from human and 
mouse genetic studies, which show that mutations leading to the deregulation of 
FGF signals cause a variety of developmental disorders, including dominant 
skeletal diseases and cancer (Table 1 and 2). Accurate FGF signalling is 
responsible for determining certain cells to become mesoderm, for the production 
of blood vessels, bronchial branching in lung development, limb outgrowth, neural 
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cell differentiation and survival, growth of metanephric mesenchymal cells in 
kidney organogenesis and much more (Langman, 2006). 
 
As mentioned above, imbalances in FGF levels and/or mutation of the 
genes encoding for FGFs or their receptors have been associated with numerous 
diseases, cancers and other pathological states: FGFs transform fibroblasts and 
are aberrantly expressed in human tumours, they prevent apoptosis and support 
tumour growth and angiogenesis (Moon, 2006). For example, homozygous 
deletions in FGF3 were identified to cause hereditary deafness, leading to total 
inner ear agenesis (Tekin et al., 2007). Loss-of-function mutations in FGF8 lead to 
Kallmann’s syndrome, a developmental disorder characterised by the failure of 
sexual maturation and infertility, hypogonadism and anosmia (Falardeau et al., 
2008). Likewise, loss-of-function mutations in FGF10 cause Lacrimo-auriculo-
dento-digital syndrome. LADD is an autosomal-dominant, multiple congenital 
anomaly disorder characterised by aplasia, atresia or hypoplasia of the lacrimal 
and salivary systems, cup-shaped ears, hearing loss, and dental and digital 
anomalies (Milunsky et al., 2006).  
 
It is clear that FGF receptors play very important roles in human limb and 
craniofacial development as it has been shown that missense mutations of 
FGFR1-3 in humans result in at least 14 congential bone diseases that are broadly 
classified into two groups: chondrodysplasia syndromes and craniosynostosis 
syndromes (Yin et al., 2008). Chondrodysplasia affects primarily the skeleton 
formed through endochondral ossification, resulting in short-limbed dwarfism, 
while craniosynostosis affects mainly bones formed through intramembraneous 
ossification, leading to premature fusion of the craniofacial sutures (Chen and 
Deng, 2005).  
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Mutations in FGFR1 can cause Pfeiffer syndrome, a malformation 
syndrome characterised by limb defects and by the premature fusion of the cranial 
sutures (craniosynostosis) that results in abnormal skull and facial shape (Muenke 
et al., 1994). 
 
Mutations in FGFR2 can give a variety of syndromes and give rise to 
several conditions like Pfeiffer syndrome, Crouzon syndrome (craniosynostosis, 
but normal limbs), Jackson-Weiss syndrome (craniofacial malformation and foot 
abnormalities) and Apert syndrome (craniosynostosis and severe fusion of digits). 
Mutations in FGFR2 are explained in more detail in Chapter 4.  
 
Mutations of FGFR3 cause achondroplasia. Roughly 95% of 
achondroplastic dwarfs have the same mutation of FGFR3, a base pair 
substitution in the exon encoding the transmembrane region of the protein. In 
addition, mutations in the extracellular part of the FGFR3 protein or in the tyrosine 
kinase domain result in thanatophoric dysplasia, a lethal form of dwarfism that 
resembles homozygous achondroplasia (Bellus et al., 1995). The mutations of 
fibroblast growth factor receptors that give rise to dwarfism and craniosynostoses 
are gain-of-function mutations that enable the FGF receptor to become active 
without binding its ligand.  
 
Interestingly, so far no germline mutations have been identified in FGFR4 
(Wilkie, 2005). 
 
As described above, germ-line alterations in FGFRs are associated with 
many congenital skeletal disorders. Interestingly identical mutations of somatic 
character are found in many types of cancers. Understanding the roles of FGFRs 
mutations in deregulation of signalling pathways may provide insights into the 
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mechanism of developmental pathologies and cancer progression.  
 
1.5 Fgf knockout mice phenotypes  
 
 Significant progress in understanding the mechanisms of normal and 
abnormal development has come through the joined forces of embryology and 
molecular biology. Thanks to advanced techniques in mouse genetics allowing 
generation of transgenic and gene knockout animals, the roles of various 
molecules whose disruption leads to serious developmental abnormalities and/or 
embryonic lethality have been elucidated. Phenotypes of Fgf knockout mice range 
from early embryonic lethality to subtle changes in adult physiology, to no 
identifiable phenotype (see table below).  
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Fgf 
 
Phenotype of knockout mouse Physiological role 
 
Fgf1  
 
Normal 
(Miller et al., 2000) 
Not established 
 
Fgf2  
 
Loss of vascular tone 
Slight loss of cortex neurons 
(Zhou et al., 1998) (Dono et al., 
1998) 
Not established 
 
Fgf3  
 
Inner ear agenesis 
(Tekin et al., 2007) 
Inner ear development 
(Tekin et al., 2007) 
Fgf4  Embryonic lethal 
(Feldman et al., 1995) 
Cardiac valve leaflet formation 
Limb development 
(Sugi et al., 2003) (Sun et al., 2002)  
(Feldman et al., 1995) 
Fgf5  
 
Abnormally long hair 
(Hebert et al., 1994) 
Hair growth cycle regulation 
(Hebert et al., 1994) (Drogemuller et al., 
2007) (Housley and Venta, 2006) 
Fgf6  
 
Defective muscle regeneration 
(Floss et al., 1997) 
Myogenesis 
(Armand et al., 2006) (Floss et al., 1997) 
Fgf7 
 
Matted hair 
Reduced nephron branching in 
kidney 
(Guo et al., 1996) (Qiao et al., 
1999) 
Branching morphogenesis 
(Qiao et al., 1999) 
Fgf8  
 
Embryonic lethal 
(Meyers et al., 1998) 
Brain, eye, ear and limb development  
(Liu and Joyner, 2001) (O'Leary et al., 
2007) 
Fgf9  Postnatal death 
Gender reversal 
Lung hypoplasia 
(Colvin et al., 2001a) 
Gonadal development 
Organogenesis 
(Colvin et al., 2001a) (Colvin et al., 2001b) 
Fgf10  
 
Failed limb and lung development 
(Kato and Sekine, 1999) 
Branching morphogenesis  
Multiple organogenesis defects 
(Kato and Sekine, 1999) 
Fgf16  
 
Embryonic lethal 
(Lu et al., 2008) 
Heart development 
(Lu et al., 2008) 
Fgf17  
 
Abnormal brain development 
(Xu et al., 2000) 
Cerebral and cerebellar development 
(Xu et al., 2000) 
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Fgf18  
 
Delayed long-bone ossification 
(Liu et al., 2002)  
(Ohbayashi et al., 2002) 
Bone development 
(Liu et al., 2002) 
(Ohbayashi et al., 2002) 
Fgf19  
 
Increased bile acid pool 
(Inagaki et al., 2005) 
Bile acid homeostasis 
Lipolysis 
Gall bladder filling 
(Fu et al., 2004) (Tomlinson et al., 2002) 
(Nishimura et al., 1999) 
Fgf20  
 
No knockout model Neurotrophic factor 
(Ohmachi et al., 2003) 
Fgf21  Late-onset adiposity 
(Badman et al., 2009) 
Fasting response 
Glucose homeostasis 
Lipolysis and lipogenesis 
(Kharitonenkov et al., 2005) 
(Nishimura et al., 2000) 
Fgf22  
 
No knockout model Presynaptic neural organiser 
(Umemori et al., 2004) 
Fgf23  Hyperphosphataemia 
Hypoglycaemia 
Immature sexual organs 
(Shimada et al., 2004) 
(Sitara et al., 2004) 
Phosphate homeostasis 
Vitamin D homeostasis 
(Yamashita et al., 2000) 
(Saito et al., 2003) 
 
 
Table 1 Phenotypes of Fgf knockout mice (Beenken and Mohammadi, 2009). 
 
 
Fgfr 
 
Phenotype of knockout mouse Physiological role 
 
Fgfr1 Embryonic lethal 
(Deng et al., 1994) 
Mesoderm formation 
Neural patterning 
 
Fgfr1b Normal 
(Partanen et al., 1996) 
Not established 
 
Fgfr1c 
 
Embryonic lethal 
(Partanen et al., 1996) 
Mesoderm formation 
Fgfr2 
 
Embryonic lethal 
(Xu et al., 1998) 
Impairment in placental development 
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Fgfr2b 
 
Failed limb and lung development 
(De Moerlooze et al., 2000) 
Branching morphogenesis 
Multiple organogenesis defects 
(De Moerlooze et al., 2000) 
(Revest et al., 2001) 
Fgfr2c 
 
Delayed long-bone ossification 
(Eswarakumar et al., 2002) 
Bone development 
Fgfr3 Bone overgrowth  
Deafness 
(Deng et al., 1996) 
(Colvin et al., 1996) 
Bone development 
Fgfr3b 
 
Normal 
(Eswarakumar and Schlessinger, 
2007) 
Not established 
Fgfr3c Overgrowth of endochondral bones 
(Eswarakumar and Schlessinger, 
2007) 
Bone development 
 
Fgfr4 
 
Normal 
(Yu et al., 2000) 
Liver function 
 
 
Table 2 Phenotypes of Fgfr knockout mice. 
 
 
Knockout studies have shown that Fgf10 null mice die shortly after birth, 
since this growth factor is critical for epithelial-mesenchymal interactions 
necessary for the development of epithelial components of multiple organs and 
tissues, including the limbs, lungs, and white adipose tissue (Sekine et al., 1999). 
Fgf7 knockout mice on the other hand, are viable with a subtle muscle 
regeneration phenotype and, surprisingly, no impairment in wound healing (Guo et 
al., 1996). Fgfr2b knockout mice die at birth from multiple developmental defects, 
phenocopying Fgf10 knockout mice (Min et al., 1998). Fgfr2b null mice fail to 
develop limbs or lungs due to loss of the progenitor cells by apoptosis, which 
suggests that FGFR2b is essential for organogenesis and that FGF10 is its key 
ligand (De Moerlooze et al., 2000). FGFR2b ligands are also essential for wound 
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healing in a variety of tissues including skin, intestine and liver (Chen et al., 2002) 
(explained in more detail in 1.6.2).  
 
1.6 FGFs in skin development and homeostasis 
 
1.6.1 Skin structure 
 
 
 
 
Figure 1.5 Transverse H&E stained section of mouse back skin; epidermis (EP), dermis 
(DE), hair follicle (HF), sebaceous gland (SG), adipose layer (AP), panniculus carnosus 
muscle (PCM). 
 
The skin is a dynamic, regenerating organ. In the human it comprises 
about 15% of the total body weight and forms the largest organ in the human 
body.  The skin represents the interface with the external world so it serves also 
as the body’s primary defence structure. Skin performs very specific functions, 
such as providing a permeability barrier, mechanical integrity, maintenance of 
body temperature, sensation, ultraviolet protection, recognition and defence 
against infections as well as wound repair and regeneration. In the anatomy of the 
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skin the epidermis, dermis, and the subcutaneous fat layer can readily be 
distinguished (Fig 1.5) (Freinkel, 2001). 
 
The epidermis is a multilayered, stratified, continually renewing epithelium 
that forms the barrier between the organism and its environment (Fig 1.6). In 
humans the epithelium thickness ranges from 0.4 to 1.5 mm while the full-
thickness skin is 1.5 to 4.0 mm. The primary cell in the epidermis is the 
keratinocyte, with its role being to provide the aforementioned barrier and to effect 
repair and regeneration of the tissue following injury. Additional cells include 
melanocytes (cells of neural crest origin that produce pigment to absorb ultraviolet 
light), Langerhans cells (mobile, dendritic antigen-presenting cells), and Merkel 
cells (cells with both neuroendocrine and epithelial features) that synapse with the 
dermal sensory axons and adjacent epithelial cells and are sensitive to 
mechanical stimuli (especially pressure). The non-keratinocyte population 
accounts for less than 20% of the epidermal cells in normal adult human skin. 
There are three epidermal appendages: the sweat glands, the pilosebaceous 
follicles that produce the hair and sebaceous excretions, and the nails that cover 
the distal phalanges. The normal turnover rate for the epidermis is about 28 days 
in a human (Fore, 2006). 
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Figure 1.6 Architecture of the epidermis. Epidermis is organized into layers of 
keratinocytes, which comprise the interfollicular epidermis, interspersed with hair follicles. 
Proliferating cells (pink) are confined to the basal layer whereas differentiated cells occupy 
the suprabasal layers (green). As cells differentiate, they leave the basal layer and migrate 
towards the epidermal surface, changing shape until they enter the outermost cell layer as 
flattened cornified cells. Finally, these cells are shed from the epidermal surface. In the 
mouse, the outermost cornified cell layers are arranged in stacks of large hexagonal cells, 
but in human epidermis the cornified layer is less clearly organized (Jones and Simons, 
2008). 
 
The epidermis is separated into layers anatomically as the skin develops 
and matures from the basal layer (stratum basale) adjoining the basement 
membrane to the outer layer, the stratum corneum (Fig 1.6). The epidermal 
regenerative layer contains the basal keratinocytes, which undergo mitosis. The 
developing keratinocytes mature and undergo terminal differentiation forming the 
spinous layer (stratum spinosum), the granular layer (stratum granulosum) and, 
finally, the stratum corneum. The stratum corneum is responsible for the skin 
barrier that protects the skin, preventing water loss, maintaining satisfactory 
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hydration of the skin, and preventing over-hydration in addition to many other 
protective functions (Fore, 2006). 
 
The dermis is located between the subcutaneous fat and dermal-epidermal 
junction. It is the connective tissue component of the skin and it provides its 
elasticity and tensile strength. The dermis also protects the body from mechanical 
injury, binds water and contains sensory stimuli receptors. Moreover the dermis 
and its blood supply are responsible for delivering nutrients and circulatory 
support, as the epidermis has no blood supply of its own. In human skin, two main 
regions of the dermis can be distinguished - the uppermost papillary dermis and 
the lower reticular dermis. The highest concentration of cells is found within the 
papillary dermis and around the blood vessels. The cellular components include 
the fibroblast, monocyte, histiocyte, Langerhans cells, lymphocytes, and 
eosinophils, along with the vascular- and lymphatic-associated cells. These 
comprise approximately 10% of the dermal content. The dermis is primarily a 
connective tissue matrix made up of approximately 90% collagen (mostly Type I) 
which provides both tensile strength and elasticity to the skin, along with elastin 
fibres, blood vessels, and lymph vessels, with some muscle fibres and 
pilosebaceous and sweat glands - structures that originate in the deep dermis and 
subcutaneous layer (Fore, 2006). 
 
It is important to recognise and bear in mind in biological research the 
significant differences between mouse and human skin. Aside from the obvious 
size difference between mice and humans, the epithelium in fur-covered mouse 
skin is composed of densely distributed hair follicles, whereas epithelium in human 
skin contains much fewer hair follicles. That is important as in human epidermis 
there are differences in protein expression in the outer root sheath of the follicles 
compared with the interfollicular areas (Schon et al., 1995). Mouse epidermis 
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generally comprises only 2–3 keratinocyte layers and is only one quarter the 
thickness of human epidermis (Fig 1.6) plus it has a faster epidermal turnover with 
terminal differentiation of keratinocytes taking only two weeks (Berking et al., 
2002). Moreover, mouse dermis is substantially thinner than human dermis and, 
interestingly, wounding is noticeably different as the major mechanism of wound 
closure in mouse skin is contraction, whereas in humans re-epithelialisation and 
granulation tissue formation are the major mechanisms involved (Galiano et al., 
2004). Finally, mice have an entire cutaneous muscle layer (panniculus carnosus) 
(Fig 1.5) that is only present in an undeveloped form in humans as the platysma 
and other small muscles of the face and neck. 
 
1.6.2 FGFs and wound healing 
 
Wound healing is a complex process that starts at the moment of injury 
and continues until well after the epidermis has healed over. Wound healing is 
complete when the strength and continuation of damaged tissues are regenerated, 
underpinned by the formation of new connective tissue and the re-growth of 
epithelium. The whole process involves proliferation of the epithelial cells, 
formation of granulation tissue, and recruitment of inflammatory cells (Schafer and 
Werner, 2007). A variety of different cell types are involved in this process, but I 
will focus on the important roles of fibroblasts, keratinocytes and dendritic 
epidermal T cells (DETCs or ??T cells) in wound repair. 
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Figure 1.7 A diagrammatical cross-section through wounded skin. Upon injury, dermal 
fibroblasts (blue) and ??T cells (red) secrete FGF7 and FGF10, and keratinocytes (green) 
express FGF22. FGFs activate FGFR1-3b expressing keratinocytes at the wound edge 
and stimulate re-epithelialisation by inducing proliferation, migration and differentiation 
(adapted from Braun et al. 2004). 
 
 In the wound healing process (Fig 1.7), a number of stages can be 
distinguished. First is the formation of a blood clot, which is vital for rapid 
termination of blood loss and maintenance of the skin’s protective function. This 
clot provides a scaffold for migrating keratinocytes and hence reconstitution of the 
epidermis. In parallel, the clot provides the primary scaffold for dermal 
reconstitution as it progresses through granulation tissue formation and final scar 
tissue maturation. Soon after blood clot formation the inflammatory phase 
commences, with activation of antibacterial protection pathways and recruitment of 
key cells into the wound site. Early on the scene are neutrophils, which release 
free radicals in an oxidative burst to kill bacteria. Soon after macrophages appear, 
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phagocytosing dead tissue and producing growth factors that stimulate new tissue 
formation and proliferation of fibroblasts (Schafer and Werner, 2007). The 
haemostatic clot is lysed by proteases derived from invading cells and replaced by 
early granulation tissue (days 4-6) composed primarily of hyaluronate but also of 
newly synthesised cell-derived fibronectin. In the proliferation phase that follows, 
cells proliferate at the wound site to make new tissue and capillaries (part of the 
granulation tissue). The keratinocytes of the epidermis migrate over the surface of 
this tissue to seal the wound, while fibroblasts migrate into the wound bed and 
differentiate into myofibroblasts, allowing them to drive connective tissue 
contraction. In the final stage of the process, that in humans can take up to two 
years, tissue maturation occurs, involving remodelling of the tissues, new collagen 
formation and scarring reduction. During that time most of the endothelial cells, 
macrophages and myofibroblasts undergo apoptosis or exit from the wound. A 
mature scar is never as strong as the original intact skin (Schafer and Werner, 
2007). 
 
 As mentioned above, major cell types, including keratinocytes, fibroblasts, 
dendritic epidermal T cells (DETCs or ??T cells) and macrophages, are essential 
for efficient wound healing (Fig 1.7). All of these cells have been identified as 
expressing a variety of FGFs and their receptors. In order to study the involvement 
of FGFs in wound repair, genetically engineered mouse models have been 
established. Since my primary interest is in the FGF7 subfamily of growth factors, I 
will focus on the role of FGF7, FGF10, FGF22 and their receptors in the wound 
healing process. It has been discovered that FGF7 and FGF10 predominantly 
were expressed by fibroblasts and ??T cells, but what exactly is their role during 
wound closure? In 1992, Werner et al. established that, in response to injury, 
within 24 h after wounding Fgf7 mRNA was up-regulated dramatically (more than 
100-fold). Fgf7 mRNA was detected in dermal fibroblasts adjacent to the wound 
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and in fibroblasts of the granulation tissue (Werner et al., 1992). In addition, ??T 
cells are a major source of FGF7 and FGF10 in skin wounds (Jameson et al., 
2002). 
 
Accessory to the ligands, all FGFR1-3 are expressed in normal and 
wounded mouse skin. FGFR2b is expressed in keratinocytes of the normal and 
wounded epidermis, as well as in hair follicles adjacent to wounds. FGFR1 was 
found in the regenerating epidermis as well as in wounded blood vessels. The 
strong upregulation of FGF7 in fibroblasts and ??T cells after skin injury, coupled 
with the expression of its receptor in keratinocytes, suggested that FGF7 might 
stimulate wound re-epithelialisation in a paracrine manner (Werner and Grose, 
2003).  
 
The first transgenic mice generated to investigate the role of FGFs in 
wound healing expressed a dominant-negative Fgfr2b mutant (lacking a tyrosine 
kinase domain) in the epidermis, under the control of a Keratin 14 promoter 
(Werner et al., 1994). The mutant receptor blocked the signal transduction 
normally downstream of stimulation with FGFs 1, 3, 7 and 10. The skin phenotype 
of the transgenic animals was characterised by epidermal atrophy, hair follicle 
abnormalities and dermal hyperthickening. However, perhaps the most interesting 
fact was that mice suffered a severe delay in wound re-epithelialisation after injury, 
when compared with wild-type littermates. At day 5 after injury, the number of 
proliferating keratinocytes in the hyperproliferative epithelium was 80–90% 
reduced compared with control mice (Werner et al., 1994). These results 
demonstrated an important role for FGF receptor signalling in wound repair, 
although the exact FGF responsible for this defect could not be defined by this 
study. 
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FGF7 seemed to be a strong candidate because of its up-regulation in 
response to injury. Surprisingly, Fgf7 knockout mice not only lacked any obvious 
phenotypic abnormalities (Table 1), but also the wound healing process in these 
mice appeared to be completely normal, suggesting that FGF7 is not required for 
wound healing (Guo et al., 1996). The most likely explanation for this is 
redundancy in ligand signalling. Although FGF7 might normally be the most 
important ligand of FGFR2b in the skin, the lack of the protein in Fgf7 knockout 
mice could be compensated for by other known ligands for this receptor, like 
FGF10, which shows a similar pattern of expression in normal and wounded skin 
(Werner and Grose, 2003). Unfortunately, the importance of FGF10 in wound 
healing cannot be studied in Fgf10 knockout mice as they die shortly after birth 
(Table 1) due to, among other defects, a failure in lung development (Min et al., 
1998, Sekine et al., 1999). Nevertheless, examination of Fgf10 knockout newborn 
mouse skin revealed that the granular layer of the epidermis was thinner than that 
of control mice. The expression of the epidermal differentiation marker loricrin, 
also was reduced dramatically but transglutaminase 1 (TGase 1), another marker 
of late terminal differentiation, was expressed normally in the upper spinous and 
granular layers of both the control and Fgf10 knockout skin. Similarly, Keratin 14 
was expressed normally in the basal layer and hair follicles of Fgf10 knockout 
newborns (Suzuki et al., 2000). Furthermore full-thickness Fgf10 knockout skin 
grafts transplanted onto nude mice revealed that Fgf10 knockout skin grafts 
generated abundant pigmented hairs, comparable to controls, without any 
differences in morphology of hair follicles and no major abnormalities on the 
surface or inner structure of the examined hairs (Suzuki et al., 2000).  
 
Interestingly, one phenotype shared by both Fgf10 and Fgfr2b null mice is 
that their eyes remain open at birth. This is due to a failure of the eyelid epidermis 
to cover the eye during late embryogenesis, in the equivalent of a developmental 
 43 
wound healing model. In vitro scratch assays, looking at cell migration of primary 
keratinocytes isolated from the eyelid epidermis of wild type and Fgf10 knockout 
foetuses, revealed no difference in cell migration in wild type compared to 
knockout keratinocytes, although in the mutant cultures the lamellipodia of the 
cells were not oriented toward the gap and the filopodia appeared to be thinner 
(Tao et al., 2005).  
 
??T cells seem to be a key source of FGFR2b ligands in the wounded 
epidermis two days after wounding. Mice lacking ??T cells show a significant delay 
in wound healing and impaired epidermal cell proliferation, most likely due to the 
lack of ??T cell - derived FGF7 and FGF10 in the healing wound (Jameson et al., 
2002). 
 
FGF7 and FGF10 signalling is transduced mainly via FGFR2b. Total 
FgfR2b knockout mice do not survive beyond birth. However, at term, the skin of 
these mice is clearly abnormal with a semi-transparent appearance (Revest et al., 
2001). Epidermal specific deletion of Fgfr2b under the control of Keratin 5 Cre 
transgene gives no such dramatic phenotype, though the epidermis shows 
hyperthickening with age. Interestingly 10% of mutant mice develop spontaneous 
papillomas (Grose et al., 2007). 
 
FGFR1b on the other hand, expressed in normal and wounded mouse 
skin, has been reported to be down-regulated in wounds of healing-impaired 
genetically diabetic mice (Zhang et al., 2004). That suggested FGFR1b down-
regulation is associated with wound healing defects, but mutant mice lacking 
Fgfr1b did not reveal any obvious abnormalities, neither in the skin, nor in the 
wound healing process. FGFR1b thus seems to be dispensable for skin 
development and wound repair (Zhang et al., 2004). 
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Interestingly, epidermal specific Fgfr1/2 double knockout mice are 
characterised by the same phenotypical changes as the dominant-negative Fgfr2b 
mutant mice (Sabine Werner – personal communication) thus emphasising further 
the importance of FGFR signalling in the process of maintaining skin homeostasis.  
 
Understanding the role of FGFR in the process of wound repair was 
possible thanks to introduction of the Cre-Lox system, which has proven both 
useful and efficient. Unfortunately, it is not an adequately useful tool in 
investigating the role of individual ligands in the healing process, as there are no 
Cre lines specific for the key ligand-producing cell types - fibroblasts and ??T cells.  
 
What emerges from the above picture is that there is a clear role for FGF 
signalling in the wound healing process and that this role is protected by 
redundancy at the level of both ligand and receptor. However, there is at least one 
more FGF not to have been investigated so far in the wound healing process. 
FGF22 is expressed towards the end of the repair process and it has been 
suggested to play a role in differentiation of wound keratinocytes (Beyer et al., 
2003).  
 
1.6.3 FGFs and skin carcinogenesis 
 
Cancer is a term used for diseases in which abnormal cells divide without 
control and are able to invade other tissues. The origin of the word cancer is more 
than 2,300 years old and it is credited to the Greek physician Hippocrates (460-
370 B.C.). Hippocrates used the terms karkinoma, which refer to a crab, most 
likely because the finger-like spreading projections from a cancer reminding the 
shape of an animal. The world's oldest documented case of cancer was found in 
Egypt and dates back to 1500 b.c.  
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There are more than 100 distinct types of cancer and subtypes of tumours 
can be found within specific organs (Hanahan and Weinberg, 2000). Several lines 
of evidence indicate that tumourgenesis in humans is a multi-step process and 
that these steps reflect genetic alterations that drive the progressive 
transformation of normal human cells into highly malignant derivatives. The 
immense number of cancer cell genotypes is a manifestation of six essential 
alterations in cell physiology that collectively dictate malignant growth: self-
sufficiency in growth signals, insensitivity to growth-inhibitory (antigrowth) signals, 
evasion of programmed cell death (apoptosis), limitless replicative potential, 
sustained angiogenesis, and tissue invasion and metastasis. The genomes of 
tumour cells must acquire increased mutability in human lifetime in order for the 
process of tumour progression to reach completion in several decades time. 
Malfunction of specific tumour suppressor genes, like p53, has been invoked to 
explain this increased mutability (Hanahan and Weinberg, 2000). That combined 
with mutated oncogenes, such as Ras, mimicking normal growth signalling 
contributes to uncontrolled cancer progression.  
 
 As a consequence of the insults it receives in the course of its protective 
duties, the skin is a clear target for cancer-causing genetic damage. Cancer of the 
skin arises predominantly from cells positioned within the epidermis. The main 
neoplasms of cutaneous epithelial cells are basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC). A distinct type of skin cancer arises from 
melanocytes, giving rise to malignant melanoma (Green and Khavari, 2004).  
 
Non-melanoma skin cancers like BCC and SCC are the most commonly 
diagnosed cancer in white populations worldwide, with about 100,000 people 
diagnosed each year in the UK alone. At the same time around 8,000 people are 
diagnosed with malignant melanoma. Incidence of this type of cancer quadrupled 
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in British males between 1975 and 2001, tripled in British females and is 
increasing in most white populations worldwide (Cancer Research UK, 2005). 
 
Skin SCC is a malignant tumour of keratinising cells of the epidermis or its 
appendages. It is the second most common malignant tumour of the skin. SCC 
may occur anywhere on the skin as well as on mucous membranes with 
squamous epithelium. The occurrence of SCC is usually related to UV light 
exposure (especially UVB radiation), therefore people with fair skin are at 
increased risk. Also, exposure to ionising radiation, arsenic or other chemical 
agents may increase the chances of developing cutaneous SCC. SCC may also 
develop in chronic inflammatory or degenerative conditions including scars, ulcers, 
sinus tracts and other pre-existing dermatologic conditions. Moreover patients with 
decreased immunologic competence are at increased risk of developing this 
tumour (Drake et al., 1992).  
 
 SCCs have the ability to infiltrate locally and cause tissue destruction. 
Initially developing as carcinoma in situ, tumours later become invasive, involving 
dermis, subcutis, musculature, cartilage and, unlike BCC, may metastasise to 
regional lymph nodes and subsequently spread to the lung, liver or brain (Johnson 
et al., 1992). 
 
1.7 FGFs and their receptors in cancer 
 
 Human genetic studies have identified numerous activating FGFR 
mutations that are responsible for autosomal dominant bone morphogenetic 
disorders (Chen and Deng, 2005). Such mutant FGFR2 would be expressed in 
many other tissues besides the bones, yet individuals carrying these mutations 
have not been reported to have a high incidence of cancer. Interestingly though, 
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many FGFR mutations responsible for conditions like craniosynostosis and 
dwarfism through somatic mutations, contribute to the development of cancer. The 
underlying mechanism of FGF signalling activation is largely tumour specific, 
although in general the mechanisms fall into three main groups; 1) Genomic 
alteration of FGFR leading to ligand independent activation, 2) Ectopic expression, 
or splicing, of FGFR leading to aberrant ligand dependent signalling, 3) Increased 
FGF expression from the cancer cell acting in an autocrine fashion, or in a 
paracrine fashion from stromal tissue (Turner and Grose, 2010). 
 
Pathological FGF signalling is a characteristic of various malignancies. For 
example, modifications to FGF expression are known to cause salivary gland 
aplasia (FGF10) and autosomal dominant hypophosphatemic rickets (FGF23). 
Glioblastoma brain tumours exhibit FGFR1 kinase domain gain-of-function 
mutations (Rand et al., 2005), and FGFR1 is activated abnormally in malignant 
prostate cells (Giri et al., 1999). On the other hand, kinase domain loss-of-function 
mutations are observed in FGFR2 in melanoma (Gartside et al., 2009) and 
overexpression and gain-of-function mutations in FGFR3 occur in multiple 
myeloma, an incurable B-cell malignancy (Chesi et al., 1997). Gain-of-function 
FGFR3 mutations are also the most commonly observed mutations in bladder 
cancer (Cappellen et al., 1999), and activating FGFR3 mutations are observed in 
benign skin tumours (Hafner et al., 2006). FGFR4 mutations promote metastasis 
of prostate cancer by increasing cellular motility and invasiveness, nonetheless 
FGFR4 has potential value as a prognostic marker since Arg388 is associated 
with increased aggressiveness of prostate cancer (Wang et al., 2004). Moreover, 
this same allele in FGFR4 is a predictor of poor clinical prognosis in head and 
neck squamous cell carcinoma (Streit et al., 2004).  
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1.8 Therapeutic approaches 
 
Despite major advancements, pharmaceutical companies still face 
challenges in the development of successful, highly specific therapeutic 
approaches to the key FGF signalling dependent forms of human cancer. Direct 
inhibition of FGFRs appears to be of great clinical value and a number of FGFR 
tyrosine kinase inhibitors have already been developed. Some of them are in early 
phase clinical trials. All of those inhibitors were designed originally as VEGFR2 
ATP competitors, but as the VEGFR2 and FGFR kinase domains have high 
structural similarity, a number of the VEGFR inhibitory compounds also inhibit the 
FGFRs (Turner and Grose, 2010). Since the kinase domains of FGFR1-3 are 
highly similar it might not be possible to develop more selective inhibitors. 
Sunitinib, a receptor tyrosine kinase inhibitor that has some activity against 
FGFRs, already has been approved by the Food and Drug Administration (FDA) 
for treatment of patients with renal cell carcinoma and gastrointestinal stromal 
tumours (Chow and Eckhardt, 2007). Other developed compounds are listed in the 
table below.  
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Small molecular tyrosine kinase inhibitors 
Drug name Company Spectrum of activity Clinical 
development 
SU5402 In vitro reagent Selective FGFR inhibitor (now 
superseded) 
N/A 
AZD2171 AstraZeneca FGFR, VEGFR inhibitor Phase II 
Ki23057 Kirin Brewery FGFR, PDGFR, VEGFR, c-kit 
inhibitor 
N/A 
PD173074 In vitro reagent Selective FGFR inhibitor N/A 
TKI258 Novartis FGFR, PDGFR, VEGFR 
inhibitor 
Phase II 
BIBF 1120 Boehringer 
Ingelheim 
FGFR, PDGFR, VEGFR 
inhibitor 
Phase III 
BMS-582664 
(Brivanib) 
Bristol-Myers 
Squibb 
FGFR, VEGFR inhibitor Phase II 
E7080 Eisai FGFR, PDGFR, VEGFR 
inhibitor 
Phase I 
TSU-68 Taiho 
Pharmaceutical 
FGFR, PDGFR, VEGFR 
inhibitor 
Phase I/II 
PKC412 Novartis FGFR, PDGFR, VEGFR, FLT3, 
PKC, c-KIT inhibitor 
Phase II (as 
FLT3 inhibitor) 
 
FGFR antibodies and FGF ligand traps 
Name Company Target  
IMC-A1 ImClone FGFR1c blocking antibody N/A 
PRO-001 ProChon Biotech FGFR3 blocking antibody N/A 
R3Mab Genentech FGFR3 blocking antibody N/A 
1A6 Genentech FGF19 blocking abtibody N/A 
FP-1039 Five Prime Therapeutics FGF ligand trap (multiple FGFs) Phase I 
 
FGF ligand for mucosal chemoprotection 
Palifermin 
(Kepivance) 
Biovitrum AB recombinant FGF-7 (activates 
FGFR2b) 
Licensed 
        (Turner and Grose, 2010) 
Table 3 FGF therapeutics 
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Aims 
 
To understand the biological role of Fgf-22 through the generation and 
characterisation of a Fgf22 knockout mouse model. 
 
To further investigate the role of FGFR2b in cancer development and progression. 
 
To provide a greater understanding into the role of FGF and FGFR interactions 
involved in normal and pathological conditions, especially cancer. 
 
Hypothesis  
 
FGF22 is involved in skin development, homeostasis and repair. 
 
FGFR2, a putative tumour suppressor gene in mouse skin, is mutated in human 
squamous cell carcinoma. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
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CHAPTER 2: Materials and methods  
 
2.1 Materials 
 
2.1.1 Chemicals and other consumables 
 
[?-32P] dCTP       Perkin Elmer, USA 
?-mercaptoethanol      Sigma, Dorset, UK 
Adenine      Sigma, Dorset, UK 
Agarose      Invitrogen, Paisley, UK 
Alcian Blue 8GX Sigma, Dorset, UK 
Alizarin Red Sigma, Dorset, UK 
Ampicillin Boehringer, Mannheim, 
Germany 
AvaI restriction enzyme New England BioLabs, 
Hitchin, UK 
Avidin/Biotin block Vector Labs, Peterborough, 
UK 
BigDye Terminator v3.1 Cycle Sequencing Kit AB, Warrington, UK  
Bovine serum albumin  (BSA)    Sigma, Dorset, UK 
Cell strainers 100 ?M Marathon Laboratory 
Supplies, London, UK 
Chelex-100 resin BioRad, Hemel Hempstead, 
UK 
Chloroform      BDH, Poole, UK 
Cholera toxin       Sigma, Dorset, UK 
Chromatography paper (3MM)    Whatman, Maidstone, UK 
Collagen I       Upstate Scientific, USA  
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Collagen I coated 60cm culture dishes  VWR, Lutterworth, UK  
DAPI mounting medium  Vector Labs, Peterborough, 
UK 
Defined keratinocyte-SFM medium   Gibco, Paisley, UK 
Diethylpyrocarbonate (DEPC)   Sigma, Dorset, UK 
Diaminobenzidine (DAB substrate)    Dako, Denmark 
Dimethylformamide (DMF)     BDH, Poole, UK 
Dispase I  Roche, Welwyn Garden City, 
UK 
Dimethylsulphoxide (DMSO) Sigma, Dorset, UK 
ECL reagent       Amersham Biosciences, UK 
Ethylenediaminetetraacetic acid (EDTA)  BDH, Poole, UK 
Epidermal growth factor (EGF)   Sigma, Dorset, UK 
Ethanol Fisher Scientific, 
Loughborough, UK 
Ethidium bromide     Sigma, Dorset, UK 
Fetal calf serum (FCS)    Biosera, Ringmer, UK 
Formamide      Sigma, Dorset, UK 
Full Range Rainbow Molecular Weight Marker  Amersham, Biosciences, UK 
Gel extraction kit QIAquick    Qiagen, Crawley, UK 
GelPilot DNA Loading Dye     Qiagen, Crawley, UK 
Gentamycin      Gibco, Paisley, UK 
Glycine      Sigma, Dorset, UK 
HincII restriction enzyme New England BioLabs, 
Hitchin, UK 
HindIII restriction enzyme New England BioLabs, 
Hitchin, UK 
Hydrocortisone     Sigma, Dorset, UK 
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Hydrogen peroxide  Fisher Scientific, 
Loughborough, UK 
Hyperladder I      Bioline, London, UK 
In situ Hybridisation Kit    BioChain, USA 
Insulin       Sigma, Dorset, UK 
Iodine solution      Sigma, Dorset, UK 
Isopropanol  Fisher Scientific, 
Loughborough, UK 
Liothyronine      Sigma, Dorset, UK 
Mayer’s haematoxylin     BDH, Poole, UK 
MegaMix      Cambio, Cambridge, UK 
Methanol Fisher Scientific, 
Loughborough, UK 
Microspin G-25 Column  GE Healthcare, Amersham, 
UK 
Milk dried, skimmed      Marvel, UK 
M.O.M. Block Vector Labs, Peterborough, 
UK 
Mouse Leptin ELISA kit    Millipore, Watford, UK 
Sodium phosphate (Na3PO4)    Sigma, Dorset, UK 
Sodium chloride (NaCl)     BDH, Poole, UK 
Sodium fluoride (NaF)     Sigma, Dorset, UK 
NuPAGE 4-12 % Bis-Tris polyacrylamide gel Invitrogen, Paisley, UK 
NuPAGE MES SDS 20x Running Buffer   Invitrogen, Paisley, UK 
NuPAGE LDS sample loading buffer   Invitrogen, Paisley, UK 
Nytran SuPerCharge membrane   Schleicher&Schuell, Germany 
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PAP pen  Zymed, Invitrogen, Paisley, 
UK 
PCT Epidermal Keratinocyte     Millipore, Watford, UK 
Medium calcium free (CnT-07CF) 
PCR purification kit     Qiagen, Crawley, UK 
Pepsin Digest ALL-3 solution Zymed, Invitrogen, Paisley, 
UK 
Permount Mounting Medium Fisher Scientific, 
Loughborough, UK 
Phenol Fluka Chemie, Switzerland 
Phenylmethanesulphonylfluoride (PMSF)   Sigma, Dorset, UK 
Ponceau S Solution      Sigma, Dorset, UK 
Porcelain spot plate (6, 12 well)   VWR, Lutterworth, UK 
Protease inhibitor cocktail     Calbiochem, Nottingham, UK 
Proteinase K      Sigma, Dorset, UK 
Protran nitrocellulose transfer membrane   Schleicher&Schuell, Germany 
QIAprep Spin Miniprep Kit 250    Qiagen, Crawley, UK 
Ready-To-Go DNA Labelling Beads (dCTP)  GE Healthcare, Amersham, 
UK 
Re-Blot Plus Mild Solution (10x)   Invitrogen, Paisley, UK 
RIPA Lysis 10x buffer     Upstate Scientific, USA 
Sodium dodecyl sulfate (SDS)  National Diagnostics, Hessle, 
UK 
Sodium acetate     BDH, Poole, UK 
Sodium orthovanadate      Sigma, Dorset, UK 
StreptABComplex/HRP    Dako, Denmark 
SuperScript™ II RT     Invitrogen, Paisley, UK 
SYBR Green PCR Kit     Qiagen, Crawley, UK 
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TRI reagent      Sigma, Dorset, UK 
Tris-base      Sigma, Dorset, UK 
Trypsin (2.5%)      Gibco, Paisley, UK 
Tween 20       Sigma, Dorset, UK 
Vectashield mounting media Vector Labs, Peterborough,  
with DAPI       UK 
X-gal  Melford Laboratories, Suffolk, 
(5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside) UK 
X-Ray film       FUJIFILM, Japan 
Xylene Fisher Scientific, 
Loughborough, UK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 57 
2.1.2 Antibodies 
 
Primary Antibody Incubation Dilution Supplier 
?-BrdU antibody 
(rat monoclonal) 
1 hour room 
temperature 
1:500 in 1 % BSA in 
PBS 
Abcam, Cambridge, 
UK 
?-hFGFR2 
(rabbit polyclonal) 
overnight at 4°C 1:2000 in 3 % BSA in 
PBS-T 
Abcam, Cambridge, 
UK 
?-Loricrin 
(rabbit polyclonal) 
1 hour room 
temperature 
1:500 in 5 % BSA in 
PBS 
Abcam, Cambridge, 
UK 
?-mKeratin 14 
(rabbit polyclonal) 
overnight at 4°C 1:1000 in 5 % BSA in 
PBS 
Covance, USA 
?-p63 
(mouse monoclonal) 
overnight at 4°C 1:50 
in M.O.M. Diluent 
Abcam, Cambridge, 
UK 
?-Phospho-ERK 
(rabbit polyclonal) 
1 hour room 
temperature 
1:1000 in 3 % BSA in 
PBS-T 
Cell Signaling, USA 
?-hTubulin 
(mouse monoclonal) 
1 hour room 
temperature 
1:2000 in 3 % BSA in 
PBS-T 
Sigma, Dorset, UK 
?-mVimentin 
(mouse monoclonal) 
overnight at 4°C 1:1000 in 3 % BSA in 
PBS-T 
Sigma, Dorset, UK 
 
Table 4 Primary antibodies. 
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Secondary antibody Dilution Supplier 
polyclonal goat ?-mouse 
HRP conjugated 
1:1000 in 3 % BSA in 
PBS-T 
Dako, Denmark 
polyclonal goat ?-rabbit 
HRP conjugated 
1:1000 in 3 % BSA in 
PBS-T 
Dako, Denmark 
polyclonal goat ?-rat 
HRP conjugated 
1:100 in 1% BSA in PBS Dako, Denmark 
goat ?-rabbit 
rhodamine conjugated 
1:100 in 5% BSA in PBS Millipore, Watford, UK 
 
Table 5 Secondary antibodies. 
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2.1.3 Primers 
 
2.1.3.1 Primers for genotyping  
 
Fgf22 
 
Fgf22 wt_F    5’-TTGTGAACCAAGATGGCAGG-3’ 
Fgf22 wt_R   5’-CCAGCTTTGGACTTCATCTG-3’  
 
Fgf22 ko_F   5’-TCGACTAGAGGATCAGCTTG-3’ 
Fgf22 ko_R   5’-CAGGCCAGCATAGTCTACTT-3’ 
 
The Fgf22 wt primers amplify a 286bp fragment and the Fgf22 ko primers amplify 
a 133bp fragment from the targeted allele. 
 
Cre/Fgfr2 
 
Cre_F    5’-TCGCTGCCAGGATATACGTA-3’   
Cre_R    5’-CTGACCAGAGTCATCCTTAG-3’ 
 
This pair of primers is specific for the CRE cDNA. The Cre primers amplify a 
384bp fragment in a positive sample.  
 
Fgfr2 5’Flox IIIb   5’-CTGCCTGGCTCACTGTCC-3’ 
Fgfr2 3’Flox IIIb    5’-GGCATGCAAATGCAAGGTC-3’ 
 
These primers allow the amplification and identification of the Fgfr2 wild type and 
floxed alleles. If the mouse is Fgfr2+/+, the primers amplify a 400bp fragment. Since 
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the primers flank one of the engineered loxP sites, the floxed allele contains an 
additional 90bp between the primer sites. Thus the Fgfr2 primers amplify a 490bp 
fragment from the floxed allele. 
 
2.1.3.2 Primers for RT-PCR  
 
Fgf22 
 
Fgf22_F   5’-ATTCTAGAATGCGCAGCCGCCTCTGG-3’ 
Fgf22_R   5’-ATGGGCCCTCAAGACGAGACCAAGAC-3’ 
 
The pair of primers amplifies a 482bp fragment from the targeted allele in a wild 
type mouse. If the mouse is Fgf22 knockout then no product is obtained. 
 
Fgfr2b 
 
FGFR2IIIa_F    5’-AAGGTTTACAGCGATGCCCA-3’ 
FGFR2TM836_R   5’-TCTGGGGAAGCTGTAATCTC-3’ 
 
The pair of primers amplifies a 290bp fragment or 287bp fragment for the FGFR2b 
and FGFR2c respectively. 
 
2.1.3.3 Primers for Real-Time RT-PCR  
 
Fgf7  
 
Fgf7_F    5’-GAACAAAAGTCAAGGAGCAACC-3’ 
Fgf7_R   5’-GTCATGGGCCTCCTCCTATT-3’ 
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The pair of primers amplifies a 202bp fragment. 
 
Fgf10  
 
Fgf10_F   5’-GAGAAGAACGGCAAGGTCAG-3’ 
Fgf10_R   5’-CTCTCCTGGGAGCTCCTTTT-3’ 
 
The pair of primers amplifies a 289bp fragment. 
 
Fgf22 
 
Fgf22_F   5’-ATTCTAGAATGCGCAGCCGCCTCTGG-3’ 
Fgf22_R   5’-ATGGGCCCTCAAGACGAGACCAAGAC-3’ 
 
The pair of primers amplifies a 482bp fragment in a wild type mouse. 
 
Fgfr1IIIb  
 
FGFR1IIIb_F    5’-TTAATAGCTCGGATGCGGAG-3’  
FGFR1IIIb_R    5’-ACGCAGACTGGTTAGCTTCA-3’  
 
The pair of primers amplifies a 110bp fragment. 
 
Fgfr2IIIb  
 
FGFR2IIIa_F    5’-AAGGTTTACAGCGATGCCCA-3’   
FGFR2IIIb_R    5’-AGAGCCAGCACTTCTGCATT-3’  
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The pair of primers amplifies a 145bp fragment. 
 
2.1.3.4 Primers for sequencing 
 
M13_F    5’-GTAAAACGACGGCCAG-3’ 
M13_R    5’-CAGGAAACAGCTATGAC-3’ 
 
2.1.3.5 Mycoplasma screening primers 
 
FWD 1    5’-ACTCCTACGGGAGGCAGCAGTA-3’ 
FWD 2    5’-CTTAAAGGAATTGACGGGAACCCG-3’ 
Common REV   5’-TGCACCATCTGTCACTCTGTTAACCTC-3’ 
 
2.1.3.6 Loading control primers  
 
HPRT (Hypoxanthine-guanine Phosphoribosyl Transferase) 
 
FWD    5’-CCTGCTGGATTACATTAAAGCGCTG-3’  
REV    5’-GTCAAGGGCATATCCAACAACAAAC-3’ 
 
The pair of primers amplifies a 351bp fragment. 
 
GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) 
 
mGAPDH419’   5’-TGATGGGTGTGAACCACGAGA-3’ 
mGAPDH716’   5’-ATGCCAGTGAGCTTCCCGTT-3’ 
 
The pair of primers amplifies a 297bp fragment. 
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2.2 Mice 
 
2.2.1 Conditional knockout mice (K5-R2b null) 
 
Conditional knockout mice, lacking Fgfr2b in the epidermis (K5-R2b null), 
were generated as follows: female mice were bred to homozygosity for a floxed 
allele (Fgfr2bflox/flox), with loxP sites inserted into the introns flanking the IIIb exon of 
the Fgfr2 gene (De Moerlooze et al., 2000). These were crossed with male mice 
carrying one copy of the Cre recombinase transgene under the control of the 
Keratin 5 promoter (Ramirez et al., 2004) in addition to the homozygous 
Fgfr2bflox/flox allele. Provided that the Cre allele is transmitted paternally, only 
epithelia derived from Keratin 5 - expressing cells are targeted for deletion. 
Maternal transmission results in ubiquitous excision of the floxed sequence caused 
by Cre expression in the maternal germ line (Ramirez et al., 2004). Mice were 
maintained on a mixed C57Bl6/J?129ola background for in vitro primary 
keratinocyte studies. In the meantime male K5Cre+ve; Fgfr2bflox/+ mice were 
backcrossed with female FVB/N mice to generate Fgfr2bflox/+ mice. The male 
K5Cre+ve; Fgfr2bflox/flox F1 mice were then backcrossed again with female FVB/N 
mice for a total of 6 generations to obtain K5-R2b null mice on an FVB/N 
background, as FVB/N mice show a high frequency of conversion from papillomas 
to carcinomas (Woodworth et al., 2004). These mice will be used for future skin 
carcinogenesis studies.  
 
Littermate controls (Fgfr2bflox/flox Cre negative) were maintained alongside 
K5-R2b null mice under identical husbandry conditions. Newborn litters were used 
for preparation of primary keratinocytes or were left with the parents until weaning 
at the age of 21 days. Adult female Fgfr2bflox/flox mice, 6 weeks to 6 months old, 
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were used for breeding together with K5Cre+ve; Fgfr2bflox/flox males, such that the 
litters generated were 50% skin specific knockout of Fgfr2b and 50% control. 
 
2.2.2 Creation of Fgf22 knockout mice 
 
 
 
Figure 2.1 Fgf22 knockout gene construct. 
 
The targeted gene construct above had already been prepared by Dr 
Richard Grose. As for all 22 members of the FGF family, the Fgf22 gene consists 
of three exons. It has been shown previously for Fgf7 that sequences of exon 1 
are essential for its association with heparin and for subsequent binding to FGFR2 
(Ron et al., 1993). Since the first intron of Fgf22 is small (1275 bp), all three exons 
were targeted for deletion. A targeting vector for the Fgf22 coding exons was 
constructed in pBluescript SK+ plasmid, using isogenic mouse embryonic stem 
cells as a source of genomic DNA. Two Fgf22 genomic fragments were used as 5' 
(5 kb) and 3' (1.2 kb) arms. The vector was designed to eliminate the entire coding 
region of exon 1 and the whole of exon 2 and 3 (Fig 2.1). This region was replaced 
by a neomycin resistance gene flanked with loxP sites. The targeting vector DNA 
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was transfected into ES cells, and the transfectants were subjected to positive 
(G418) selection. ES cell clones were picked and grown in a 96 well plate format, 
on irradiated fibroblast feeder cells. Up to this point, all experiments were 
performed by the Transgenic Service unit at CR-UK Clare Hall Labs. DNA from 
surviving colonies was isolated and screened for the desired homologous 
recombination by Southern blot analysis (as described below). Of a total of 192 ES 
clones analysed, 2 scored positive for homologous recombination and displayed 
identical hybridisation patterns. The two mutant clones were injected separately 
into C57Bl6/J blastocysts. Since ES cells are derived from male embryos, high-
percentage male chimaeric animals, as judged by having more than 50% brown 
coat colour, were mated with C57Bl6/J females. Heterozygous offspring were then 
mated to produce homozygous mutants, which occurred at the expected 
Mendelian frequency of 25%. To confirm that the targeted homologous 
recombination resulted in abrogation of Fgf22 mRNA expression, reverse 
transcriptase PCR analysis was conducted on RNA extracted from tissues of wild 
type, heterozygous and knockout mice (as described below).  
 
2.3 Genotyping, PCR and DNA gel electrophoresis  
 
2.3.1 DNA isolation 
 
To determine the genotype of a mouse, three to five week old mice were 
ear-snipped or, in case of newborn pups used for keratinocyte isolation, 3 mm of 
tail tip was cut, for the isolation of genomic DNA. Tissue was digested overnight in 
a 1.5 ml Eppendorf tube at 55°C in 40 ?l of tissue digestion buffer (0.025% SDS, 
125 mM Tris-base [pH 8], 0.5 mM NaCl) containing 1 ?l Proteinase K (50 ?g/?l), 
added to lysis buffer immediately prior to incubation.  
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The following day, 16 ?l of 5 M NaCl solution was added to the tubes. The 
samples were mixed by vortexing and incubated at 55°C for another 10 min to 
allow any precipitate to dissolve. The samples were mixed by vortexing and 
centrifuged for 15 min at 13,000 rpm and room temperature. 40 ?l of the 
supernatant was transferred into a fresh 1.5 ml Eppendorf tube and 24 ?l of 
Isopropanol was added. The samples were mixed and centrifuged for 10 min with 
the same conditions as above to precipitate the DNA pellet. 
 
The supernatant was aspirated off and the pellet was washed with 100 ?l 
of 70% Ethanol by vortexing briefly and centrifuging for 10 min at 13,000 rpm, 
room temperature. The Ethanol was aspirated off, the pellet was air-dried prior to 
resuspension in 40 ?l of EB buffer at 55°C for one hour.  
 
The samples were stored at 4°C until genotype was confirmed. 1 ?l of each 
sample was used for PCR.  
 
2.3.2 Polymerase chain reaction (PCR) 
 
The polymerase chain reaction allows the amplification of any DNA 
fragment from template DNA using suitable oligodeoxynucleotide primers and 
enables identification of mutant or wild-type alleles of a gene. All PCR reactions 
were carried out using MegaMix in 20 ?l reaction volume in thin-walled PCR 
plates. A negative control was always performed with all the mix components 
except the DNA sample.  
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Reaction mix:  18.8 ?l   MegaMix 
   0.1 ?l  3’primer (100mM stock) 
   0.1 ?l  5’primer (100mM stock) 
   1 ?l  sample 
 
The reaction was performed in a (Techne Flexigene) DNA thermal cycler 
(Krackeler Scientific, USA) with the following programme: 
 
PCR-programme: Initial Denaturation 3 min 94
o
C  
   Denaturation  30 sec 94
o
C 
   Annealing  30 sec 60
o
C          35 cycles 
   Extension  1 min 72
o
C 
   Final Extension  10 min 72
o
C 
 
2.3.3 Electrophoresis 
 
PCR products were separated on a 2% Agarose/TBE gel. A 100 ml 
Agarose gel was made by mixing 2 g Agarose with 100 ml of 1x TBE, microwaving 
it at high power for 3 minutes until the Agarose was dissolved then cooling it down 
to 56°C. Afterwards, 10 ?l of 5 mg/ml Ethidium bromide solution was added. The 
solution was poured in a medium horizontal gel electrophoresis system gel tank 
tray (Horizon, USA) and two 20-well combs were immersed in the Agarose to 
create wells.  
 
10 ?l of PCR mix was loaded into the gel and separated at 100 V 
(PowerEase 500, Invitrogen, Paisley, UK) for 1 hour. Bands were visualised under 
UV light and photographed using an AutoChemi System (UVP BioImaging 
Systems, Cambridge, UK).  
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2.4 RNA isolation 
 
For all the RNA experiments, sterile, RNase-free plastic tubes and pipette 
tips were used. Water and PBS used were pre-treated with diethylpyrocarbonate 
(DEPC) to block RNases. 0.1% DEPC was added, solutions were shaken and 
then left for at least 16 hours, before autoclaving to destroy the DEPC.  
 
Isolation of total RNA from tissues and cell monolayers was performed 
using TRI reagent. TRI reagent is an improved version of the single-step total RNA 
isolation reagent developed by Chomczynski and Sacchi (Chomczynski and 
Sacchi, 1987). It is a mixture of guanidine isothiocyanate and phenol in a mono-
phase solution that effectively dissolves DNA, RNA, and protein. 
 
Tissue samples used for RNA extraction were snap-frozen in liquid 
nitrogen and stored in liquid nitrogen. Just before RNA extraction, samples were 
transferred into a suitable container and immediately homogenised in TRI reagent 
(1 ml per 50-100 mg of tissue) using an Ultra-Turrax T25 homogeniser (IKA 
Labortechnik, Germany). Cell monolayers were lysed directly on the culture dish 
using 1 ml of the TRI reagent per 10 cm2 of culture plate surface area. After 
addition of the reagent, the cell lysate was homogenised by passing through a 
1000 ?l pipette (several times). To ensure complete dissociation of nucleoprotein 
complexes, samples were allowed to stand for 5 minutes at room temperature. 
Then 0.2 ml of Chloroform per ml of TRI reagent used was added. The sample 
was covered tightly and shaken vigorously for 15 seconds, then allowed to stand 
for 2-15 minutes at room temperature. The resulting mixture was centrifuged at 
13,000 rpm for 15 minutes at 4°C (Sorvall fresco, Thermo Fisher Scientific, USA). 
Centrifugation separated the mixture into 3 phases: a red organic phase 
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(containing protein), an interphase (containing DNA), and a colourless upper 
aqueous phase (containing RNA). 
 
The aqueous phase was transferred to a fresh tube and 0.5 ml of 
Isopropanol per ml of TRI reagent used in sample preparation was added. The 
sample was mixed and allowed to stand for 5-10 minutes at room temperature, 
before centrifugation at 13,000 rpm for 10 minutes at 4°C. This precipitated the 
RNA to form a pellet on the side and bottom of the tube. The supernatant was 
removed and the RNA pellet was washed by adding 1 ml (minimum) of 75% 
Ethanol per 1 ml of TRI reagent used for sample preparation. The sample was 
vortexed and then centrifuged at 10,000 rpm for 5 minutes at 4°C. The RNA pellet 
was air-dried for 5-10 minutes. 
 
An appropriate volume of DEPC treated water was added to the RNA 
pellet (100-500 ?l). To facilitate dissolution, it was mixed by repeated pipetting and 
then incubated at 55-60°C for 10-15 minutes. 
 
2.5 cDNA synthesis 
 
cDNA was generated by reverse transcription from RNAs isolated from 
tissues or cell lines. Random hexamer primers were used to prime the reverse 
transcriptase reaction and ensure the efficient amplification of all mRNAs in a 
sample. Random hexamers are mixtures of 6 base-pair primers with varying 
sequences that bind to complementary RNA sequences. This results in a very 
high probability that all transcripts will be reverse transcribed at near 100% RT 
efficiency and avoid the bias towards 3’end of messages seen when using oligo 
dT primers (Bookout and Mangelsdorf, 2003). For cDNA synthesis, the 
SuperScript™ II RT enzyme was used. 
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A 20 ?l reaction volume was used for 1 ng – 5 ?g of total RNA. The 
following components were added to a nuclease-free 500 ?l Eppendorf tube. 
 
Reaction mix:  1 ?l   random hexamers (50 ng/?l) 
   1 ng - 5 ?g total RNA    
1 ?l  dNTP Mix (10 mM each) 
   the volume was made up to 12 ?l with sterile, distilled water 
 
The mixture was heated to 65°C for 5 minutes and then quickly chilled on 
ice. The contents of the tube were collected by brief centrifugation and the 
following were added: 
 
4 ?l   5X First-Strand Buffer  
2 ?l   0.1 M DTT  
1 ?l RNaseOUT (40 units / ?l)  
(required if using <50 ng starting RNA) 
 
The contents of the tube were mixed gently and incubated at 25°C for 2 
minutes. Then the enzyme was added:  
 
1 ?l (200 units) of SuperScript™ II RT 
 
The contents of the tube were mixed by pipetting gently up and down and 
the reaction was incubated at 25°C for 10 minutes to allow primer binding. 
Incubation at 42°C for 50 minutes allowed reverse transcription to occur, prior to 
the reaction being inactivated by heating to 70°C for 15 minutes. cDNA samples 
were used immediately for PCR whenever possible, and the remainder was stored 
at -20°C. 
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2.6 PCR product digestion  
 
The ligand binding domain of FGFR2 undergoes alternative splicing to give 
two isoforms, IIIb or IIIc (see cartoon below). RT-PCR was performed on RNA 
isolated from a range of cell lines. Primers targeted to the exons flanking the 
alternatively spliced region yielded similarly sized PCR products.  
 
 
 
 
Figure 2.2 FGFR2 splicing isoforms. 
 
Since exon IIIb contains an AvaI site not present in exon IIIc and exon IIIc 
contains two HincII sites not present in exon IIIb, digestion of PCR products with 
the restriction endonucleases, HincII and AvaI, revealed which isoform of the 
receptor was expressed (Fig 2.2). 
 
All PCRs were carried out using MegaMix in a reaction volume of 20 ?l in 
PCR plates. A negative control was always performed with all the mix components 
except the cDNA sample.  
 
 
 72 
Reaction mix:  18.8 ?l   MegaMix 
   0.1 ?l  FGFR2IIIa F primer (100mM stock) 
   0.1 ?l  FGFR2TM836 R primer (100mM stock) 
   1 ?l  cDNA sample 
 
The reaction was performed in a (Techne Flexigene) DNA thermal cycler 
with the following programme: 
 
PCR-programme: Initial denaturation 3 min 94
o
C  
   Denaturation  30 sec 94
o
C 
   Annealing  30 sec 60
o
C          35 cycles 
   Extension  45 sec 72
o
C 
   Final extension  10 min 72
o
C 
 
10 ?l of each PCR product was analysed on a 2% Agarose/TBE gel. The 
pair of primers amplifies a 290bp fragment from the targeted allele. The remainder 
of the reactions were restriction digested with AvaI or HincII enzymes in a digest 
mix as described below.  
 
Digest mix:  10 ?l   PCR product 
   2 ?l  10x buffer 3 (NEB) 
   0.2 ?l  BSA (100x) 
   1 ?l  HincII enzyme (10 units/?l) 
   the volume was made up to 20 ?l with sterile, distilled water 
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Or alternatively: 
 
Digest mix:  10 ?l   PCR product 
   2 ?l  10x buffer 4 
   1 ?l  AvaI enzyme (10 units/?l) 
   the volume was made up to 20 ?l with sterile, distilled water 
 
Samples were incubated at 37°C for a minimum of 2 hours. Digestion 
products were analysed on a 2% Agarose/TBE gel. AvaI enzyme digestion 
produces 182 and 108bp bands, where HincII enzyme digestion produces three 
bands of 119, 115 and 53bp. 
 
2.7 Real-time Polymerase Chain Reaction (PCR)  
 
Real-time PCR gives the possibility of monitoring the progress of the PCR 
amplification as it occurs. Data therefore are collected throughout the PCR 
process, rather than at the end of the reaction. In real-time PCR, reactions are 
characterised by the point in time during cycling when amplification of a target is 
first detected, rather than determining the amount of target accumulated after a 
fixed number of cycles. The higher the starting copy number of the nucleic acid 
target, the sooner a significant increase in fluorescence is observed 
(www.protocol-online.org). 
 
SYBR Green dye was used in all the Real-Time PCR reactions. SYBR 
Green dye has the ability to bind to double-stranded DNA formed during PCR. As 
soon as it is added to a sample it binds to all double-stranded DNA present in the 
sample. Then, during the PCR, DNA Polymerase amplifies the target sequence 
creating the PCR products. The dye immediately binds to each new copy of 
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double-stranded DNA and upon excitation emits light. As the PCR progresses, 
more amplicons are created and, since the SYBR Green dye binds to all double-
stranded DNA, it results in an increase in fluorescence intensity proportionate to 
the amount of PCR product produced (Essentials of Real Time PCR, Applied 
Biosystems). 
 
 In brief, 265 ng RNA from each wound sample was used for reverse 
transcription into 20 ?l cDNA as described earlier (2.5). All the Real-Time PCR 
reactions were carried out in a 20 ?l reaction volume in 96 well PCR plates, 
always in triplicate. A negative control was performed with all the mix components 
except the cDNA sample.  
 
Reaction mix:  1 ?l   cDNA 
0.1 ?l   forward primer  
(0.5 ?M working concentration) 
0.1 ?l   reverse primer  
(0.5 ?M working concentration) 
10 ?l  SYBR GREEN PCR Master Mix 
8.8 ?l  RNase-free H2O 
 
Serial dilutions (1, 0.75, 0.5, 0.25, 0.1, 0.01, 0.001) of one of the samples 
were used to establish a standard curve for each of the primer sets used in the 
Real-Time PCR reaction. The reaction was performed in a StepOne Plus Real-
Time PCR System (Applied Biosystems) thermal cycler with the following 
programme: 
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PCR-programme:  Incubation  2 min 50°C  
Taq activation   15 min  95°C 
Denaturation   15 sec 95°C  
Annealing   30 sec 60°C      40 cycles 
Extension   30 sec 72°C  
Final melt curve (dissociation step) from 60°C to 95°C.  
 
GAPDH primers were used as internal control. The results were evaluated 
using the 2-??ct method (Livak and Schmittgen, 2001). 
 
2.8 TOPO cloning 
 
TOPO Cloning kit (Invitrogen, UK) was used for quick, routine PCR product 
cloning. The key ingredient of the TOPO Cloning system is the enzyme, DNA 
topoisomerase I, which functions both as a restriction enzyme and as a ligase (Fig 
2.3). In vivo it is essential during replication as it cleaves and rejoins DNA. 
Vaccinia virus topoisomerase I recognises specific sequence and cleaves one 
DNA strand, enabling the DNA to unwind. The enzyme then religates the ends of 
the cleaved strand and releases itself from the DNA. TOPO vectors are linearised 
with this enzyme covalently bound to each 3´ phosphate. This enables the vectors 
to readily ligate DNA sequences with compatible ends. 
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Figure 2.3 TOPO® Cloning Technology, Invitrogen 
 
2.8.1 TOPO TA cloning reaction 
 
Because of the TOPO vector properties mentioned above, fresh PCR 
product was always used for cloning reactions. The following components were 
added to a nuclease-free 500 ?l Eppendorf tube. 
 
Cloning reaction mix:  4 ?l   fresh PCR product 
    1?l  salt solution    
1 ?l  TOPO vector 
    
The contents of the tube were mixed gently, incubated for 5 minutes at 
room temperature before placing on ice.  
 
2.8.2 Transforming One Shot TOP10 competent cells  
 
TOP10 competent E.coli cells were thawed on ice using one vial per 
transformation. 2 ?l of cloning reaction mix was added into one vial of cells and 
mixed gently without pipetting up and down. The vial was left on ice for 30 
minutes. Afterwards the cells were heat shocked for 30 seconds in a water bath 
equilibrated to 42°C and then transferred immediately to ice. 250 ?l of room 
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temperature SOC medium was added to the tubes and, after closing tightly, they 
were shaken horizontally (200 rpm) for 1 hour at 37°C in a shaking incubator.  
 
2.8.3 Plating bacteria 
 
Antibiotic selection plates were prepared in advance. A 400 ml bottle of LB 
(Luria-Bertani) broth [1% (w/v) tryptone, 0.5% (w/v) yeast extract and 1% (w/v) 
sodium chloride] with 1.5% (w/v) agar was microwaved at low power until the agar 
melted. After cooling to approximately 60°C, 400 ?l of 100 mg/ml Ampicillin was 
added. The solution was poured into 10 cm Petri dishes (10 ml/dish) within a 
sterile area close to a bunsen flame and was left to set. The plates were stored at 
4°C.  
 
For blue/white colony screening, 40 ?l of 40 mg/ml X-gal in 
dimethylformamide (DMF) was spread on the top of the selective agar plate 30 
minutes before plating the bacteria. 50 ?l of transformed cells were plated on pre-
warmed selective plates and incubated upside down overnight at 37°C. 
 
2.8.4 DNA Miniprep 
 
The following day 10 white colonies per plate were picked using separate 
pipette tips, which were then ejected into universal tubes containing 5 ml of LB 
broth supplemented with 100 ?g/ml of Ampicillin. The cap on the universal tube 
was closed loosely, taped shut and the tubes were shaken (200 rpm) at 37°C 
overnight. Clare Hall Media Production Services (CRUK) supplied the bacterial 
medium. 
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2.8.5 PCR identification of positive clones 
 
To confirm that the transformation was successful, a diagnostic PCR 
reaction was performed using MegaMix in 20 ?l reaction volume with 1 ?l of 
miniprep culture. To ensure DNA release, bacteria were lysed in a first step by 
heating the reaction mix to 94°C for 10 minutes.  
 
Reaction mix:  18.8 ?l   MegaMix 
   0.1 ?l  3’primer (100mM stock) 
   0.1 ?l  5’primer (100mM stock) 
   1 ?l  miniprep sample 
 
The reaction was performed with the following programme: 
 
PCR-programme: Initial Denaturation 10 min 94
o
C  
   Denaturation  30 sec 94
o
C 
   Annealing  30 sec 60
o
C          35 cycles 
   Extension  45 sec 72
o
C 
Final Extension  10 min 72
o
C 
 
2.8.6 Plasmid extraction 
 
The bacterial cultures from identified positive miniprep clones were 
harvested by centrifugation at 10,000 rpm for 10 minutes at room temperature, 
and the plasmid DNA was isolated using the QIAprep Spin Miniprep Kit 250 
(Qiagen). The QIAprep miniprep procedure is based on alkaline lysis of bacterial 
cells followed by adsorption of DNA onto silica in the presence of high salt. The 
procedure consists of three steps: preparation and clearing of a bacterial lysate, 
adsorption of DNA onto the membrane, followed by washing and elution of 
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plasmid DNA. Bacteria are lysed under alkaline conditions in NaOH/SDS (Buffer 
P2) in the presence of RNase A. SDS solubilises the phospholipid and protein 
components of the cell membrane, leading to lysis and release of the cell 
contents, while the alkaline conditions denature the chromosomal and plasmid 
DNAs, as well as proteins. The lysate is neutralised and adjusted to high-salt 
binding conditions by the addition of Buffer N3. The high salt concentration causes 
denatured proteins, chromosomal DNA, cellular debris, and SDS to precipitate, 
while the smaller plasmid DNA renatures and stays in solution. Such prepared 
samples are ready for purification on the silica membrane by selective adsorption 
of plasmid DNA in high-salt buffer and elution in low-salt buffer. Only DNA is 
adsorbed on the membrane, while RNA, cellular proteins, and metabolites are 
found in the flow-through. Then, endonucleases are removed by a brief wash with 
Buffer PB and salts are removed by a wash with Buffer PE. High-quality plasmid 
DNA is then eluted from the column with 50 - 100 ?l of Buffer EB or water.  
 
DNA concentration was determined by using a NanoDrop ND-1000 
photospectrometer (NanoDrop Technologies, USA). Samples were measured at 
260 nm and EB Buffer was used as a blank control. Samples were stored            
at -20°C. 
 
2.9 Sequencing 
 
2.9.1 Routine sequencing 
 
For routine sequencing of TOPO constructs, in order to confirm both 
sequence and orientation, samples (400 - 800 ng of template plasmid DNA per 
reaction) were sent to the Genome Centre (QMUL).  
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2.9.2 Mutation screening sequencing  
 
 Genomic DNA extracted from SCC cell lines was sequenced in a search 
for point mutations within FGFR2. Primers were designed within introns, 
approximately 50 bp up- and downstream from the exons of interest. These were 
amplified by PCR (conditions as described above), and the PCR products cloned 
into TOPO vector as described. Purified plasmid DNA was sequenced using 
Cancer Research UK, London Research Institute sequencing services. 
 
2.9.2.1 Labelling  
 
BigDye Terminator v3.1 Cycle Sequencing Kit was used for DNA labelling.  
 
Reaction mix:   3.7 ?l   5? buffer 
0.5 ?l   BigDye Terminator Mix 
1 ?l   3.3 ?M Forward or Reverse Primer 
       1 ?l    200 ng plasmid DNA  
13.8 ?l  sterile water 
 
The reaction was performed with the following programme: 
 
 PCR-programme: Denaturation  1 min 96
o
C  
   Denaturation  30 sec 96
o
C 
   Annealing  15 sec 50
o
C          25 cycles 
   Extension  4 min 60
o
C 
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2.9.2.2 Precipitation of labelled products  
 
After the labelling reaction, 2 ?l of Sodium acetate (3 M pH 5.2), 2 ?l of 
EDTA (125 mM stock concentration) and 50 ?l of 100% Ethanol were added to 
each sample. This was mixed and incubated at room temperature for 30 minutes 
prior to centrifugation for 20 minutes at 14,000 rpm at room temperature. 
Afterwards the supernatant was discarded and the pellet was washed in 1 ml of 
70% Ethanol. Samples were centrifuged for another 15 minutes, the supernatant 
was discarded and the pellet was air-dried.  
 
2.10 Cell lysis and Western blotting 
 
2.10.1 Cell Lysis 
 
Cultured cell monolayers were grown to 65-80% confluence. The media 
from the cells was aspirated off and the culture dishes were placed on ice. The 
monolayer was washed twice with ice cold PBS and lysed with radio 
immunoprecipitation assay (RIPA) Lysis buffer supplemented with 2 mM Sodium 
orthovanadate, 10 mM NaF, 1mM PMSF and 1:100 dilution of protease inhibitor 
cocktail for 2 minutes on ice.  
 
After lysis, cells were scraped, transferred to Eppendorf tubes and passed 
through a 25G gauge needle 20 times with a 1 ml syringe. Lysed cells were 
incubated on ice for a further 10 minutes and then centrifuged at 10,000 rpm for 
10 minutes at 4°C. The supernatant was then stored at –20°C.  
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2.10.2 Determination of protein concentration 
 
Protein concentration for each sample was determined using the Bio-Rad 
DC Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA, USA), as follows: 5 ?l 
of each sample was mixed in a 96-well microtitre plate with 200 ?l of Bio-Rad 
reagent B and with 25 ?l of a solution obtained by mixing 1 ml of reagent A with 20 
?l of reagent S. Protein standards were prepared by diluting a 5 mg/ml solution of 
BSA in lysis buffer to obtain solutions of a concentration of 2, 1.6, 1.2, 0.8, 0.4, 
0.2, 0.1 and 0 mg/ml. 5 ?l of each standard in duplicate was incubated with Bio-
Rad reagents as described above. After 15 minutes incubation at room 
temperature, protein concentrations were read using an Anthos 2001 plate reader 
(Anthos Labtec Instruments, Austria) 96-well microtitre plate spectrophotometer 
set at a 650 nm wavelength.  
 
2.10.3 Gel electrophoresis 
 
 1mm thick NuPAGE 4-12% Bis-Tris polyacrylamide gels were used for 
Western blot analysis of FGFR2 and p-ERK1/2 proteins. Gels were run in an X 
Cell SureLock gel tank (Invitrogen, Paisley, UK) using 1x NuPAGE MES SDS 
Running Buffer. Equal amounts of protein from all the tested cell lysates were 
mixed with 4x NuPAGE LDS sample buffer, supplemented with 50 mM DTT, that 
breaks disulphide bonds creating reducing conditions, boiled for 3 minutes at 
100ºC and centrifuged at 10,000 rpm for 3 minutes. The sample supernatants and 
Full Range Rainbow Molecular Weight Marker were then loaded onto the gel and 
run at 130 V for 1.5-2 hours, after which the gel was prepared for Western blotting.  
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2.10.4 Western blotting 
 
Western blotting is a technique that separates proteins according to their 
molecular weight, and is used to analyse the expression levels of proteins, which 
are recognised via the binding of specific antibodies. For the detection of specific 
proteins, electrophoretically separated proteins were transferred onto a 
nitrocellulose membrane. After blocking of non-specific binding sites, the 
membrane was incubated with the primary antibody and the corresponding 
secondary antibody, coupled to an enzyme that catalyses the detection reaction. 
 
The resolved gel, after cutting off the wells and the bottom of it, was laid on 
a Protran nitrocellulose transfer membrane of equal dimensions to the gel and 
sandwiched between 2 pieces of 3MM Whatman Chromatography paper. Air 
bubbles were removed by rolling a glass tube over the “sandwich”, which was then 
assembled in an X Cell II Blot Module transfer apparatus following the 
manufacturer’s instructions. The gel was immersed in transfer buffer (0.72 g Tris-
base, 3.6 g Glycine, 100 ml Methanol brought to 500 ml with distilled water). 
Proteins ranging in size from 30-90 kDa were transferred at 12 V overnight. 
Afterwards, membranes were stained with Ponceau S Solution to check the quality 
of the transfer. The dye was washed away in distilled water. 
 
2.10.5 FGFR2 Western blot 
 
40 ?g of total protein from normal human keratinocytes and SCC cell line 
lysates were loaded onto 1 mm thick NuPAGE 4-12% Bis-Tris polyacrylamide 
gels. After transfer the membrane was blocked in 5% milk in 0.01% Tween in PBS 
(PBS-T) for 1 hour, washed three times x10 minutes in PBS-T and then incubated 
overnight at 4°C with a rabbit polyclonal anti-FGFR2 antibody, diluted 1:2000 in 
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3% BSA in PBS-T solution. The following day the blot was washed three times in 
PBS-T and incubated for 1 hour at room temperature with an HRP conjugated 
polyclonal goat anti-rabbit antibody diluted 1:1000 in 3% BSA in PBS-T. Following 
three washes in PBS-T, the blot was incubated with ECL reagent. 
Chemiluminescence was detected by exposure to Fuji medical X-Ray film. 
Afterwards, the membranes were stripped by incubating in Re-Blot Plus Mild 
Solution for 20 minutes at room temperature.  
 
After stripping previous antibody, membranes were blocked again in 5% 
milk solution, washed as previously described and then incubated with different 
antibodies. Mouse monoclonal ?-Tubulin antibody was used to determine protein 
loading. 
 
2.11 Genomic DNA extraction from cell monolayers 
 
Cultured cell monolayers were grown to 80% confluency. The media from 
the cells was aspirated off and the cells trypsinised as described below. The cell 
suspension was transferred into a 15 ml falcon tube and centrifuged 5 min at 
5,000 rpm. The supernatant was removed, the cell pellet resuspended in PBS and 
washed twice with 10 ml PBS, centrifuging between washes. Afterwards, the pellet 
was resuspended in 800 ?l of tissue digestion buffer (as described above) and 5 ?l 
of Proteinase K (50 ?g/?l) was added. The sample was incubated overnight at 
37°C in a shaking incubator. The following day the sample was transferred into a 2 
ml Eppendorf tube and 960 ?l of Phenol was added. It was vortexed and left to 
stand for 5 minutes and vortexed again followed by centrifugation for 10 min at 
maximum speed. The upper aqueous phase was transferred into a fresh tube and 
the volume was measured. Phenol/Chloroform equal to the volume of the aqueous 
phase was added and the sample mixed and centrifuged as above. The aqueous 
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phase was transferred into a fresh tube and 1/10 the volume 3 M Sodium acetate 
(pH 5.2) and 3 times the volume 100% Ethanol was added. The sample was 
shaken gently until the DNA precipitated out and then was centrifuged as above. 
The DNA pellet was washed in 70% Ethanol, centrifuged and after the supernatant 
was removed it was air-dried, dissolved in EB buffer and placed in a shaking stage 
incubator for a two hours at 37°C. Finally the DNA concentration was measured as 
described previously. 
 
2.12 Southern Blotting 
 
Southern blotting is a technique, developed by Edwin M. Southern in the 
1970s, to determine the presence of a particular sequence of DNA within a DNA 
sample (Southern, 1975). It involves electrophoresing digested DNA fragments on 
an Agarose gel and then transferring them to a nylon membrane by capillary 
action. Once immobilised, the DNA can then be allowed to hybridise with a 
radioactive probe corresponding to the region of interest. 
 
Firstly, 10 ?g genomic DNA was digested with an appropriate restriction 
enzyme in 50 ?l reaction volume.  
 
Digest mix:  10 ?g   DNA 
   5 ?l  10x buffer 2  
   2 ?l  HindIII enzyme (20 units/?l) 
   1 ?l  sample 
   0.125 ?l Spermidine (1M stock) 
   0.5 ?l  BSA 
   6 ?l  RNase A (1mg/ml stock) 
   the volume was made up to 50 ?l with sterile, distilled water 
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The samples were incubated at 37°C, vortexing three times per hour. After 
two hours another 2 ?l of restriction enzyme was added and the samples were left 
at 37°C overnight.  
 
The following day, samples were prepared for electrophoresis by adding 
10 ?l of x5 GelPilot DNA Loading Dye and run on 0.8% Agarose/TBE gel (as 
described above) at 70 V for seven hours. Molecular weight ladder (Hyperladder I) 
was loaded alongside as a reference. 
 
The gel with the separated genomic DNA fragments was photographed 
with a ruler next to it, in order to measure the distance from the wells to bands of 
interest. The gel was depurinated in 0.25 N HCl for 15 minutes with gentle rocking. 
The acid was neutralised by rinsing the gel in 0.4 M NaOH briefly for 5 minutes. 
 
The gel containing the denatured DNA was assembled in a blot to transfer 
DNA to a positively charged nylon membrane. A gel tray was placed upside-down 
in a buffer chamber filled with 0.4 M NaOH. A piece of Whatman 3MM paper was 
placed on top of the tray with its edges immersed in the transfer buffer, thus 
forming a wick. The Agarose gel was placed upside-down on top of this platform, 
followed by nylon membrane (Nytran SuPerCharge) pre-soaked in water and 
marked in the top right-hand corner. Saran wrap was used to seal the edges of the 
membrane. Three layers of wet Whatman 3MM paper cut to the gel size were laid 
on top of the membrane. Each time a new layer was added a glass tube was 
rolled on top of it to remove any trapped air bubbles. A stack of paper towels and a 
glass plate were assembled with a 200 g weight on top and the DNA was left to 
transfer overnight by capillary action.   
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The next day, the transfer setup was disassembled and the nylon 
membrane removed and rinsed twice in 2x SSC for 5 minutes. The membrane 
was put between two new sheets of 3MM paper and left to air dry for 2 hours. If it 
was not used immediately it was stored between filter papers. 
 
2.12.1 ES cells screening probe preparation  
 
The 5’Fgf22 (400-bp) and 3’Fgf22 (600-bp) probes were isolated from 
Fgf22pBluescript SK+ plasmid construct by digesting with BamHI, HindIII, and 
EcoRI enzymes respectively. 
  
5’ Construct Digest mix: 4 ?g   DNA 
   5 ?l  10x BamHI buffer 
   0.5 ?l  BSA (100x) 
   4 ?l  BamHI enzyme (20 units/?l) 
   the volume was made up to 50 ?l with sterile, distilled water 
 
3’ Construct Digest mix: 4 ?g   DNA 
   5 ?l  10x EcoRI buffer 
   2.5 ?l  HindIII enzyme (20 units/?l) 
2.5 ?l  EcoRI enzyme (20 units/?l) 
   the volume was made up to 50 ?l with sterile, distilled water 
 
The samples were incubated at 37°C for 2 hours. The digested products 
were separated using gel electrophoresis and photographed (as described 
earlier). The desired bands were cut out and eluted from the gel by using a 
QIAquick gel extraction kit (Qiagen) as described in the protocol. The gel slice was 
melted in the provided solution and subsequent steps were performed as 
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described above. Dependent on the concentration of the fragment, the product 
was eluted in 20-50 ?l EB buffer. 
 
2.12.2 Probe Labelling  
 
Ready-To-Go DNA Labelling Beads (dCTP) were used to prepare the 
radio- labelled probe for the Southern Blot analysis. The beads contain buffer, 
dATP, dGTP, dTTP, FPLCpure Klenow Fragment and random 
oligodeoxyribonucleotides. 50 ng of the purified DNA probe was diluted to a 
volume of 45 ?l with distilled water. This was heated to 95°C for 3 minutes to 
denature the DNA, and then quickly moved to ice for 2 minutes. The sample was 
centrifuged briefly and then transferred into the labelling bead mixture in an 
Eppendorf tube where 5 ?l of [?-32P] dCTP was added. The whole mixture was 
incubated for 30 minutes at 37°C. 
 
The 32P-labelled probe was purified using a MicroSpin G-25 Column. First, 
the resin in the column was resuspended by vortexing, then the bottom tab of the 
column was snapped off, the column placed in a 1.5 ml Eppendorf and centrifuged 
for 1 minute at 3,000 rpm. The labelled probe was added and the column was 
centrifuged again for 2 minutes at 3,000 rpm, collecting the flow through 
containing the purified, labelled probe. This was boiled for 3 minutes and 
transferred to ice immediately. The contents of the tube were collected by brief 
centrifugation. 
 
2.12.3 Hybridisation 
 
To block non-specific binding, the membrane was pre-hybridised for 30 
minutes at 55°C in 5 ml of the pre-warmed hybridisation buffer (15% HYB or 
 89 
Church Buffer: 0.2 M Sodium phosphate mix [pH 7.2], 1 mM EDTA [pH 8], 1% 
BSA, 7% SDS, 15% Formamide in water) in a glass tube in a Micro-4 hybridisation 
oven (Hybaid, Teddington, UK). 40 ?l of the 32P-labelled probe was added to the 
solution and hybridisation allowed to proceed at 60°C overnight. 
 
The membrane was washed three times for 30 minutes at 65°C in wash 
buffer (40 mM sodium phosphate mix pH 7.2, 1 mM EDTA pH 8, 1% SDS in 
water). While still wet, the membrane was covered in Saran wrap and exposed to 
a storage phosphor screen (Molecular Dynamics, USA). After overnight exposure 
the screen was read by a phosphor image scanner (Storm 860 – Molecular 
Dynamics, USA). 
 
2.13 Tissue fixation and wax embedding 
 
Tissue fixation and subsequent wax embedding are routine histological 
techniques for morphological studies. The fixation has the purpose of preserving 
the structure and components of the tissue. This is the first and critical step of a 
protocol before the sections for microscopy could be obtained.  
 
2.13.1 Eye dissection 
 
Mice were killed by cervical dislocation and the eyes were carefully 
removed with the help of fine watchmaker forceps. The optic nerve was preserved 
together with the eye, for orientation, and the complete tissue was placed in cold 
PBS. After eyeball dissection, tissues were fixed in a solution of 4% of 
Paraformaldehyde (PFA), pH 7.4 for 24 hours at 4oC, then the tissues were 
washed twice in PBS for 30 min. Tissues were put in a new tube with PBS and left 
overnight at 4oC.  
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2.13.2 Oesophagus and stomach dissection 
 
Maximal length of the oesophagus, reaching from trachea to stomach, was 
dissected out and rinsed in cold sterile PBS pH 7.4. The tissue was then fixed in 
99% Ethanol plus 1% Glacial Acetic Acid overnight at 4oC. The next day tissue 
was washed twice in 70% Ethanol and then stored in Ethanol until further 
processing. 
 
 
 
 
 
Figure 2.4 Drawing of the stomach, ventral aspect (Biology of the Laboratory Mouse, The 
Jackson Laboratory). 
 
Stomach and 5 mm proximal duodenum were cut open along the greater 
curvature (Fig 2.4) and flushed gently with cold, sterile PBS pH 7.4. The tissue 
was gently stretched, pinned and immersed in 10% Neutral Buffered Formalin 
(NBF) overnight (Figure 2.5). The tissue was rinsed in 70% Ethanol, and three 
longitudinal vertical strips were cut as illustrated in Figure 2.5. The Experimental 
Pathology Department, Cancer Research UK provided support with tissue 
sectioning. 
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Figure 2.5 Stomach and proximal duodenum were cut and pinned open prior to fixation 
(Ruehl-Fehlert et al., 2003). Three strips were taken as indicated by the numbers on the 
picture. 
 
2.14 Tail epidermis whole-mounts 
 
To prepare whole-mounts of mouse tail epidermis, a scalpel was used to 
slit the tail lengthways. Skin was peeled from the tail, cut into pieces (0.5x0.5 cm2) 
and incubated in 5 mM EDTA in PBS at 37°C for four hours. Forceps were used to 
gently peel the intact sheet of epidermis away from the dermis and the epidermal 
tissue was fixed in 1% Acetic Acid and 95% Ethanol overnight at 4°C. After rinsing 
in 100% Ethanol, they were rehydrated through a graded alcohol series to water 
and transferred to PBS. Then the specimens were counterstained for 10 seconds 
in a 1:4 dilution of Mayer's haemalum/water and mounted in 30% Glycerol in PBS.  
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2.15 Immunohistochemistry 
 
Immunohistochemical staining was performed on formalin-fixed paraffin 
embedded (FFPE) sections to determine the localisation of specific proteins in 
tissue sections. Negative controls were always performed, where sections were 
incubated with just secondary antibody. 
 
2.15.1 ?-FGFR-2 antibody 
 
Paraffin-embedded human skin and tumour sections (4 ?m) were 
subjected to immunostaining using the streptavidin-peroxidase technique. All the 
incubation steps were performed in an humidified chamber.  
 
Formalin-fixed paraffin embedded (FFPE) sections were deparaffinized by 
soaking slides in Xylene twice, each time for 15 minutes. Sections then were 
rehydrated through incubation for 5 minutes at each concentration of an Ethanol 
gradient: 100% I, 100% II, 95%, 90%, 80%, 70%, 50% and twice in distilled water. 
Next, endogenous peroxidase activity was blocked by incubation for 30 minutes 
with 0.3% Hydrogen peroxide in Methanol. Slides were washed in PBS twice, 2 
minutes each time. Afterwards individual sections on slides were circled with a 
PAP pen.  
 
For antigen retrieval, slides were incubated with pre-warmed Pepsin Digest 
ALL-3 solution for 5 minutes at 37°C in an humidified chamber. Slides were 
washed twice in PBS, 2 minutes each time, and Avidin solution was applied for 10 
minutes at room temperature. Slides were washed as above, then Biotin solution 
was applied for 10 minutes at room temperature. Slides were washed and 
incubated for 15 minutes with 10% normal goat serum in PBS at room 
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temperature to block non-specific antibody binding. Tissue sections were 
incubated for 16 hours at 4°C with polyclonal ?-FGFR-2 antibody diluted 1:1000 in 
1% BSA in PBS. Negative controls were also performed where sections were 
incubated with rabbit ?-IgG antibody, 1:1000 dilution or just secondary antibody. 
 
The following day, slides were washed in PBS, and in the meantime 
streptavidin-peroxidase complex mix (StreptABComplex/HRP),  [1 ml TBS + 1 ?l 
reagent A +1 ?l reagent 2] was prepared, mixed and left on ice for 30 minutes 
prior to use. 
 
Bound antibodies were detected with biotinylated goat anti-rabbit IgG 
secondary antibody (1:500 dilution in 1% BSA in PBS). Tissue sections were 
incubated for 30 minutes at room temperature and then washed in PBS. Sections 
were then treated with streptavidin-peroxidase complex for 30 minutes. 
Afterwards, slides were washed and Diaminobenzidine (DAB substrate) [1 drop of 
chromogen in 1 ml of substrate buffer] was applied for 5 minutes. The slides were 
washed in running water for 2 minutes and then stained in Mayer’s haematoxylin 
for 90 seconds in order to counter stain the nuclei. The slides were washed in 
running tap water for 1 minute, then in PBS for 1 minute and finally in filtered 
water. Afterwards slides were dehydrated through an Ethanol series into Xylene 
(as above but in reverse order). The stained slides were mounted on coverslips 
using Permount mounting medium. 
 
2.15.2 ?-BrdU antibody 
 
Paraffin sections were de-waxed as described earlier (2.15.1).  
To block endogenous peroxidase activity, the slides were immersed in 1.5% 
Hydrogen peroxide in Methanol for 15 minutes. After washing in PBS slides were 
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incubated in 1N HCl at 60°C for 8 minutes to allow DNA denaturation. Next, slides 
were incubated twice for 10 minutes in 70% Ethanol/0.1M Tris pH 7.5 and washed 
twice in 70% Ethanol for 5 minutes. Slides were rinsed briefly in dH2O and washed 
in PBS twice for 10 minutes. Individual sections on slides were circled with a PAP 
pen and anti-BrdU antibody solution (1:500 dilution in 1% BSA/PBS) was applied. 
Samples were incubated with the antibody for 1 hour at room temperature in an 
humid chamber.  
 
Afterwards, slides were washed in PBS twice for 10 minutes and incubated 
with secondary goat anti rat antibody solution (1:100 dilution in 1% BSA/PBS) for 
45 minutes at room temperature. Slides were washed in PBS twice for 10 minutes. 
Streptavidin-peroxidase complex mix was prepared as described previously and 
left for 30 minutes on ice before use. Sections were then incubated for 45 minutes 
at room temperature with the ABC solution. Afterwards, slides were washed in 
PBS twice for 10 minutes, rinsed in tap water for 5 minutes and DAB substrate 
was applied for 3 minutes. From then on slides were treated as described 
previously (2.15.1).  
 
2.15.3 ?-p63 antibody 
 
Paraffin sections were de-waxed as described earlier (2.15.1).  
Endogenous peroxidase activity was blocked by 40 minutes incubation in 1.5% 
Hydrogen peroxide in Methanol. After washing in PBS twice for 2 minutes slides 
were microwaved (900W; medium setting) for 20 minutes in 10 mM Sodium citrate 
buffer solution [pH 6] to allow antigen retrieval. Slides were left at room 
temperature to cool, then washed in PBS for 3 minutes. Individual samples on 
slides were circled with a PAP pen and Avidin/Biotin block was applied as 
described previously. After washing in PBS twice for 2 minutes non-specific 
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binding was blocked by applying M.O.M. Mouse Ig Blocking Reagent for 1 hour at 
room temperature. Later, slides were washed in PBS twice for 2 minutes and 
incubated in prepared M.O.M. Diluent for 5 minutes. Excess solution was tipped 
off and 1:50 dilution of the mouse primary monoclonal anti-p63 antibody was 
applied.  
 
The next day, streptavidin-peroxidase complex mix was prepared and left 
on ice for 30 minutes prior to use. Slides were washed in PBS twice for 2 minutes 
and then working solution of M.O.M. Biotinylated Anti-Mouse IgG Reagent was 
applied for 10 minutes. Slides were washed in PBS twice for 2 minutes then 
incubated in ABC solution for 45 min at room temperature. After another three 5 
minute washes in PBS, DAB substrate was applied for 8 minutes. From then on 
slides were treated as described previously (2.15.1).  
 
2.15.4 ?-Loricrin antibody  
 
Paraffin sections were de-waxed as described earlier (2.15.1).  
To allow antigen retrieval slides were microwaved (900W; medium setting) for 20 
minutes in 10 mM Sodium citrate buffer solution [pH 6]. Afterwards slides were left 
to cool to room temperature (about 15 minutes) and then rinsed twice in PBS. 
Non-specific binding was blocked by incubating sections with 5% BSA/PBS at 
room temperature for 1 hour. Then primary rabbit anti-Loricrin antibody solution 
(1:500 in 5% BSA/PBS) was applied overnight at 4°C. The next day, three 10 
minute PBS washes were performed and secondary goat anti-rabbit rhodamine 
conjugated antibody solution (1:100 in 5% BSA/PBS) was applied and incubated 
for 1 hour in the dark at room temperature. After another three 10 minutes PBS 
washes, also in the dark, and a quick rinse in dH20, slides were mounted with 
Vectashield mounting media with DAPI (Vector Laboratories).  
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2.15.5 ?-Keratin14 antibody  
 
Paraffin sections were de-waxed as described earlier (2.15.1).  
Endogenous peroxidase activity was blocked by 40 minutes incubation in 1.5% 
Hydrogen peroxide in Methanol. Slides were then washed twice for 2 minutes in 
PBS and individual sections were circled with a PAP pen. Avidin solution was then 
applied for 10 minutes at room temperature. Slides were washed as above and 
Biotin solution was applied for 10 minutes at room temperature. Slides were 
washed and incubated for 1 hour with 5% BSA/PBS at room temperature to block 
non-specific antibody binding. Meanwhile, primary antibody solution was prepared 
(1:1000 in 5% BSA/PBS) and centrifuged for 5 minutes at 13,000 rpm at 4°C. 
Tissue sections were incubated overnight at 4°C with polyclonal rabbit anti-mouse 
K14 antibody.  
 
The next day, slides were washed three times for 5 minutes in PBS and 
1:100 dilution of a secondary goat anti-rabbit antibody in blocking solution was 
applied. Sections were incubated for 45 minutes at room temperature. From then 
on slides were treated as described previously (2.15.1).  
 
2.16 Alcian Blue and Alizarin Red skeletal staining  
 
The combination of Alcian Blue and Alizarin Red allows a differential 
staining of cartilage and bone (Green, 1952). In the process of staining cartilage 
becomes blue while the bone gains red colour. Treatment with Potassium 
hydroxide (KOH) and Glycerol dissolves muscle and connective tissue but spares 
stained tissues resulting in a clear picture of skeletal structure.  
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Whole mice, including the tails, were skinned and all their internal organs 
were removed. Any excess fat, especially behind the neck and between clavicles, 
also was removed. The carcasses were then left to fix in 95% Ethanol for 3 days 
at room temperature. Afterwards the skeletons were placed in Alcian Blue staining 
solution (below) for 14 days on a shaker to ensure even staining. Staining solution 
was replaced with 95% Ethanol for 1-2 days. The tissue on skeletons was then 
cleared in 1% KOH for several days. Afterwards the skeletons were put into fresh 
1% KOH with Alizarin Red staining solution (below) on a shaker for 1-3 days. 
When evenly stained, the skeletons were drained and put into 100% Glycerol. 
Glycerol was replaced twice before staining was completed. 
 
Alcian Blue staining solution   Alizarin Red staining solution 
4 volumes of 95% Ethanol   Make 1% KOH in water 
1 volume of Acetic acid    Add alizarin red powder to 
0.015% Alcian Blue 8GX   1% final concentration. 
Stir for 30 minutes, do not filter.   Dissolve well, do not filter. 
 
2.17 Sirius red staining 
 
 In bright-field microscopy, Sirius red stains collagen fibres in red on a pale 
yellow background. Nuclei, if stained, are black, grey or brown. The same slides, 
when examined through a microscope with cross-polarised light show that the 
larger collagen fibres (Collagen type I) are bright yellow or orange, and the thinner 
ones, including reticular fibres and collagen type III, are green. The birefringence 
is considered to be highly specific for collagen fibres. Keratohyaline granules and 
some types of mucus, for example, also stain red but do not display any 
birefringence. The principle of the method is that collagen forms the ground 
substance of connective tissue and it is composed of three amino acids. It stains 
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strongly with acid red dyes due to the affinity of the cationic groups of the proteins 
for the anionic reactive groups of the acid dyes. 
 
 Paraffin sections were de-waxed and hydrated as described earlier (2.7.1.). 
Sections were stained in Picro-sirius red (below) for one hour, then washed in two 
changes of acidified water (below). Most of the water from the slides was removed 
by vigorous shaking, sections were dehydrated in three changes of 100% Ethanol, 
cleared in Xylene and mounted.  
 
Picro-sirius red     Acidified water 
0.5 g Sirius Red F3B      5 ml Glacial Acetic Acid 
500 ml of saturated aqueous   995 ml of water 
solution of Picric Acid            
Add a little solid picric acid  
to ensure saturation. 
 
2.18 ELISA 
 
The type of ELISA performed was a Sandwich ELISA. It is based, 
sequentially, on binding of leptin in the sample by a pre-titred antiserum and 
immobilisation of the resulting complexes in the wells of a microtitre plate. After 
washing, purified biotinylated detection antibody is allowed to bind to the 
immobilised leptin followed by binding of streptavidin conjugated horseradish 
peroxidase (HRP) to the immobilised biotinylated antibodies. Quantification of 
immobilised antibody enzyme conjugates takes place by monitoring (HRP) activity 
in the presence of the substrate 3,3’,5,5’-tetramethylbenzidine (TMB). The enzyme 
activity is measured spectrophotometrically by the increased absorbancy at 450 
nm, corrected from the absorbancy at 590 nm, after acidification of formed 
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products. Since the increase in absorbency is directly proportional to the amount 
of captured leptin in the unknown sample, the latter can be derived by interpolation 
from a reference curve generated in the same assay with reference standards of 
known concentrations of mouse leptin. 
 
2.18.1 Sample collection and storage  
 
To prepare serum samples, whole mouse blood was directly drawn into a 
centrifuge tube that contained no anti-coagulant. Blood was left to clot at room 
temperature for 30 minutes and then samples were centrifuged at 7,000 rpm for 
15 minutes at 4°C. Serum supernatant was removed, aliquoted and stored at -
20°C for later use. 
 
2.18.2 Assay procedure 
 
All the reagents were pre-warmed to room temperature immediately before 
use. The 10x concentrated HRP wash buffer was diluted 10 fold by mixing the 
entire contents of both buffer bottles with 900 ml distilled water. Each well of the 
assembled microtitre assay plate was washed 3 times – each time with 300 μl of 
diluted wash buffer. Wash buffer was then decanted and the residual amount from 
all wells was removed by inverting the plate and tapping it onto absorbent towels. 
30 μl of Assay Buffer was added to background wells, standard wells, and QC1 
and QC2 wells, while 40 μl of assay buffer was added to sample wells. Then, 10 μl 
of matrix solution was added to the background wells, standard wells, and QC1 
and QC2 wells. Next 10 μl of assay buffer was added to the background wells and 
10 μl of mouse leptin standards was added, in duplicates, in the order of 
ascending concentration to the appropriate wells. Next, 10 μl of QC1 and 10 μl of 
QC2 was added to the appropriate wells. Finally 10 μl of the unknown samples 
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were added sequentially in duplicate to the remaining wells, followed by 50 μl of 
antiserum solution, added to each well used in the assay. The plate was covered 
with a plate sealer and incubated at room temperature for 2 hours on an orbital 
plate shaker set to rotate at moderate speed. Following this incubation, the seal 
was removed, solutions decanted from the plate as described before, and wells 
were washed 3 times with diluted wash buffer (300 μl per well per wash). Next, 
100 μl of detection antibody was added to each well and the plate was sealed and 
incubated with moderate shaking at room temperature for 1 hour. As before, the 
seal was removed, solutions decanted and wells were washed 3 times with diluted 
wash buffer (300 μl per well per wash). Then, 100 μl of enzyme solution was 
added to each well. The covered plate was incubated with moderate shaking at 
room temperature for 30 minutes. After 6 washes were performed as described 
above, 100 μl of substrate solution was added to each well and the covered plate 
was left for approximately 10 to 15 minutes, upon which a blue colour developed 
in the wells of leptin standards (with intensity proportional to increasing 
concentrations of leptin). Colour development was monitored by using 370 nm 
filter on the spectrophotometer. When the absorbance was between 1.2 and 1.8 at 
370 nm, the stop solution was added to terminate the colour development. 100 μl 
of stop solution was added and the plate was shaken by hand to ensure complete 
mixing of solution in all wells. This resulted in change of blue colour into yellow 
after acidification. The absorbance was read at 450 nm and 590 nm in a plate 
reader within 5 minutes and the difference of absorbance units was recorded. 
 
2.19 Basic cell culture 
 
 Routine tissue culture provides a core facility for the development, 
maintenance and provision of cultured cells. Cultured cells must be provided with 
an appropriate surface for attachment, promoting cell seeding and spreading, 
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presence of exogenous serum containing the necessary nutrients, and culture 
conditions that enable an adequate mass transfer of nutrients and oxygen along 
with waste removal.   
 
2.19.1 General principles 
 
 Cell culture treatments were carried out in a laminar flow hood which 
provided a sterile environment. The hood was decontaminated with 70% Ethanol 
before and after each work session. All tissue culture reagents were filter-sterilised 
using a 0.22 μm syringe-driven or vacuum driven filters (Millipore, Watford, UK) 
and stored in a sterile container at 4°C. Upon use, media was pre-warmed in a 
37°C water bath. Cells were grown in an humidified atmosphere, appropriate CO2 
levels and temperature was maintained in incubators.  
 
2.19.2 Tissue culture media and solutions 
 
2.19.2.1 CR-UK stock media 
 
Cancer Research UK Central Services supplied many of the buffers and 
media that were used. These included PBS, Trypsin-Versene, E4, normal DMEM, 
Hams-F12, Pen/Strep, L-Glutamine. 
 
2.19.2.2 Human SCC keratinocyte medium 
 
E4 and Hams-F12 3:1 volume supplemented with 10% Foetal calf serum, 
L-Glutamine and 0.4 ?g/ml Hydrocortisone, 10-10 M Cholera toxin, 5 ?g/ml 
Transferrin, 2x10-11 M Liothyronine, 1.8x10-4 M Adenine, 5 ?g/ml Insulin and 10 
ng/ml hEGF. All of the above mentioned are final concentrations. 
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2.19.2.3 Early passage HaCaT keratinocyte medium 
 
E4 supplemented with 10% Foetal calf serum and Pen/Strep (100 ?g/ml). 
 
2.19.2.4 Primary murine keratinocyte media 
 
PCT Epidermal Keratinocyte Medium calcium free (CnT-07CF) including 
provided supplements together with 8% calcium free Foetal calf serum (South 
American Origin) and Pen/Strep (100 ?g/ml). Additionally, calcium concentration in 
low calcium media was 0.05 mM and 1.3 mM in high calcium media.  
 
2.19.2.4.1 Preparation of calcium free FBS 
 
 100 g of Chelex-100 resin was mixed with 400 ml of dH20 using a magnetic 
stirrer. Next the solution was adjusted to pH 7.4 with 4 M HCl and the liquid was 
carefully decanted without disturbing the pellet. The resin slurry was transferred 
into 500 ml of FBS and stirred at room temperature for 3 hours. Afterwards, FBS 
was carefully decanted, filtered through 0.22 μm pore size filter, aliquoted and 
stored at -20°C.  
 
2.19.3 Mycoplasma screening 
 
As a precaution, routine mycoplasma PCR-based screening was 
performed for all cell lines. This PCR detects mycoplasma by amplification of 16S 
– 23S spacer region in rRNA operons. Sequences of primers included are 
common to 14 different species of mycoplasma. 
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After a minimum of two days culturing, growth medium was collected into a 
50 ml falcon tube and centrifuged for 5 minutes at 4500 rpm. Most of the 
supernatant was removed, leaving only 500 ?l. The pellet was resuspended by 
repeated pipetting up and down and 1 ?l was added to the PCR mix. Nested 
PCRs were carried out using MegaMix in a reaction volume of 20 ?l. A positive 
control of medium known to be contaminated with mycoplasma was always 
performed alongside with a negative control with all the mix components except 
the supernatant sample.  
 
Reaction mix:  17.7 ?l   MegaMix 
   0.5 ?l  FWD 1 primer (100 pmol/?l) 
   0.5 ?l  Common REV primer (100 pmol/?l) 
   0.3 ?l  Formamide 
   1 ?l  sample 
 
The following programme was used: 
 
PCR-programme: Denaturation  3 min 94
o
C  
   Denaturation  30 sec 94
o
C 
   Annealing  30 sec 55
o
C          35 cycles 
   Extension  1 min 72
o
C 
   Final Extension  10 min 72oC 
 
1 ?l of the PCR product was used for sequential PCR with exactly the 
same conditions as described above apart from different forward primer used in 
the reaction mix. 
 
The first round of PCR amplified a 720 bp fragment. The second nested 
PCR reaction primers amplified a 145 bp fragment. 
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2.19.4 Early passage HaCaT keratinocyte cell culture 
 
 Early passage HaCaT keratinocytes were a gift from Petra Boukamp, 
DKFZ, Germany. To avoid rapid loss of cells via differentiation, they were neither 
passaged too often nor split at too high a ratio. At confluence (or postconfluence, 
optimum 3 to 4 days past confluence), cells were pretreated with 0.05% EDTA in 
PBS to disassemble desmosomes. The cells were incubated at 37°C until wide 
intercellular spaces were visible microscopically (up to 20 minutes). EDTA was 
aspirated off and 3 ml of a 1:1 mixture of EDTA and Trypsin solution was added 
(final concentrations 0.025% and 0.05%, respectively). Cells were incubated at 
37°C for 2 to 5 minutes until they came off the plastic culture dish upon shaking. 
Complete culture medium with 10% FCS was added to stop Trypsin activity and 
the cell solution was transferred to a 15 ml falcon tube and centrifuged for 3 
minutes at 1,200 rpm. Afterwards the supernatant was aspirated off and the cells 
were resuspended in complete culture medium with 10% FCS and plated at 
maximal split ratio of 1 in 10. The medium was changed every 2 days and the 
optimal time between passages (7 to 10 days) was maintained. 
 
2.19.5 Primary murine keratinocyte cell culture 
  
Primary keratinocytes were isolated from dorsal skin and tails of adult 
mice. The skin area chosen to obtain keratinocytes should be in the resting phase 
(telogen) of the hair cycle, meaning that shaven hair reveals pink skin without dark 
patches, if the mice are on an agouti background. 
 
Mice aged one to three months were killed by cervical dislocation. The hair 
from the dorsal skin of the mouse was removed with clippers and depilatory cream 
(Nair) was applied onto hair-free surface for approximately 3 minutes. Afterwards, 
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excess depilatory cream was removed with cotton gauze and the mice were 
washed under running water with gentle rubbing. The mice were transferred into 
the tissue culture hood, where they were washed twice for 2 minutes in Iodine 
solution, rinsed in sterile water and finally in 70% Ethanol. Mice were placed in 
Petri dishes, their skin was cut from torso to tail and peeled off using scissors and 
forceps. Skin was also removed from tails. Removed skin was placed, epidermis 
side down, on a sterile surface (rough underside of an autoclaved porcelain spot 
plate) and the hypodermis was carefully scraped off using a scalpel blade. Next 
the skin was stretched flat and a piece of autoclaved Whatman no. 1 filter paper 
was applied onto the exposed surface of the dermis. The skin, including the 
attached paper, was cut into 1 cm wide strips using sterile scissors and placed 
dermis side down on the surface of recently thawed 1% Trypsin in PBS (back skin) 
or 0.25% Trypsin in PBS (tail skin). Back skin was incubated with the Trypsin for 2 
hours at 37oC and tail skin was left in the solution overnight at 4oC. The epidermis 
was easily peeled off using curved forceps and placed into ice cold PCT 
Epidermal Keratinocyte Medium containing high calcium concentration. Collected 
epidermis was then cut and minced in the medium with sterile scissors, until 
pieces were small enough to enter the tip of a 10 ml pipette. The resulting 
suspension was then triturated by pipetting up and down about 30 times. 
Afterwards it was transferred into a 50 ml conical tube, also kept on ice, leaving 
most of the stratum corneum squames behind. The cell suspension was then 
centrifuged at 1,450 rpm for 5 minutes. The cell pellet was resuspended in high 
calcium medium and filtered through a 100 ?m cell strainer into a new 50 ml 
conical tube. The cell strainer was rinsed with additional dose of high calcium 
medium to release cells entrapped by remaining stratum corneum pieces. Another 
centrifugation step was performed at 1,450 rpm for 5 minutes and the cell pellet 
was resuspended in 10 ml of high calcium medium. The cells were counted, then 
centrifuged again and resuspended in the desired volume of low calcium medium 
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to obtain cell concentration of 1 to 1.25 million cells/ml. Next, the cells were plated 
in Collagen I coated 60 mm dishes (3 ml of cell suspension containing 
approximately 3 million cells).  
 
Primary keratinocytes were incubated at 36°C and 7% CO2 overnight. The 
next day, the medium containing unattached cells was aspirated off, the dish was 
rinsed with calcium/magnesium free PBS and fresh low calcium media was added. 
Thereafter cells were fed every other day.  
 
2.19.5.1 Coating flasks for keratinocyte cell culture 
 
Flask-coating Collagen I solution was prepared by combining 2.76 ml rat 
tail Collagen (3.6 mg/ml stock) with 0.23 ml Glacial Acetic Acid and 197.47 ml 
sterile dH2O. Routinely, a 3 cm dish was coated with 1 ml of coating solution and 
incubated for 30 minutes at 37°C. Afterwards, excess coating solution was 
aspirated off and the dish was washed twice with calcium/magnesium free PBS 
immediately prior to seeding cells.  
 
2.19.5.2 Passaging primary keratinocytes 
 
Primary keratinocytes were passaged when cells reached 70-80% 
confluence. Medium was removed and the cell monolayer was washed twice with 
calcium/magnesium free PBS. Then, 1% Trypsin was added and cells were 
incubated for 30 min at 36°C, 7% CO2. Once the cells detached, 5 ml of PCT 
Epidermal Keratinocyte low calcium medium containing 8% calcium free FCS was 
added to quench the trypsinisation. Cells were carefully resuspended, transferred 
to a 50 ml conical tube and centrifuged at 1,450 rpm for 5 minutes. Afterwards, the 
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cell pellet was resuspended in fresh medium and the cells were plated onto pre-
coated dishes at a 1:2 split ratio. 
 
2.19.6 Storage and recovery of liquid nitrogen stocks 
 
2.19.6.1 Cryopreservation of cultured cells 
 
Cultures can be preserved effectively in the presence of a cryoprotectant, 
such as dimethylsulphoxide (DMSO), which reduces the damage from ice crystals. 
Cells to be stored were harvested in log phase growth. Following trypsinisation, 
cells were washed in complete medium and resuspended in medium containing 
10% DMSO at 1-2x106 cells per ml. One ml of cell suspension was placed in a 
Nunc cryotube in an insulated container and placed at -80°C for 8 hours, before 
transferring vials to -196°C liquid nitrogen for long-term storage.  
 
2.19.6.2 Thawing cell stocks 
 
 Cryopreserved cells are fragile and require quick thawing and immediate 
retrieval into complete medium. Vials to be recovered from liquid nitrogen were 
placed in a water bath at 37°C to thaw rapidly. As soon as the vial contents were 
thawed the cell suspension was transferred to 15 ml Falcon tubes containing 10 ml 
of pre-warmed complete medium and centrifuged at 1,200 rpm for 3 minutes. The 
supernatant was removed to get rid of cryoprotectant and cells were resuspended 
in fresh full medium and transferred to culture dish or flask.  
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2.20 In vitro wound closure assay- Scratch assay 
 
 Primary keratinocytes derived from Fgf22 wild type and knockout mice 
were seeded at a density of 3 million cells per well in pre-coated 6-well plates. 
Cells were allowed to grow until the correct confluency was achieved, when the 
culture medium was aspirated off and the monolayer was washed with 
calcium/magnesium free PBS. Next, the cells were starved in low serum media 
(1% FBS) for 2 hours. Then, using a plastic 200 ?m pipette tip, scratches were 
made across and along each well forming a cross. The medium was aspirated off 
and replaced with normal PCT Epidermal Keratinocyte low calcium medium 
containing 8% calcium free FCS. To determine the rate of cell migration, a picture 
of each well at exactly the same point was taken at 0, 6, 12, 18 and 32 hours post-
wounding using Time-lapse microscope set up (Zeiss, Hertfordshire, UK). Time-
lapse microscopy allows to monitor changes in the amount and speed of cell 
migration in real-time. Scratch widths were measured at 20 points along their 
length using ImageJ software (National Institutes of Health, Bethesda, MD). The 
percentage of migration was determined relative to the scratch width at 0 hours. 
Experiments were performed in triplicate.  
 
2.21 Organotypic co-culture 
 
Figure 2.6 Schematic representation of a skin organotypic. 
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Human foreskin fibroblasts (HFF), immortalised human skin keratinocytes 
(HaCaT) and human SCC keratinocytes cell lines were used for organotypic co-
culture (Fig 2.6). Protocol for co-culture was adapted from (Stark et al., 2004). 
Collagen type I (3.49 mg/ml, Upstate) was mixed with 0.1% Acetic acid and kept at 
4°C. The ice cold Collagen solution (80% of total volume, 4 mg/ml) was then 
mixed with 10x Hank’s salt with phenol red (10% of total volume) and adjusted to 
pH 7.4 by adding about 40 ?l of 2 M NaOH per 6 ml collagen mixture while gently 
stirring on ice to avoid air bubbles and premature gelation. The fibroblast number 
necessary for the desired concentration in the gel (3x105 per ml) was resuspended 
in FCS (10% of total volume) and added to the gel solution on ice under cautious 
stirring. With cooled pipettes aliquots of the collagen gel mixture were poured into 
a 24 well plate (1 ml per well). For gelation, plates were incubated for 1 hour at 
37°C in an humidified incubator. Afterwards, the gels were equilibrated by 
complete immersion in human SCC keratinocyte culture medium for 24 hours.  
 
The next day medium was removed and keratinocytes, at a density of 
1x106 in 1 ml of human SCC keratinocyte medium, were plated on top of the 
collagen structure. The keratinocytes usually attached within 12-24 hours and 
formed a nearly confluent layer on top of the collagen gel.  
 
The day after, co-cultures were raised to the air-liquid interface thus 
restricting nourishment to diffusion from below (Fig 2.6). This air-lift procedure was 
defined as the start of the culture time of organotypic co-cultures. Firstly, 
membrane discs coated with Collagen were prepared by cutting 100 ?m pore size 
membrane (Tetko Inc., USA) and autoclaving it. Sterile membrane pieces were 
coated with a Collagen mixture (7 volumes of Collagen I, 1 volume 10x Hanks salt, 
1 volume FBS, 1 volume medium) in a Petri dish and incubated for 15 minutes at 
37°C in an humidified incubator. Next, 1% Glutaraldehyde in PBS was added so 
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that the membranes were submerged in the solution. They were then incubated at 
4°C for 1 hour and washed 4 times in PBS. In the mean time autoclaved metal 
grids were placed in wells of a 6-well plate, followed by Collagen coated 
membranes. Carefully transferred collagen gels were placed on top of each 
construction and about 4.5 ml of culture medium was added so it just contacted 
with the lower part of the gel. Medium was changed every 2-3 days. Organotypic 
co-cultures were grown for 6 days. On the day of harvesting co-culture gels 
together with the membranes were washed twice in PBS and then fixed in 4% 
PFA overnight at 4°C. The next day gels were washed twice in PBS, transferred to 
labelled bijous containing 70% Ethanol and stored at 4°C ready for processing.  
 
2.22 Mouse growth curves  
 
Timed matings of 8 pairs of wild type and 8 pairs of knockout mice were 
set up. Starting from birth, male and female pups were weighed individually twice 
a week. After weaning, at 2.5-3 weeks, pups were ear marked and a weight record 
was kept for each individual pup, weighed twice a week throughout the 
experiment. Control and experimental animals were housed separately. 
Measurements were taken up to 5 months of age, and mice were fed normal 
mouse chow ad libidum throughout the experiment. 
 
2.23 In vivo wound healing 
 
The purpose of this experiment was to determine whether or not mice 
lacking FGF22 were able to heal cutaneous wounds. 4 week old female and male 
mice were used for the purpose of the experiment. Mice were housed in isolator 
cages of up to 3 mice. Control and knockout animals were housed separately.  
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All mice were anaesthetised using inhaled Halothane, prior to having their 
backs shaved with clippers. The dorsal skin was wiped clean with alcohol, and the 
mice given an injection (s.c) of Rimadyl analgesic (25 ?l per 25 g mouse). A fold of 
back skin was laid on a firm cushion of dental wax or cardboard and a clean 3 mm 
punch biopsy was used to make two full thickness skin wounds. Analgesic was re-
administered as above post-operatively. Mice were observed regularly. If at any 
stage the mice appeared in distress they were killed humanely. For 24 hours after 
the initial wounding, cages were lined with paper to avoid dust getting into the 
wound. For the remainder of the experiment, sawdust was used as bedding. 
 
At 0, 1, 5, 14 and 21 days after wounding, the wound healing process was 
examined. For each time point, 3 female and 3 male mice, both for wild type and 
knockout animals, were used. At the appropriate time point, mice were killed by 
anaesthetic overdose and cervical dislocation and the tissue was removed for 
histological analysis. One hour prior to sacrifice, mice were injected with BrdU. 
After termination, wounds were removed together with 2 mm of surrounding tissue 
and one wound per mouse was fixed in acetic ethanol fixative for pathological 
analysis. The other wound was snap-frozen in liquid nitrogen to allow RNA 
expression analysis. 
 
2.24 Topical administration of DMBA / PMA to mice 
 
The purpose of this experiment was to determine whether or not mice 
lacking FGF22 were more susceptible to developing skin tumours than wild type 
littermates, following treatment with the carcinogen DMBA and the tumour 
promoter TPA.  
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Female mice used for the purpose of the experiment were divided into four 
cohorts, 10 mice in each, at seven weeks of age. Within two groups of wild type 
mice, one was treated with Acetone (vehicle only control) and the other with 
DMBA in the initiation step. The same experiment set up was used for knockout 
animals. All the mice were treated with TPA in the promotion step. Mice were 
housed in isolator cages of up to 5 mice. Control and experimental animals were 
housed separately. For 48 hours after the initial DMBA treatment, cages were 
lined with paper to avoid the production of contaminated dust. 
 
Prior to the experiment, all mice had their backs shaved using clippers. 
After 8 days, 1 mg of DMBA (25 ?g x 20 mice plus 500 ?g extra) in the labelled, 
sealed container was supplied to the animal house facility. It was then diluted in 8 
ml acetone (200 ?l acetone per 25 ?g of DMBA). Then it was checked whether the 
hair had not re-grown on mice thus confirming that their hair follicles were in the 
resting phase of the hair cycle (telogen). Afterwards, 200 ?l working strength 
DMBA per mouse was applied for two mice groups - one wild type and one 
knockout. As a control, other two mice groups (wild type and knockout) had just 
200 ?l Acetone administered. These treatments, and the subsequent TPA 
treatments, were done under yellow light. At day fifteen (one week after initial 
painting), aliquots of TPA stock solution (100x stock = 6 mg dissolved in 1620 ?l 
DMSO) were supplied as 100 ?l aliquots in a screw cap tube (enough for 50 x 200 
?l applications, after adding to 10 ml Acetone). Mice in all the groups were given a 
7.4 ?g dose of TPA dissolved in 200 ?l Acetone and applied to their back with a 
dedicated syringe. These procedures were performed by Robert Rudling in the 
Clare Hall Laboratories Animal Facility.  
 
From day 15 onwards, all the mice were given weekly doses of TPA, as 
described above. Throughout the experiment animals were monitored for the 
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appearance of papillomas and tumours. If possible, one hour prior to killing, mice 
were injected with BrdU. After death, tissues of interest (papillomas / tumours / 
lymph nodes) were removed and either fixed in NBF or frozen and embedded in 
optimal cutting temperature compound (OCT).  
 
2.25 Micro CT 
 
 Animals, killed by anaesthetic overdose, were imaged on a 
NanoSPECT/CT scanner (Bioscan, Paris, France). The scanner uses an X-ray 
source and a detector system, which are mounted on a gantry that rotates around 
a bed holding the animal. The animals were scanned with an X-ray tube voltage of 
45 kVa. Data were acquired at 1° angular increment over 360°, producing 360 
views. Each frame was exposed for 1,500 ms with ultra fine frame resolution. This 
protocol gave a total scan time of 49 minutes. CT images were reconstructed 
using InVivoScope 1.39 program.  
 
2.26 Ethical regulations 
 
 All animals were used in accord with United Kingdom Home Office 
regulations. Human skin tissue was obtained from people undergoing surgery, 
following informed consent and approval of the study (obtained by Dr Catherine 
Harwood, ICMS, QMUL).  
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CHAPTER 3: Fibroblast growth factor 22 
 
3.1 Introduction 
 
3.1.1 Fgf22 expression profile 
 
Fgf22 is a relatively recently identified, and understudied, member of the 
FGF family of growth factors. Its cDNA was isolated for the first time in 2001 by 
Nakatake et al. from human placenta and mouse skin (Nakatake et al., 2001).  
 
In mouse embryonic development, expression of Fgf22 was not detected 
until quite late in gestation – embryonic day 16.5 (E16.5 – with full term being 20 
days) (Beyer et al., 2003), but the authors did not look for expression earlier than 
E9.5. Another group, looking at earlier stages of embryonic development, reported 
that Fgf22 mRNA transcripts were found in the unfertilised mouse egg, morula and 
early blastocyst (E3.5) as well as in mouse trophoblast stem cells (TSCs) (Zhong 
et al., 2006). Furthermore, Fgf7 mRNA transcripts were absent in pre-implantation 
embryos (Taniguchi et al., 1998) and Fgf10 mRNA was detected in mouse eggs 
and pre-implantation embryos, but not in mouse TSCs or human trophoblast 
placental cells, suggesting that the embryonic mRNA might be from maternal 
transcripts, still present in the inner cell mass cells, or produced by differentiated 
trophectoderm (Zhong et al., 2006).  
 
In the adult mouse, Fgf22 expression, examined by Northern blot analysis, 
was detected in the skin and brain, but not various other organs including heart, 
kidney, spleen, thymus, liver, stomach, intestine, lung and testis (Nakatake et al., 
2001). A different group, using RNase protection assay for expression analysis, 
reported Fgf22 expression in the epidermis, tongue, and brain, but again not in 
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heart, kidney, spleen, liver, stomach, intestine, uterus, skeletal muscle or lung 
(Beyer et al., 2003).  
 
3.1.2 FGF signalling in hair follicle morphogenesis 
 
By in situ hybridisation, Fgf22 mRNA in the skin was found to be 
expressed preferentially in the inner root sheath (IRS) of the hair follicle (Nakatake 
et al., 2001). Therefore, Fgf22 was predicted to play a role in hair development. As 
discussed later, all FGF7 subfamily members have been reported to affect this 
process. During hair development, signals from the dermal papilla to the bulge 
follicular stem cells induce epidermal cell differentiation during anagen to produce 
a keratinised hair fibre (Fig 3.1). The dermal papilla is a specialised cluster of 
mesenchymal cells within the dermis and its signalling stimulates stem cells to 
proliferate and differentiate into IRS, medulla and cortex cells, which together with 
the cuticle cells terminally differentiate into the mature hair fibre (Schlake, 2005). 
The IRS can be divided into three layers: the cuticle, Huxley layer and Henle layer, 
based on structure, patterns of keratinisation and incorporation of trichohyalin. The 
IRS stops at the level of the sebaceous gland to leave only the hair cortex and 
surrounding cuticle to protrude above the epidermis (Fig 3.1). 
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Figure 3.1 Diagram of the structure of a hair and its growth cycle (adapted from 
www.keratin.com and www.face2facemk.co.uk). 
 
 A single hair follicle undergoes successive growth cycles. The hair growth 
cycle describes the changing morphology of the shaft, grossly, and the follicle, 
histologically, over time. The four major stages of the cycle are: anagen (the 
period of active growth), catagen (the period of cessation of the growth and 
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regression), telogen (the period of relative inactivity) and exogen (the event of the 
old hair fiber shedding) (Fig 3.1) (Plikus and Chuong, 2008).  
 
FGF7 and FGF10 are expressed in the dermal papilla of the hair follicle 
(Rosenquist and Martin, 1996) and, as mentioned previously, FGF22 is expressed 
in the inner root sheath of the hair follicle (Nakatake et al., 2001). Interestingly, 
Fgf7 knockout mice display an abnormal hair phenotype – greasy, matted hair of 
unkempt appearance in older male mice (Guo et al., 1996). Also, transgenic mice 
that overexpress Fgf7 in the epidermis demonstrate abnormal patterns of hair 
growth (Guo et al., 1993), and subcutaneous or intraperitoneal injections of 
recombinant FGF7 into nude mice stimulate hair growth by extending the anagen 
phase of the hair cycle (Danilenko et al., 1995). Furthermore, treatment with FGF7 
significantly stimulates hair fibre elongation in human scalp hair follicle organ 
cultures (Iino et al., 2007). Since both Fgf10 and Fgfr2b knockout mice die at birth, 
their hair phenotype is harder to study (Suzuki et al., 2000). Nevertheless, 
examination of late stage Fgfr2IIIb knockout embryos revealed a reduction in hair 
follicle development, producing significantly fewer hair follicles which were 
developmentally retarded (Revest et al., 2001). Given the neonatal lethal 
phenotype of these mice, Petiot et al. examined full-thickness skin grafts from late-
stage Fgfr2IIIb null and wild type foetuses, grown on the back of nude mice, and 
showed that FGFR2b signalling was crucial for normal epidermal growth and 
development as well as for subsequent hair follicle morphogenesis (Petiot et al., 
2003). Transgenic mice expressing dominant-negative Fgfr2IIIb in differentiating 
hair keratinocytes developed abnormally thin, but otherwise normal, hairs 
characterised by single columns of medulla cells in all hair types (Schlake, 2005). 
Mice lacking Fgfr2b only in the epidermis developed similarly thin and silky pelage 
hair (Grose et al., 2007). Taken together, these studies show a clear requirement 
for FGFR2b in normal hair follicle morphogenesis.  
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Of the other members of the FGF family, FGF5 is expressed in the outer 
root sheath (ORS) of the hair follicle (Hebert et al., 1994). Fgf5 knockout mice 
grew significantly longer hair due to prolonged anagen and delayed catagen 
during the hair cycle, displaying an angora phenotype (Hebert et al., 1994).  
 
Interestingly, there is a large variation in Fgf7, 10 and 22 mRNA 
expression throughout the hair cycle (which lasts about 21 days in mice) with both 
Fgf7 and Fgf10 expressed at highest levels at anagen V (day 8), when hair grows 
vigorously, and Fgf22 strong expression at anagen VI (day 18), when hair follicle 
length reaches its maximum and is eventually shed (Komi-Kuramochi et al., 2005). 
This pattern of expression resembles, to some extent, the one found during the 
wound healing process (Beyer et al., 2003).  
 
3.1.3 FGFs in wound healing 
 
FGFs 7, 10 and 22 have been implicated in the wound healing process. 
FGF7 is produced by various types of mesenchymal cells and acts specifically on 
epithelial cells expressing the only known high-affinity receptor for the ligand - 
FGFR2IIIb. FGF7 is weakly expressed in normal murine and human skin, but upon 
injury the expression is hugely up-regulated (Werner et al., 1992). FGF10 levels 
also are increased rapidly following wounding (Tagashira et al., 1997) and levels 
of both growth factors decline once re-epithelialisation is complete.  
 
In contrast, FGF22 expression declines during the first days after wounding 
and remains low until day 5 after injury. Subsequently, the expression increases 
above basal levels at day 7 after wounding and remains elevated until day 13, 
being localised to the hyperthickened epidermis of fully healed wounds (Beyer et 
al., 2003). These findings have been confirmed by another group, who reported 
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that Fgfs 7, 10 and 22 were all strongly expressed in the skin of young mice. 
However, following wounding, only Fgf7 and Fgf10 mRNA expression increased, 
while expression of Fgf22 mRNA declined to approximately half its level in healthy 
skin (Komi-Kuramochi et al., 2005). Somewhat surprisingly, considering the above 
findings, the healing process of full-thickness incisional wounds in Fgf7 knockout 
mice was not obviously affected and the proliferation rate of the keratinocytes at 
the wound edge was not impaired (Guo et al., 1996). This was unexpected, since 
transgenic animals expressing a kinase-deficient, dominant-negative FGFR2b 
revealed a severe delay in wound re-epithelialisation of full-thickness excisional 
wounds, when at day 5 after injury, the number of proliferating keratinocytes in the 
hyperproliferative epithelium was 80–90% reduced compared with control mice 
(Werner et al., 1994). The mutant receptor blocked signal transduction upon ligand 
stimulation by forming non-functional heterodimers between mutated receptors 
lacking functional tyrosine kinase domain and full-length wild type receptors. The 
truncated FGFR2b thus inhibited actions of FGF7, FGF10, FGF1 and FGF3. The 
most likely explanation for impaired wound healing in these mice was a blockade 
of the redundancy in ligand signalling and FGF10 compensation effect. Supporting 
this hypothesis, a significant delay in wound re-epithelialisation was seen in mice 
lacking dendritic epidermal T cells (DETC) – an important source of FGF7 and 
FGF10 in the healing wound (Jameson et al., 2002). Moreover, Fgf10 and Fgfr2b 
null mice, among many others, share a notable phenotype of eyes remaining open 
at birth. This is due to a failure of the eyelid epidermis to cover the eye during late 
embryogenesis, in the equivalent of a developmental wound healing model (Tao et 
al., 2005). Interestingly, epidermal specific Fgfr1/2 double knockout mice are 
characterised by the same phenotypic changes as the dominant-negative Fgfr2b 
mutant mice (Sabine Werner – personal communication) thus emphasising further 
the importance of FGFR signalling in skin homeostasis. 
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Treatment of injured epithelia with FGF7 results in an improved wound 
healing response (Werner, 1998) and recombinant FGF7 already is in use in the 
clinic for the treatment of chemoradiation-induced oral mucositis. Palifermin, an N-
terminally truncated form of FGF7 with increased stability, is an approved drug for 
the treatment of chemoradiation-induced oral mucositis in patients undergoing 
bone marrow transplantation (Spielberger et al., 2004). When administered on 3 
consecutive days before high-dose chemotherapy, as well as for 3 days following 
haematopoietic stem cell transplantation, Palifermin reduced the median duration 
of mucositis from 9 to 6 days, and reduced the incidence of grade 4 mucositis from 
62% to 20%. This corresponds with a significant improvement in patient quality of 
life (Spielberger et al., 2004).  
 
3.1.4 FGFs in the brain 
 
FGF signalling is also known to be essential for brain development. It has 
been shown that at least 14 FGFs and all four FGF receptors are expressed in the 
developing or mature nervous system. Members of the FGF7 subfamily are 
involved in the process of brain development as well. FGF22, along with FGF7 
and FGF10, is a presynaptic organiser with roles in vesicle clustering and neurite 
branching (Umemori et al., 2004). In the developing brain, Fgf22 transcripts are 
present in both the external and internal granule cell layer of the cerebellum at 
postnatal day 7 (Yaguchi et al., 2009). Fgf22 expression is not found at other 
developmental stages. FGF7 is expressed at high levels by Purkinje cells, while 
both FGF7 and FGF10 are expressed at very low levels by granule cells from 
post-natal day 8. All three members of the FGF7 subfamily exhibit presynaptic 
organising activity, with FGF22 reportedly expressed by specific neuronal 
populations during the period when they develop synapses. FGF22 is thought to 
affect synaptic development of mossy fibres and presynaptic differentiation in the 
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cerebellar granule layer of the brain. Inactivating FGF22 or its receptor FGFR2 
markedly reduced synapse formation between pontine axons and cerebellar 
granule cells, both in culture and in developing mice, indicating that FGF22 is a 
crucial presynaptic organiser in the cerebellum (Umemori et al., 2004). Secreted 
from cerebellar granule cells, it recruits axons projected from pontine and 
vestibular neurons expressing FGFR2b. In other words, FGF22-FGFR2b 
signalling organises synapse formation by inducing axon projection toward FGF22 
secreting cells. 
 
 Unexpectedly, during the process of Fgf22 knockout mouse 
characterisation, I discovered that the gene plays a role in metabolism and can 
affect body weight. Not much is known about FGFs contribution to control of 
metabolism and up till recently only FGF21 seemed to be involved in the process. 
In fact, pharmacologic studies show that FGF21 has broad metabolic actions in 
obese rodents and primates that include enhancing insulin sensitivity, decreasing 
triglyceride concentrations, and causing weight loss (Kliewer and Mangelsdorf, 
2010). What makes FGF21 different from FGF22 is the fact that it can diffuse 
away from its tissues of origin and function as hormone, whereas FGF22 is 
thought to act in autocrine manner, not to mention that the pattern of tissue 
expression between those two FGFs is utterly different. Interestingly though, latest 
findings on FGF7 suggest that this well-established paracrine growth factor can 
stimulate adipogenesis in autocrine fashion (Zhang et al., 2010). Additionally, due 
to its spatialtemploral expression in the hypothalamus, FGF5 is thought to be 
involved in regulation of feeding behavior (Li et al., 1999).  
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3.1.5 Other sites of Fgf22 expression 
 
Recently, Fgf22 expression was reported in bone. Together with Fgfs 2, 7 
and 18, Fgf22 mRNA was detected in the perichondrium and growth plate of rat 
long bones. Moreover, levels of Fgf22 expression increased with age and 
decreasing growth velocity when assayed by quantitative real-time RT-PCR 
(Lazarus et al., 2007). 
 
Fgf22 expression was also detected in the retina of the eye by cDNA 
microarray analysis (Takeuchi et al., 2008). The group investigated the effect of 
nilvadipine, a calcium channel blocker, upon the retina of the retinal degeneration 
slow mouse (peripherin 2 mutant) and found increased expression of FGF22 after 
treatment. The retinal degeneration slow mouse is a model of retinitis pigmentosa 
- a group of heterogeneous diseases of inherited retinal degeneration 
characterised by night blindness, constricted visual field or ring scotoma, and 
bonespicule like pigmentation of the retina (Jansen and Sanyal, 1984). 
Interestingly, strong expression of fibroblast growth factor binding protein 1 
(mentioned in more detail later) was also detectable by immunohistochemical 
analysis in the eye, particularly in the retina, outer plexiform layer, ciliary body, 
rods, and cones (Aigner et al., 2000). 
 
 
 
 
 
 
 
 
 124 
Tissue Age  Author 
embryo E0 – E3 
E16.5 
(Zhong et al., 2006) 
(Beyer et al., 2003) 
skin epidermis 
inner root sheath of the hair follicle 
hyperthickened epidermis of healed 
wounds 
7 weeks 
P1 
8 weeks 
(Komi-Kuramochi et al., 2005) 
(Nakatake et al., 2001) 
(Beyer et al., 2003) 
tongue unspecified (Beyer et al., 2003) 
brain 
cerebellum 
unspecified 
P7 
P8 
(Nakatake et al., 2001) 
(Yaguchi et al., 2009) 
(Umemori et al., 2004) 
retina of the eye 14 weeks (Takeuchi et al., 2008) 
bone P7 (Lazarus et al., 2007) 
  
Table 6 Fgf22 expression profile.  
 
 
3.1.6 Properties of FGF22 protein 
 
Murine FGF22, which shows 87% amino acid identity to the human 
sequence, consists of 486 nucleotides that encode a protein of 162 amino acids 
with a calculated molecular mass of 19 kDa (Beyer et al., 2003) (Fig 3.2). It shares 
46% amino acid identity with FGF10 and 40% identity with FGF7 (Nakatake et al., 
2001). 
 
 
 125 
 
 
Figure 3.2 Amino acid sequence comparison of human and mouse FGF22. 
 
Although much is known about the Fgf22 expression pattern, bizarrely it is 
not clear whether FGF22 is a secreted protein. On one hand FGF22 has an 
hydrophobic amino terminus of about 20 amino acids, which is a typical signal 
sequence, so it is thought to be secreted (Fig 3.2) (Nakatake et al., 2001). On the 
other hand, the protein lacks a consensus sequence for N-terminal glycosylation, 
which is in contrast to FGF7 and FGF10 and is a feature of most secreted FGFs 
(Beyer et al., 2003). Also, in transiently transfected COS-1 cells (monkey kidney 
origin, fibroblast-like) with an HA-tagged Fgf22 construct, FGF22 could not be 
detected in conditioned medium, even after a 50-fold concentration of the 
supernatant and addition of heparin to the culture medium (Beyer et al., 2003). 
Contrastingly, cells transfected with Fgf7 and Fgf10 expression constructs readily 
secreted those growth factors into the culture medium (Beyer et al., 2003). Others 
reported that FGF22, with a putative N-terminal signal peptide, remains attached 
to the cell surface rather than being secreted (Itoh and Ornitz, 2004). However, 
there was an account of a stably transfected BHK (baby hamster kidney) cell line 
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secreting FGF22 into culture medium (Zhang et al., 2006). It is also speculated 
that FGF22 remains bound to 34 kDa fibroblast growth factor binding protein 1 
(FGFBP1), which is a molecule described as typically associated with cell 
membrane proteoglycans. Thus, following secretion, FGF22 could quickly be 
immobilised by FGFBP1, only to be released at a later time, or aided by FGFBP1 
in its interaction with FGFR2b (Beer et al., 2005). 
 
Subcellular localisation of FGF22 protein is also not clear and seems to 
depend on the cell type. In MCF-7 cells (human breast adenocarcinoma), FGF22 
appears to be localised predominantly to large nuclear bodies, characteristic of the 
nucleolar localization seen with some other FGFs, such as FGF1, FGF2 and 
FGF3. However, in COS-1 cells, FGF22 was reticular and perinuclear, as 
expected for association with the ER/Golgi network and similar to the subcellular 
localization of FGF7 (Beyer et al., 2003). 
 
 By investigating an Fgf22 total knockout mouse model I wanted to 
contribute to a better understanding of the diversity in FGF signalling and function, 
especially in skin development and homeostasis. 
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3.2 Results 
 
3.2.1 Generation of Fgf22 knockout mice 
 
To generate mutant mice lacking Fgf22, an homologous recombination 
approach was taken, whereby key elements of the Fgf22 genomic sequence were 
replaced by a Neomycin selection cassette.  
 
The Fgf22 targeting construct was designed and prepared by Dr Richard Grose, 
such that homologous recombination eliminated the entire coding region of the 
Fgf22 gene (exons 1, 2 and 3). This coding region was replaced by a Neomycin 
resistance gene flanked by loxP sites cloned between approximately 5kb and 
1.2kb of upstream and downstream homologous genomic DNA sequence, 
respectively, from the murine Fgf22 locus (Fig 3.3). The homologous arms were 
generated by PCR amplification from genomic DNA isolated from 129/ola 
embryonic stem (ES) cells. After ES cell transfection and positive antibiotic 
selection, two G418-resistant clones were identified as homologous recombinants 
by Southern blot analysis after EcoRI digestion (Fig 3.4), using a probe external to 
the homologous sequence to confirm correct targeting.  
 
The two mutant clones were injected separately into C57Bl6/J blastocysts. 
Male chimaeric animals of at least 70% 129ola contribution (as judged by coat 
colour) were mated with C57Bl6/J females to obtain germline transmission. The 
heterozygous offspring of these mice were then mated to produce homozygous 
mutants, which occurred at the expected Mendelian frequency of 25%.  
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To identify the Fgf22 knockout mice, PCR genotyping was performed on 
ear snip or tail snip DNA with primers for the wild type (wt) allele generating a 
286bp product and null (ko) allele a 130bp product (Fig 3.5). 
 
In order to verify that the targeted homologous recombination resulted in 
abrogation of Fgf22 mRNA expression, total RNA was isolated from mouse brain, 
known to express Fgf22 at a detectable level. Following cDNA synthesis, PCR 
was performed using primers spanning exon1 and exon3 of the Fgf22 coding 
sequence. As expected, relative to control wild type mouse brain, Fgf22 mRNA 
expression was reduced in heterozygous brains and completely absent in 
knockouts (Fig 3.6).  
 
To check levels of Fgf22 mRNA expression in wild type mice, Real Time 
RT-PCR was performed. RNA was obtained from the oesophagus, a novel site of 
Fgf22 expression discovered during my characterisation of Fgf22 knockout mice. 
Real Time RT-PCR assay demonstrated a statistically significant difference 
(P<0.05) in relative Fgf22 mRNA expression levels between wild type male and 
female tissue with females expressing notably less of the growth factor (Fig 3.7). 
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Figure 3.3 Targeting strategy for the Fgf22 knockout mouse. The structures of 
the wild type allele and the disrupted allele are shown. In the wild type allele, 
exons 1 to 3 are represented by black boxes. E indicates EcoRI restriction enzyme 
recognition sites. The primers used for routine genotyping are represented by 
arrows.  
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Figure 3.4 Fgf22 Southern Blot. Total DNA extracted from ES cells was digested 
with EcoRI restriction enzyme and separated by electrophoresis on a 0.8% 
Agarose/TBE gel according to size. The DNA was blotted onto nylon membrane 
and hybridised overnight with a radioactively-labelled probe. The membrane was 
washed and exposed to a storage phosphor screen overnight. Clear bands at 
8.3kb and 6.2 kb (arrows) corresponding to the predicted size of the wild type and 
knockout fragment respectively can be seen in the last lane. A total of 192 ES 
clones was analysed and 2 scored positive for homologous recombination and 
displayed identical hybridisation patterns (data not shown). 
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Figure 3.5 Genotyping mice. PCR analysis of genomic DNA isolated from ear 
snips of 3 weeks old pups from an heterozygous breeding pair. Genotyping results 
determined the presence or absence of null (ko) and wild type (wt) alleles at the 
Fgf22 locus. WT (+/+) samples showed a single Fgf22 wt band at 286bp (mice 
nos. 1, 3, 4, 7 and 8), Fgf22 ko (-/-) displayed a single ko allele at 130bp (mouse 
no. 2) and heterozygous (+/-) samples amplified both wt and ko alleles (mice nos. 
5 and 6). 
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Figure 3.6 Confirmation of gene deletion. A) RT-PCR analysis of cDNA 
generated with random hexamers from RNA isolated from mouse brain. Results 
show the presence/absence of Fgf22 gene expression. Wild type (+/+) samples 
display a Fgf22 band at 286bp, Fgf22-heterozygous samples (+/-) display same 
size band whereas Fgf22 knockout (-/-) lack the presence of a correct size band. 
B) GAPDH primers display a single band at 297bp and were used as a control for 
RNA quality and concentration. Blank represents PCR reaction mix without cDNA. 
Experiment was carried out on 3 Fgf22 wild type, 3 Fgf22 heterozygous and 3 
Fgf22 knockout male mice. 
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Figure 3.7 Comparison of Fgf22 mRNA expression level in male and female 
wild type mice. mRNA levels of Fgf22 were determined by Real Time RT-PCR 
analysis performed on cDNA generated from mouse oesophagus RNA. There was 
a statistically significant difference (P<0.05) in relative levels of the growth factor 
expression, with GAPDH used as normalising control, when male and female 
tissue was compared. Experiments were carried out on 6 female and 6 male mice 
(n=6) and error bars represent standard error among the samples. 
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3.2.2 Characterisation of Fgf22 knockout mice 
 
Fgf22 knockout animals, born according to predicted Mendelian ratios, 
were viable and fertile. Knockout mice did not display any obvious gross 
abnormalities.  
 
Since FGF22 is a member of the FGF7 subfamily of FGF ligands, I 
examined expression of Fgfs 7 and 10 in knockout mice. Relative mRNA levels of 
Fgf7 were not altered and, Fgf10 levels were reduced in knockout male animals, 
when examined by Real Time RT-PCR (Fig 3.8). 
 
As FGF22 is both a ligand for FGFR2b and is expressed in the skin, I first 
performed a detailed analysis of those epidermal structures known to be altered in 
mice lacking Fgfr2b in the epidermis. There were no evident differences in pelage 
growth or sebaceous gland morphology between knockout and wild type mice. All 
the major hair types (zigzag, guard and awl) were present in knockout mouse skin 
and these hairs did not demonstrate any morphological differences when 
compared with those of wild type littermates (Fig 3.9). Whole-mount staining of the 
sebaceous glands in adult tail skin did not reveal any discernible differences 
between knockout and wild type mice (Fig 3.10). H&E stained sections of back 
and tail skin from wild type and knockout mice also appeared identical when 
examined histologically, in terms of epidermal, dermal and adipose thickness as 
well as hair follicle frequency (Fig 3.11).  
 
Since there were no obvious defects in the unchallenged skin of Fgf22 
knockout mice, I investigated their capacity to respond to skin injury and 
carcinogenic insult, both of which have been shown to depend at least in part on 
FGF signalling. Wound healing studies, where mice were subject to 3 mm 
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diameter full thickness punch biopsy wounds, showed that mice lacking Fgf22 in 
the skin were able to heal acute wounds just as efficiently as wild type mice, 
although 5 days after wounding knockout male wounds appeared to have healed 
faster (Fig 3.12A and 3.13A), with more efficient re-epithelialisation (Fig 3.13B) 
and a high rate of proliferation of cells involved in the process at this time-point 
(Fig 3.12B and 3.15). However, at all the other time-points during wound healing, 
morphometric analysis showed very similar values for both male and female Fgf22 
wild type and knockout animals (Fig 3.13 and 3.14). In addition, Sirius red staining 
of 14 and 21 day wounds demonstrated similar collagen fibre remodelling in 
healing wounds for male mice of both genotypes (Fig 3.16).  
 
By means of Real Time RT-PCR, fluctuations in FGF expression over the 
course of the wound healing process were followed (Fig 3.17). The relative levels 
of FGF22 mRNA expression increased during the course of wound closure, 
peaking at 14 days after wounding in wild type mice, when the wound already was 
healed. Interestingly, levels of Fgf7 mRNA expression mirrored the expression 
levels of Fgfr1b receptor whereas Fgf10 levels corresponded to those of its main 
receptor Fgfr2b. Moreover relative levels of Fgf7 and Fgfr1b were consistently 
high, while relative levels of Fgf10 and Fgfr2b were low. Nevertheless, in general, 
the expression levels of FGFRs and their ligands involved in wound healing 
process did not differ significantly between wild type and knockout mice.  
 
Concomitant with the wound healing study, conditions for the in vitro 
culture of primary keratinocytes were optimised. Isolated cells from wild type and 
knockout mice (Fig 3.18) were used for a simple 2D scratch wound assay. This in 
vitro assay complemented the in vivo study, proving that Fgf22 knockout 
keratinocytes were perfectly able to migrate towards the wound gap in order to 
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close it and there was no difference in the time of migration between the knockout 
and wild type animals (Fig 3.19). 
 
Finally, I challenged the mice with a classical two-step skin carcinogenesis 
assay using DMBA and TPA. These experiments were performed on female mice, 
since they involved long-term observation and multiple mice could be kept 
together. When cohorts of Fgf22 knockout female mice were subjected to two-step 
(DMBA/TPA) skin carcinogenesis treatment, they developed considerably less 
papillomas than wild type mice. Fgf22 wild type and knockout mice subjected to 
TPA treatment alone never developed papillomas (Fig 3.20). 
 
The only noticeable dissimilarity observed between unchallenged control 
and knockout animals concerned their body weight, with older Fgf22 knockout 
mice appearing much leaner than age matched wild type mice (Fig 3.21A). At 10 
weeks of age, Fgf22 knockout male mice fed on a regular mouse chow diet 
showed a significant reduction in body weight when compared with wild type male 
mice (Fig 3.21B). When a group of 66 mice in total (males and females) was 
followed over a 21-week period, the difference in male mouse weight was much 
more evident than in female mice, nevertheless female knockout mice weight also 
was reduced (Fig 3.22). Differences in the pattern of the growth curve became 
observable around the time of weaning (3-4 weeks). 
 
To investigate further the origin of this weight difference, Fgf22 expression 
was checked by RT-PCR in all the parts of the digestive system. Thus I 
discovered that the growth factor of interest was expressed at low levels in almost 
all the parts of the intestinal tract and at high levels in the oesophagus and 
stomach (Fig 3.23). The findings were validated by checking 3 more female and 
male mice of both genotypes. As expected the Fgf22 specific band was missing in 
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all knockout animal oesophagus RNA samples (Fig 3.24). Next, the morphology of 
knockout and wild type tissue sections was compared. No obvious differences in 
tissue appearance were observed. Moreover, a series of immunohistochemical 
staining (anti-p63, -K14 and -Loricrin) did not reveal any changes in expression 
pattern (Fig 3.25). Subsequently, the expression of Fgf22 in the forestomach and 
stomach was checked (Fig 3.26A), tissue morphology was examined (Fig 3.26B 
and C) and sections stained with antibodies specific to discrete stomach cell 
populations; anti-ATP4B for parietal cells (Fig 3.27), anti-Pepsinogen for chief cells 
(Fig 3.28) and anti-TFF1 antibody for pit cells (Fig 3.29). As previously, there were 
no dissimilarities observed between Fgf22 wild type and knockout tissue sections. 
I also checked serum leptin levels in Fgf22 wild type and knockout male mice by 
ELISA, but levels were not statistically different between the genotypes (Fig 3.30).  
 
During the process of Fgf22 knockout mouse characterisation, I found that 
Fgf22 was expressed in the eye (Fig 3.31). Once more, tissue morphology was 
checked (Fig 3.32) and at first glance there was no difference between the 
genotypes. Nevertheless, further investigation into the retina layers (Fig 3.33A) 
revealed changes in their thickness in knockout male mice (Fig 3.33B).  
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Figure 3.8 Evaluation of Fgf7 and Fgf10 mRNA expression levels in Fgf22 
wild type and knockout mice. Real Time RT-PCR analysis of cDNA generated 
from mouse oesophagus. The assay showed lack of significant effect on relative 
levels of Fgf7 mRNA in mouse tissue after Fgf22 deletion, although levels of Fgf10 
mRNA were significantly (P<0.05) reduced in male oesophagus. GAPDH primers 
were used for the normalising control. Experiments were carried out on 6 female 
and 6 male mice and error bars represent standard error among the samples. 
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Figure 3.9 Comparison of pelage hair structure. All major hair shaft types 
(zigzag, guard and awl) were present in both wild type and knockout animals. The 
morphology of different hair types showed no difference between Fgf22 wild type 
(A, C and E) and knockout (B, D and F) mice as shown by light microscopic 
analysis. Hairs were plucked from five 8-week old Fgf22 wild type mice (n=100 
hairs) and compared with hairs of Fgf22 knockout mice (n=100 hairs). Scale bar 
(200 ?m) identical for all pictures. 
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Figure 3.10 Normal sebaceous gland morphology. Tail epidermis whole-mount 
preparations from two and a half month old mice, stained with Mayer's haemalum, 
revealed no difference between Fgf22 wild type and knockout mice in terms of 
sebaceous gland number and morphology. Comparison was carried out on 5 
Fgf22 wild type and 5 Fgf22 knockout mice. (hair follicle is indicated by arrow and 
sebaceous gland by asterisk). 
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Figure 3.11 Skin structure. Histological analysis of H&E stained back (A, B) and 
tail (C, D) skin sections from 5 four month old Fgf22 knockout (B and D) and age-
matched 5 wild type (A and C) controls. No difference in skin thickness or 
morphology, neither in back skin (A and B) nor in tail skin (C and D), was 
observed. (EP epidermis, DE dermis, AD adipose tissue, PC panniculus carnosus, 
HF hair follicle, * sebaceous gland). Scale bar (200 ?m).  
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Figure 3.12 Wound healing in Fgf22 wild type and knockout male mice. A) 
Paraffin-embedded, acetic ethanol fixed tissue sections of 3mm punch biopsy 
wounds 5 days after wounding were stained with Haematoxylin and eosin. The 
morphology of wounds from 3 Fgf22 wild type and 3 knockout mice appeared very 
variable, but the re-epithelialised epidermis was usually thicker in knockout 
wounds. B) Tissue sections were immunostained for 5-bromo-2-deoxyuridine 
(BrdU)-positive cells (brown) at the wound site. (HE hyperproliferative epidermis, 
D dermis, G granulation tissue, BC blod clot. Wound margins are indicated by 
arrows). Scale bar (200 ?m) in A) and B) top panel; (50 ?m) in B) bottom panel. 
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Figure 3.13 Morphometric analysis of wound repair. Morphometric 
measurements of wounds were performed on Haematoxylin and eosin stained 
paraffin sections from three independent wounds for each genotype and each time 
point. A) The wound gap was calculated as the distance between two margins of 
the inward growing epithelium and was measured three times for each wound 
section. B) Tissue sections for each time point were also analysed to determine 
the area of epithelial tongue. Error bars represent SEM. 
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Figure 3.14 Granulation tissue area during wound healing. Graph represents 
mean values of the area of granulation tissue at all the time points checked after 
wounding. Two sections per wound, three mice per genotype were measured. 
Error bars represent SEM. 
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Figure 3.15 BrdU positive cell count. Mice were injected with BrdU one hour 
prior to culling. Number of proliferating cells was calculated from immunostained 
sections shown in figure 3.12B - sections from the entire wound were 
photographed and combined; the total number of BrdU positive cells per total 
wound were counted. Plots show mean of three independent wounds per 
genotype per time point where two slides per wound were counted. Error bars 
represent SEM. 
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Figure 3.16 Sirius red staining of Fgf22 wild type and knockout male mice 
wounds at day A) 14 and B) 21 post-wounding. At day 14 after wounding, 
epithelial regeneration was completed. Wounds were fully healed with a dense 
and mature multilayered epithelium. At both time points, granulation tissue showed 
organised, parallel bundles of collagen fibres. In both A) and B) top and bottom 
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panels represent the same section in bright field and dark field, respectively, 
stained with Sirius red. By means of histochemical reaction with collagen 
molecules, Sirius red enhances the normal birefringence of collagen types I, II, III 
and IV. Under polarised light, the colour of stained collagen varies as a function of 
the structural and biochemical properties of the collagen fibres. The spectrum of 
colours includes green, yellow, orange and red in a progressive way according to 
the packing of collagen molecules. (HE=hyperproliferative epidermis, D=dermis, 
G=granulation tissue, HF=hair follicle; wound margins are indicated by arrows). 
Scale bar (200 ?m).  
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Figure 3.17 Real Time RT-PCR based comparison of Fgf22, Fgf7, Fgf10, 
Fgfr1b and Fgfr2b expression in Fgf22 wild type and knockout male mice 
during wound healing. Total RNA was extracted from wound tissue and 265ng of 
RNA was subjected to Real Time RT-PCR analysis. Values were normalised to 
the corresponding values of the GAPDH housekeeping gene for individual 
samples. Plots represent mean of three wound samples for each genotype. Error 
bars represent SEM. 
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Figure 3.18 Primary cell culture. Primary keratinocytes were isolated from tail 
skin of Fgf22 wild type and knockout mice aged 2 months. Keratinocytes were 
cultured in vitro for up to 3 passages, then RNA was extracted from the cell 
monolayer and RT-PCR analysis was performed. GAPDH primers were used as a 
control for RNA quality and concentration and oesophagus cDNA was used as a 
positive control. Blank was a PCR without cDNA.  
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Figure 3.19 Scratch wound assay. In vitro wound closure was investigated in 
primary keratinocytes isolated from Fgf22 wild type and knockout male back skin 
and tail skin. A) Photographs show the migration of wild type and knockout 
primary keratinocytes to wounded regions of the monolayer culture. B) Closure of 
the wounds was monitored, photographed and measured at 6, 12, 18 and 32 
hours after wounding. Error bars represent SEM. Scale bar (200 ?m). 
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Figure 3.20 DMBA-induced tumorigenesis study. Cohorts of female mice 
(n=10) were subjected to classical two-step skin carcinogenesis treatment. Mice 
were treated with DMBA or solvent Acetone alone at 8 weeks of age and then all 
treated weekly with TPA for 15 weeks. A) At 58 weeks post initiation, when the 
experiment was terminated, 100% of DMBA treated wild type mice had developed 
papillomas while only 50% of knockout treated mice had papillomas. Control TPA 
treated mice of both genotypes never developed any neoplastic skin lesions. 
Circles represent mice killed due to papillomas exceeding size specified in the 
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Project licence. Stars represent mice deaths due to unrelated to experiment 
reasons. B) Average number of papillomas per mouse at the indicated times after 
the start of DMBA/TPA treatment. Maximum number of papillomas on a knockout 
female was 5, whereas wild type DMBA treated females never developed more 
than 2 papillomas per mouse. 
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Figure 3.21 Fgf22 knockout mice exhibit a weight loss phenotype. A) 
Representative photographs of 6 months old Fgf22 wild type and knockout 
animals fed regular mouse chow diet. Below the photograph, corresponding mice 
weights are indicated. B) Mouse body weights measured at 10 weeks of age, 
having been fed an ad libidum diet of standard mouse chow. Mean body weights 
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are shown for wild type (33.9g; n=25) and Fgf22 knockout (29.7 g; n=18) mice. A 
12% statistically significant body weight reduction in knockout males versus wild 
type males was observed (P<0.0001). Error bars represent SEM. 
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Figure 3.22 Alterations in pattern of growth curve in Fgf22 knockout mice. A) 
Growth curves for male Fgf22 wild type and knockout mice. B) Growth curves for 
female Fgf22 wild type and knockout mice. Mice were fed on a regular chow diet 
and their weight was recorded from birth until 150 days (21 weeks) of age. In total, 
13 Fgf22 wild type male and 18 female mice, comparing to 12 Fgf22 knockout 
male and 20 female mice were weighed twice a week. Each data point is the 
mean ± SEM for minimum of three animals. 
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Figure 3.23 Fgf22 mRNA expression in the digestive tract. RT-PCR analysis of 
cDNA from three 4.5 months old wild type male mice. Results showed the 
presence/absence of Fgf22 gene expression in different regions of the digestive 
system. Samples from the oesophagus and stomach displayed an intense Fgf22 
band at 226bp. Less intense bands were observed in jejunum, caecum, colon and 
rectum samples. GAPDH primers displayed a single band at 297bp and were used 
as a control for RNA quality and concentration. Blank PCR without cDNA. 
(OE=oesophagus, ST=stomach, DU=duodenum, JE=jejunum, IL=ileum, 
CA=caecum, CO=colon, RE=rectum, B=blank). 
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Figure 3.24 Fgf22 expression in the oesophagus. RT-PCR was carried out 
using total RNA isolated from mouse oesophagus to asses Fgf22 gene expression 
in female and male, wild type and knockout animals (3 mice per group). As 
expected the Fgf22 specific band was absent in samples from knockout animals. 
HPRT primers were used as loading and RNA quality controls. 
 160 
 
 
 161 
Figure 3.25 Histological analysis of oesophageal tissue. Tissue morphology of 
4 ?m sections of oesophagus prepared from 2 month old animals was compared 
and revealed no differences between wild type and knockout animals (n=6) when 
stained with A) Haematoxylin and eosin (H&E). B) p63 immunohistochemical 
staining did not show any alterations in the nuclear staining pattern. 
Immunostaining for differentiation markers C) K14 and D) Loricrin showed no 
changes in the epithelial differentiation process of the investigated tissue.           
(*= muscle, L=lumen of oesophagus,      =basal layer of epithelial cells). Scale 
bars (200 ?m) (A, C, D) and (20 ?m) (A’, B’, D). 
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Figure 3.26 Fgf22 and stomach. A) Fgf22 was expressed in the forestomach and 
stomach of wild type but not knockout mice. Blank PCR without cDNA. B) H&E 
staining of 5 Fgf22 wild type and 5 knockout mice stomachs. The forestomach is 
lined with a stratified squamous epithelium, whereas the glandular stomach 
epithelium can be subdivided into zymogenic, mucoparietal and antral regions 
depending upon cell lineages populating their gastric units. Scale bar (1 mm). C) 
Expression of the epithelial differentiation marker, Loricrin in the forestomach did 
not show any obvious alterations in the differentiation process in 5 wild type and 5 
knockout animals. Scale bar (200 ?m). 
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Figure 3.27 Stomach - parietal cells. Paraffin sections (4 ?m) from 5 Fgf22 wild 
type and 5 knockout stomachs were stained with an antibody specific to ATP4B 
protein, staining acid secreting parietal cells (brown). Parietal cells are large, 
triangular cells with very eosinophillic cytoplasm, large nucleus and a narrow 
apical part that points towards the pit. There were no noticeable differences in the 
staining pattern between wild type and knockout mice stomach sections. (L=lumen 
of stomach, M=mucosa, S=submucosa, GP=gastric pit, GG=gastric gland). Scale 
bar (100 ?m) top panel, (50 ?m) bottom panel.   
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Figure 3.28 Stomach - chief cells. Stomach sections of 5 Fgf22 wild type and 5 
knockout mice were immunostained with anti-Pepsinogen antibody to highlight the 
digestive enzyme secreting cells (brown staining). Chief cells are small, cuboidal, 
basophilic cells with the highest in number at the base of the gland (bottom panel). 
No differences in the staining pattern were observed. Scale bar (100 ?m) top 
panel, (50 ?m) bottom panel. 
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Figure 3.29 Stomach - pit cells. Fgf22 wild type (n=5) and knockout (n=5) 
stomach sections were stained with anti-trefoil factor 1 (TFF1) antibody. TFF1 is a 
stable secreted protein expressed in gastrointestinal surface mucosa of the gastric 
pits and in the overlying mucus. Pit cells are epithelial cells found in the gastric 
epithelium in the central (corpus) region of the stomach. They secrete an alkaline 
mucus that protects the epithelium against shear stress and acid. No changes in 
staining pattern between the samples were observed. Scale bar (100 ?m) top 
panel, (50 ?m) bottom panel. 
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Figure 3.30 Serum leptin levels of Fgf22 wild type and knockout male mice. 
Serum leptin concentration was determined by colorimetric sandwich enzyme-
linked immunosorbent assay (ELISA) from mice at 2 months of age. Age matched 
wild type male mice had higher serum leptin levels than knockout males but the 
difference was not statistically significant (n=4). Error bars represent standard 
error among the samples. 
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Figure 3.31 Fgf22 gene expression in the eye. When examined by RT-PCR, 
Fgf22 expression was detected in RNA isolated from the whole eye but the 
expression was undetectable in the optic nerve. GAPDH was used as the internal 
control. 
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Figure 3.32 Histology of the eye. Picture shows H&E stained transverse section 
of Fgf22 wild type mouse eye with marked in all the main tissue elements. When 
compared with H&E stained sections from the eye of Fgf22 knockout mice no 
obvious differences were found. The lens tissue is missing as a result of fixation 
and sectioning artefact, but the retinal layers were relatively well preserved. 
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Figure 3.33 Thickness of the retinal layers. A) Layers of the retina. The retina is 
a multi-layered, light sensitive sensory tissue that lines the back of the eye. Picture 
shown is an H&E stained retina of Fgf22 wild type mouse with all the layers 
marked. Scale bar (50 ?m). B) Thickness of all the retinal layers was measured in 
eye sections from 2 months old Fgf22 wild type and knockout male mice (n=3 for 
each genotype). H&E stained transverse eye sections from the left and right eye 
were measured at eight points at close distance to the optic nerve. Identical 
measurements were performed on sections above the optic nerve, at the optic 
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nerve level and below the optic nerve level. Error bars represent SEM. The same 
trend for retinal layer thinning was observed at all measured levels in knockout 
mice but the differences were statistically significant (P<0.05 and P<0.001) only at 
the level of the optic nerve. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 171 
3.3 Discussion 
 
Numerous studies on FGF7, FGF10 and their receptors have shown the 
importance of this subfamily of FGFs for normal embryonic development and adult 
tissue homeostasis. Little is known though, about the role and importance of 
FGF22 in those processes. 
 
During the first year of my PhD, I focused on investigating the function of 
FGF22 using an in vitro cell culture approach (results not shown). I obtained a 
stably transfected BHK cell line reported to express and secrete FGF22 (Zhang et 
al., 2006). Firstly, I confirmed Fgf22 expression by RT-PCR and Western blot in 
transfected cells. However, despite repeated efforts, including concentrating 
conditioned medium and adding various concentrations of heparin, I was not able 
to detect secreted FGF22. As a positive control, I performed transient 
transfections with a construct encoding FGF7, which was readily secreted by COS 
cells, but not by both BHK and HC11 transfected cells, suggesting that there was 
a problem with the secretion of recombinant proteins in these cells. HC11 is a 
mammary epithelial cell line in which, in contrast to BHK cells, FGFR2b is 
expressed, as confirmed by restriction digestion of RT-PCR products, so there is a 
question of instant uptake of the growth factor into an autocrine loop system. 
Afterwards I wanted to use cell migration and proliferation as a read out assay of 
FGF22 signalling. Scratch wound assays on HC11 cell monolayer treated with 
conditioned medium from FGF22 expressing cells showed no difference in cell 
proliferation and migration comparing to control cells. From the above I concluded 
that FGF22 is not a secreted protein, at least in these cell lines.  
 
In spite of the fact that Fgf22 was reported to be expressed at different 
stages of mouse embryonic development (Beyer et al., 2003), disruption of Fgf22 
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did not result in embryonic lethality in our knockout mouse model. Mice lacking the 
entire coding sequence of the growth factor developed normally and, when born, 
did not display any obvious abnormalities, demonstrating that FGF22 is not 
essential for embryonic development.  
 
Genotype distributions at birth matched expected Mendelian ratios and 
Fgf22 knockout mice were indistinguishable from their wild type and heterozygous 
littermates. To investigate any requirement for Fgf22 for both male and female 
fertility, a number of matings between knockout animals were performed. These 
revealed that both knockout males and females were fertile and that litter size and 
average number of pups did not vary from those observed in wild type matings. 
The time interval between the setting up of mating pairs and birth of the first litter 
was comparable between wild type and knockout mice, suggesting normal mating 
behaviour. 
 
Previous studies have shown that Fgf22 is expressed in the brain and that 
it is essential for the development of functional presynaptic structures (Umemori et 
al., 2004). RT-PCR analysis indeed demonstrated that the Fgf22 transcript was 
present in the brain of an adult wild type mouse but not in the Fgf22 knockout 
mouse (Fig 3.6). Interestingly, lack of FGF22 in the brain did not seem to affect 
mouse development or behaviour in any obvious way. It has been shown before, 
that Fgf22 is expressed in cerebellar granule cells at the same time that they are 
being innervated by mossy fibres from FGFR2b expressing vestibular and pontine 
neurons (Umemori et al., 2004). All three major FGFR2b ligands - FGF7, 10 and 
22 were shown to have presynaptic organising abilities. However, FGF22 was 
expressed at much higher levels in the cerebellum than either FGF7 or FGF10, so 
it seemed likely that it is the main presynaptic organising molecule, at least in this 
part of the brain. The cerebellum is a critical centre of motor control, responsible 
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for precise timing of coordinated, smooth movements of the skeletal muscular 
system. If Fgf22 deletion would cause any defects in the construction of synapses 
in this part of the brain we could expect balance and coordination problems in our 
mice, which never occurred.  
 
 Furthermore, our collaborator Hisashi Umemori from University of Michigan 
USA bought a commercially generated Fgf22 knockout line (not available to us as 
licencing costs $26,000) and confirmed our findings, with mice showing no overt 
phenotype under normal husbandry conditions. Nevertheless, his group studying 
Fgf22 knockout mice have preliminary data that Fgf22 and Fgf7 are highly 
expressed by CA3 pyramidal neurons in the hippocampus and both FGFs are 
presynaptic organisers in CA3. However, FGF22 promotes excitatory presynaptic 
differentiation and FGF7 promotes inhibitory presynaptic differentiation in the 
hippocampus. The balance between excitatory and inhibitory inputs on a neuron 
controls its neural excitability. When the ultrastructure of synapses in CA3 was 
examined by electron microscopy, the number of synapses formed was similar 
between Fgf22 knockout and wild type mice but the distribution of synaptic 
vesicles at excitatory synapses was more diffuse in knockout mice (Terauchi, A., 
Javed, D. Regulation of excitatory and inhibitory synapse formation by FGF22 and 
FGF7. 2008 Neuroscience Meeting Planner, Washington, DC: Society for 
Neuroscience, 2008. Online). Interestingly, knockout mice for STAM1 (signal 
transducing adapter molecule), also present in synaptic regions, are characterised 
by gradual disappearance of hippocampal CA3 pyramidal neurons with age and 
display age dependent growth retardation detectable by 2 weeks of age (Yamada 
et al., 2001). The neurological abnormality in STAM1 knockout mice was first 
suspected on the basis of observation of unusual leg-clasping reflex apart from 
normal coordination of movement, something never noticed in Fgf22 knockout 
mice. Nevertheless, given our collaboration with Dr Umemori, a specialist 
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neurobiologist, coupled with our lack of expertise in neurobiology, I did not pursue 
this site of Fgf22 expression further. 
 
Interestingly, an observation of statistically significant sex-related 
difference in basal Fgf22 mRNA expression levels was made. Wild type male mice 
expressed much higher levels of Fgf22 mRNA compared with female mice when 
assayed by quantitative RT-PCR (Fig 3.7). That was an unexpected finding but not 
an uncommon one, since a large extent of sexual dimorphism in gene expression 
has been observed before (Yang et al., 2006). In fact when liver, brain, adipose 
and muscle tissue were studied for differentially expressed genes between males 
and females, thousands of genes were identified, suggesting a widespread 
sexually dimorphic gene expression in mice. The degree of sexual dimorphism of 
actively expressed genes in various tissues ranged from 14% in brain to 70% in 
liver (Yang et al., 2006). Since most common diseases exhibit some degree of sex 
bias, a systematic understanding of the mechanisms underlying physiological 
differences between sexes is of great importance. Moreover, such an 
understanding in, for example, cancer biology could be useful in explaining gender 
differences in drug metabolism and toxicity. It also brings to attention the fact that 
there is evidence that women have been less enrolled in clinical trials and that a 
gender-specific analysis usually is not included in the evaluation of results. Gender 
differences in pharmacology have to be considered in order to improve drug safety 
efficacy and to optimise medical therapy both in men and women. 
 
Since the FGF subfamily members have similar receptor-binding properties 
and overlapping patterns of expression, functional redundancy is very likely. Due 
to that, I wanted to verify that normal development and fertility of Fgf22 knockout 
mice was not a result of Fgf7/Fgf10 compensation (Fig 3.8). Relative levels of Fgf7 
in wild type and knockout mice were variable but not significantly different. 
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Moreover, levels of Fgf10 were significantly decreased in knockout male mice 
compared to wild type mice, which potentially excludes the possibility of functional 
compensation unless FGF22 counteracts the signalling of FGF10 – in which case 
down-regulation of FGF10 would compensate for down-regulation of FGF22.  
 
Given that previous reports described Fgf22 expression in the inner root 
sheath of the hair follicle (Nakatake et al., 2001) and a clear hair phenotype in 
Fgfr2b null skin (Grose et al., 2007), the possibility of a hair phenotype in knockout 
mice was anticipated. Nevertheless, knockout mice possessed all three major hair 
types in identical proportions to wild type littermates (Fig 3.9). Also, sebaceous 
glands did not display any differences between knockout and wild type animals 
(Fig 3.10), which was somewhat disappointing since skin specific deletion of 
Fgfr2b resulted in severe sebaceous gland atrophy (Grose et al., 2007). 
 
Fgf22 expression was described in normal and wounded skin in two 
independent studies (Beyer et al., 2003). The sites and timing of Fgf22 expression 
led us to hypothesise that this growth factor may play a role in helping to control 
tissue homeostasis, perhaps by damping down FGFR2b signalling and ensuring 
that over-proliferation of keratinocytes does not occur. In theory, Fgf22 knockout 
mice could suffer from uncontrolled keratinocyte proliferation, like in psoriasis 
(McKay and Leigh, 1995), or abnormal wound healing with papillomas forming at 
the injury sites (Rappolee et al., 1988). However, the unchallenged skin of Fgf22 
knockout mice looked normal in terms of histology, layer thickness and 
organisation (Fig 3.11). I therefore analysed the capacity of Fgf22 null mouse skin 
to respond to a challenge stimulus. Mice were subject either to wounding (Fig 
3.12) or to classical two-step skin carcinogenesis (Fig 3.20), since both of these 
interventions cause an increase in keratinocyte proliferation, either transiently in 
the case of wound repair or more permanently in the case of carcinogenesis. 
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These studies allowed me to question whether FGF22 was capable of driving 
keratinocyte differentiation and/or inhibiting their proliferation.  
 
The wound healing study revealed that gross healing (Fig 3.12), as well as 
more detailed histological analysis (Fig 3.13 - 3.16), was not significantly different 
in knockout mice when compared with wild type mice, implying that mice lacking 
Fgf22 in the skin were able to heal acute wounds just as efficiently as wild type 
mice. This apparent redundancy in the FGF-FGFR axis during repair is not without 
precedent, with mice lacking Fgf7, Fgfr1b or Fgfr2b showing no obvious wound 
healing phenotype despite expression of these molecules during the repair 
process (Guo et al., 1996). Polarised light microscopy of Sirius red stained 
sections from 14 and 21 day wounds indicated no differences in collagen fibre 
organisation and maturation at the wound site, moreover wounds of wild type and 
knockout mice at 21 days, when the experiment was terminated, were 
indistinguishable (Fig 3.16). From the above picture it appeared that FGF22 is 
dispensable for the wound healing process, which was unexpected, since FGF22 
is highly expressed in the hyperproliferative wound epithelium (Beyer et al., 2003). 
Moreover, the relative levels of Fgf22 mRNA expression assayed by Real Time 
RT-PCR peaked at 14 days after wounding in wild type mice (Fig 3.17), when the 
wound was already healed, consistent with already published data. Furthermore, 
expression levels of Fgf7 and 10, Fgfr1b and Fgfr2b all of which are expressed 
during the wound healing process (Werner et al., 1992, Tagashira et al., 1997, 
Zhang et al., 2004, Werner et al., 1994) did not differ significantly between wild 
type and knockout mice (Fig 3.17). Additional evidence for wound healing not 
requiring FGF22 came from the lack of difference in time required for in vitro 
wound closure by primary keratinocytes isolated from wild type and knockout mice 
(Fig 3.19).  
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 Classical two-step skin carcinogenesis revealed that only 50% of DMBA 
treated knockout mice developed papillomas compared to 100% of treated wild 
type mice over the 58 weeks period of experiment duration (Fig 3.20). Moreover, 
the onset of papilloma formation was hugely delayed (by 27 weeks) in knockout 
mice, as well as tumour multiplicity being reduced in knockout mice. That was 
unexpected, considering the above hypothesis, coupled with the fact that data 
from our lab show mice lacking Fgfr2b in the epidermis have increased cancer 
susceptibility, develop spontaneous papillomas and demonstrate dramatic 
tumorigenesis following DMBA treatment. Results obtained from the 
carcinogenesis experiment demonstrate that tumour suppressive role of the 
FGFR2b does not act via FGF22, as Fgf22 knockout mice exhibit resistance to 
DMBA induced tumorigenesis. That suggests a possibility that Fgf22 confers 
sensitivity to chemically induced skin carcinogenesis. Moreover, it might even 
antagonise the Fgfr2b role in this process. Speculative counteraction of ligand-
receptor arrangement would involve even more potent Fgfr2b tumour protective 
action given Fgf22 deletion. One way of investigating this exciting hypothesis 
would be generating Fgf22 over-expressing mouse model and checking its 
phenotypical answer to chemically induced skin carcinogenesis. 
 
The only noticeable difference between unchallenged Fgf22 knockout and 
wild type mice was in body weight (Fig 3.21). Adult male knockout mice appeared 
much leaner when compared with age-matched wild type male mice, and detailed 
study of weight gain over time confirmed these findings (Fig 3.22). The difference 
in weight gain was first observable around the time of weaning (3 weeks of age) 
and became increasingly apparent when mice reached puberty at 5-6 weeks of 
age. Interestingly, both adult male and female wild type mice on the C57BL/6J 
background generally reached higher body mass than the record found in the 
literature for this inbred mouse strain. According to the Jackson Laboratory, at 16 
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weeks of age, C57BL/6J mouse maximum body weight for a male was 30.1 grams 
and 21.9 grams for female. In my study, by this age wild type C57BL/6J male mice 
reached 39.3 grams and female 28.7 grams and increased further upon aging. 
Nevertheless, it is well known that even mice raised with the same diet, in the 
same types of cages, with the same husbandry procedures can have a 
remarkable range of body size and composition (Reed et al., 2007). Body weight 
is usually considered as a typical polygenic characteristic, meaning that a large 
number of genes are assumed to influence it, with each having a very small effect. 
However the number, location and effect of individual genes contributing to 
variation is mostly unknown. We can speculate whether Fgf22 is a novel gene 
affecting body weight. Body weight is a composite trait resulting from fat and non-
fat, lean tissue. Most light mice have very little fat whereas heavy mice are almost 
half fat by weight (Reed et al., 2007). Some genes might affect fat or lean tissue 
whereas other genes might affect both. Interestingly, FGF10 has been reported to 
play an important role in adipogenesis since development of white adipose tissue 
was reduced in Fgf10 knockout mice (Sakaue et al., 2002). Further studies are 
required to determine whether Fgf22 gene deletion causes reduction of fat mass 
or increase in lean mass. There are a number of possible mechanisms that can 
produce weight loss; for example behavioural or hormonal differences, a subtle 
tooth or digestive tract phenotype or stimulated thermogenesis. The cause of 
weight loss in Fgf22 knockout mice is not likely a result of imbalance in appetite 
controlling hormones since serum leptin levels, an important mediator of feeding 
behaviour and energy homeostasis, in two months old knockout male mice were 
not different from those in wild type mice (Fig 3.30).  
 
Also, no obvious macroscopic problems with food absorption and digestion 
were noticed when the whole gastrointestinal tract of wild type and knockout mice 
was dissected and compared. Nevertheless, Fgf22 expression was checked by 
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RT-PCR in all the parts of the digestive system and the growth factor was 
discovered to be expressed at low levels in almost all the parts of the intestinal 
tract, with particularly high levels of expression in the oesophagus and stomach 
(Fig 3.23). Subsequently, the morphology of knockout oesophagus and stomach 
sections was examined but no obvious differences in tissue appearance were 
observed (Fig 3.25 and 3.26). Moreover, a series of immunohistochemical staining 
(anti-p63, -K14 and -Loricrin, -ATP4B, -Pepsinogen and -TFF1) for the major 
characteristic cell types of the digestive tract, did not reveal any changes in protein 
expression pattern of cell differentiation (Fig 3.27-3.29). Thus, in spite of my 
studies to date, the underlying reason for weight loss in Fgf22 knockout mice 
remains unclear. 
 
During the process of Fgf22 knockout mouse characterisation, I found that 
Fgf22 was expressed in the eye (Fig 3.31). Once more, tissue morphology was 
checked and this time it revealed changes in retinal layer thickness in knockout 
male mice (Fig 3.33). Selective thinning of inner retinal layers is common in type 1 
diabetic patients (van Dijk et al., 2009). In diabetic retinopathy, high sugar and 
blood pressure levels cause blood flow to increase, which slowly damages blood 
vessels supporting the retina. Thus I can speculate that Fgf22 knockout mice are 
diabetic, or, since it is thought that early diabetic retinopathy includes a 
neurodegenerative component (Lieth et al., 2000), that lack of Fgf22 expression in 
the brain is the root cause.  
 
It is clear that further experiments are required in order to fully understand 
the physiological role of Fgf22. Preliminary results obtained during the course of 
my PhD project are valuable in context of narrowing the number of investigative 
possibilities and hopefully pointing future research in the right direction.  
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3.4 Future directions 
 
 Undoubtedly the powerful technology of gene targeting in embryonic stem 
cells has enabled the simple generation of mice lacking a specific gene. However, 
in a significant proportion of such knockout mice, even within the FGF family, 
either no or only very subtle phenotypes could be detected. Advancements in the 
field of mouse phenotyping and use of extensive experimental pathology tests on 
each knockout mouse show that abnormal phenotypes were sometimes detected 
in physiological areas where they were not initially anticipated, or only manifested 
under certain conditions, emphasising the need for careful phenotypic 
investigation (Barbaric et al., 2007). This is exactly the case for Fgf22 knockout 
mice, in which the weight loss phenotype was entirely unexpected. However, it is 
possible that the Fgf22 knockout mouse has another phenotype, but the tests I 
used to characterise it were not sufficiently sensitive or perhaps different classes 
of tests should be carried out. Conceivably, crossing Fgf22 knockout mice with 
other FGF deficient lines to generate double or triple knockout mice would reveal 
further functions of the gene. Also, backcrossing Fgf22 knockout mice to a 
different background could prove a means to uncover a distinctive phenotype 
since, for example, Keratin 8 knockout mice have very differing phenotypes 
depending on the genetic background. On a C57BL/6J background, Keratin 8 
knockout mice died due to internal bleeding (Baribault et al., 1993), whereas on a 
FVB/N background they were viable but displayed colorectal hyperplasia 
(Baribault et al., 1994). It is also well known, that breeding strategies have 
produced mice strains with skin epithelium highly susceptible or resistant to 
tumour development or else with particular sensitivity to develop benign 
(squamous papillomas) and malignant (squamous carcinomas) tumours. For 
example a mixed background of 129ola and C57Bl6/J mouse strain is relatively 
tumour resistant while FVB/N mice are moderately susceptible to papilloma 
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formation, but the benign tumours are unusually prone to undergo malignant 
conversion (Woodworth et al., 2004). Another unwelcome possibility is simply that 
the Fgf22 gene is truly not important for development and tissue homeostasis. 
  
 Given more time, I would have liked to have continued further 
characterisation of metabolic differences in Fgf22 knockout mice. A series of 
experiments can be performed in order to do that including; monitored food intake, 
before and after fast, over a set period of time, mice fed high fat diet or put on a 
pair-fed experiment where wild type and knockout mice are restricted to eat the 
same amount of food and their weight gain is recorded. Most useful would be 
putting wild type and knockout mice into special metabolic cages. Given time I 
would have liked also to do a glucose and insulin tolerance test on those mice. 
Glucose tolerance test determines how quickly glucose is cleared from the blood 
after its administration, and it would be used to check for diabetes and insulin 
resistance in Fgf22 knockout mice. An insulin tolerance test, in which insulin is 
given intravenously, is intended to induce hypoglycemia, in response to which 
adrenocorticotropic hormone (ACTH) and growth hormone (GH) are released as a 
part of the stress mechanism. ACTH elevation causes the adrenal cortex to 
release cortisol, which is responsible for keeping stable sugar blood levels, 
physiological blood pressure and right fluid balance. Normally, both cortisol and 
GH serve as counter-regulatory hormones, opposing the action of insulin, acting 
against the hypoglycemia (Greenwood et al., 1966). Insulin tolerance test is 
routinely used for assessing the integrity of the hypothalamo-pituitary-adrenal axis.  
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CHAPTER 4: Fibroblast growth factor receptor 2 
 
4.1 Introduction 
 
4.1.1 The role of FGFR in carcinogenesis 
 
As discussed earlier, as a general rule, FGFRs encoding exon IIIb (FGFR 
IIIb) are expressed on epithelial cells while the FGFRs encoding exon IIIc (FGFR 
IIIc) are expressed on mesenchymal cells (Mohammadi et al., 2005). By contrast, 
the cognate ligands for the IIIb isoform are often expressed by mesenchymal cells, 
while ligands for IIIc are expressed by epithelial cells. This establishes a paracrine 
mechanism of signalling between epithelia and mesenchyme that is critical to 
normal development and tissue homeostasis. Deregulation of this precise 
mechanism of FGF signalling often is implicated in initiation or development of 
multiple cancer types, through directly driving cancer cell proliferation and survival, 
and also by supporting tumour angiogenesis. As our knowledge progresses we 
can now, in the tumorigenesis field, distinguish two contrasting effects of FGF 
receptor biology; tumour suppressive and oncogenic, with the segregation into one 
of the groups being dependent on receptor isoform, tissue and temporal specificity 
(Grose and Dickson, 2005).  
 
4.1.2 FGFR2 as a tumour suppressor  
 
Skin 
 
Recently, a novel role for Fgfr2b has been discovered. Genetically 
engineered mice lacking Fgfr2b in the skin epidermis were characterised by a thin 
and silky coat, sebaceous gland atrophy, increased macrophage infiltration to the 
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dermis and epidermal thickening accompanied by basal-layer dysplasia and 
parakeratosis. Of even greater interest was the fact that about 10% of mutant mice 
developed spontaneous papillomas with age and also showed great sensitivity to 
chemical carcinogenic insult by rapidly developing papillomas, some of which 
progressed to squamous cell carcinomas (Grose et al., 2007). For the first time, 
the epithelial isoform of the Fgfr2 receptor was shown to play a tumour 
suppressive role in the skin. Those interesting findings now need to be translated 
to human skin, where they will determine whether there is a tumour suppressive 
role of FGFR2b in man. 
 
 Most recently, it has been reported that 10% of melanoma tumours and cell 
lines harbour mutations in the FGFR2 gene. These novel mutations include three 
truncating mutations and 20 missense mutations occurring at evolutionarily 
conserved residues common not only in FGFR2 orthologues, but among all four 
FGFRs. Such mutations result in receptor loss of function through several distinct 
mechanisms, including loss of ligand binding affinity, impaired receptor 
dimerisation, destabilisation of the extracellular domains, and reduced kinase 
activity (Gartside et al., 2009).  
 
Bladder 
 
FGFR2b expression is reported to be decreased in about 30% of primary 
bladder tumours and 50% of bladder cancer cell lines. Down-regulation of this 
receptor in the bladder epithelium is associated with a poor prognosis (Diez de 
Medina et al., 1997). FGFR2b has an inhibitory function in bladder cancers, 
blocking cell growth both in vitro and in vivo. Receptor inactivation is an important 
step in human bladder tumour progression. Interestingly, FGFR1 is not present in 
the normal urothelium, but is expressed in many bladder carcinoma and cell lines, 
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suggesting that FGFR1 on the other hand may accelerate tumour progression 
(Ricol et al., 1999). Furthermore, gain-of-function mutations in FGFR3 are the 
most commonly observed mutations in bladder cancer (Cappellen et al., 1999). 
 
Prostate 
 
Similar findings were reported in prostate cancer where, in both mouse and 
human, decreased expression of FGFR2 results in over-expression of FGFR1, 
which in turn drives cancer progression (Jin et al., 2003). FGFR1 is normally not 
expressed in prostate epithelium, but it becomes up-regulated in about 40% of 
poorly differentiated prostate adenocarcinomas (Kwabi-Addo et al., 2004). 
Moreover it has been shown in a rat model that, when non-malignant epithelial 
cells, expressing FGFR2b, were mixed with stromal cells, they resulted in non-
malignant tumours (Yan et al., 1993). However, when the stromal cells were 
absent, epithelial cells underwent a splicing switch, from the IIIb to IIIc isoform, 
and up-regulated FGF2 expression potentially initiating an autocrine loop (Yan et 
al., 1993). The transcription factor Homeobox C6 (HOXC6) has been shown to 
directly up-regulate expression of FGFR2 but, curiously, HOXC6 is over-
expressed in prostate cancers and this increased epithelial expression correlates 
with cancer progression. Most probably, FGFR2 in this case is silenced by 
hypermethylation, which prevents receptor activation when HOXC6 is over-
expressed (McCabe et al., 2008). 
 
Salivary gland 
 
Salivary adenocarcinomas represent another type of tumour where 
FGFR2, or rather its absence, plays a major role. Normal salivary gland epithelial 
cells and benign salivary gland tumours exclusively express FGFR2. During the 
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malignant transformation of salivary gland epithelial cells, the expression of 
FGFR2 is abolished, whereas expression of FGFR1c and FGFR4 are up-
regulated (Tanaka et al., 1997). 
 
Thyroid  
 
FGFR2b mRNA is detectable in normal thyroid but not in thyroid carcinoma 
cell lines, whereas FGFR2c mRNA is not detectable in either. Alongside this, 
FGFR1 expression is up-regulated in thyroid cancer and it is postulated to act in a 
tumour-promoting manner (Thompson et al., 1998). Co-expression of FGFR1 and 
elevated levels of FGF1 and FGF2 expression in thyroid cancer potentially drive 
the cancer progression by an autocrine signalling loop (Eggo et al., 1995). These 
findings suggest that, in thyroid cancer, loss of expression of the tumour 
suppressive FGFR2 plays an important role. The mechanism of down-regulation 
recently has been identified to occur through CpG methylation in the 5’ region of 
the FGFR2 gene (Kondo et al., 2007). 
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4.1.3 FGFR2 as an oncogene  
 
 
 
 
 
Figure 4.1 Common sites of FGFR mutations and the skeletal abnormalities caused by 
such. D1-3 represent the three extracellular IgG like domains and TM represents the 
transmembrane region. 
 
Uterus 
 
Recently, there has been strong evidence emerging for FGFR2 
involvement in endometrial and breast cancer. Despite FGFR2 being highly 
expressed in normal human endometrial epithelium (endometrium), increased 
FGFR2 expression in endometrial adenocarcinomas has been associated with 
tumour progression, and gain of function mutations in FGFR2 were identified in 
16% of endometrial cancers (Pollock et al., 2007). In this study 11 different FGFR2 
mutations were identified in 30% of the endometrial cell lines and in 10% of the 
primary uterine tumours investigated. Remarkably, the majority of somatic 
mutations identified were identical to germline activating mutations in FGFR2 and 
FGFR3 that cause Apert syndrome, Beare-Stevenson syndrome, 
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hypochondroplasia, achondroplasia and severe achondroplasia with 
developmental delay and acanthosis nigricans (SADDAN syndrome) (Fig 4.1) 
(Hajihosseini, 2008). The two most common somatic mutations identified were 
S252W and N550K, plus another four novel mutations, three of which are also 
likely to result in receptor gain-of-function (Pollock et al., 2007). Mutations in the 
extracellular domain of FGFR2 lead to ligand independent dimerisation of the 
receptor via an inter-molecular cysteine di-sulphide bridge. In a different study on 
40 primary endometrial carcinoma tumour DNA samples, mutations were present 
in 12% of them, plus additional instances were found in lung squamous cell 
carcinoma and cervical carcinoma (Dutt et al., 2008). The same group also 
performed some cell culture studies and found that the small-molecule inhibitor 
PD173074 diminishes survival and anchorage-independent growth of endometrial 
cancer cell lines expressing activating FGFR2 mutations (Dutt et al., 2008).  
 
It seems that the FGFR2 gene lies within a region of significant linkage to 
endometriosis on chromosome 10q, causing the possibility that variation in FGFR2 
could contribute to the genetic risk of the disease. Nevertheless, after an in-depth 
genome-wide association study, no evidence was found for association between 
endometriosis and the key (rs2981582 and rs1219648) FGFR2 SNPs (Zhao et al., 
2008). 
 
Breast 
 
FGFR2 is amplified and over-expressed in 5–10% of breast tumours 
(Adnane et al., 1991). Two recent genome-wide association studies of breast 
cancer have identified association of common genetic variants in the FGFR2 gene 
with this disease (Easton et al., 2007). In both studies, the most significantly 
associated SNPs were identified in intron 2 of FGFR2. For example, the SNP at 
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rs2981582 lying within intron 2 of FGFR2, was reported to be associated with an 
increased risk of breast cancer. These susceptibility alleles are very common; 
approximately 14% of the UK population and 19% of UK breast cancer cases are 
homozygous for the minor allele at rs2981582. On the other hand, the increased 
risks associated with these alleles are relatively small - on the basis of UK 
population rates, the estimated breast cancer risk by age 70 years associated with 
rs2981582 ranges somewhere between 5.5% and 10.5% (Easton et al., 2007). 
These results were confirmed in another study that has also found SNPs in intron 
2 of FGFR2 (Hunter et al., 2007). Interestingly, the SNP only appears to 
appreciably increase the risk of developing oestrogen receptor (ER) positive 
breast cancer (Garcia-Closas et al., 2008), with only a minor impact on ER 
negative breast cancer. It is still not clear precisely how the SNP confers this 
increased risk of breast cancer. The probable explanation is that the SNP up-
regulates the FGFR2 gene expression by altering the binding sites of the 
transcription factors Oct-1/Runx2 (Meyer et al., 2008). Binding sites for ER and 
Oct often cluster together, suggesting a model where ER and OCT cooperate in 
regulating FGFR2 expression. The potential role of ER in determining the 
functional effects of this SNP may explain the restriction of risk attributed this SNP 
to ER positive breast cancer. 
 
Stomach 
 
 Many stomach carcinoma cell lines express elevated levels of FGFR2, 
suggesting that, in these cancers, FGFR2 may accelerate tumour progression 
(Kunii et al., 2008). In fact FGFR2 is amplified in approximately 10% of gastric 
cancer, and the amplification appears to be more frequent in undifferentiated or 
diffuse subtype of gastric cancer, as opposed to the well-differentiated intestinal 
subtype. This amplification results in a highly over-expressed and constitutively 
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phosphorylated receptor (Kunii et al., 2008). Over-expression of FGFR2 has thus 
been correlated with poor prognosis in gastric cancer. Also, some activating 
mutations in the IIIc isoform of the receptor have been described in human gastric 
cancer (Jang et al., 2001). Those mutations are identical to germ line mutations 
predisposing to skeletal dysplasia. 
 
Similarly, two somatic mutations of FGFR2 were found in a squamous cell 
lung cancer at an identical position to germ line mutations that also cause Pfeiffer 
syndrome (Davies et al., 2005). 
 
Pancreas 
 
In normal human pancreas, FGFR2 is expressed in the endocrine islet 
cells and in the ductal cells. In pancreatic cancer, and pancreatic cancer cell lines, 
FGFR2 and FGF7 co-expression has been observed (Ishiwata et al., 1998). This 
indicated a potential FGF7-dependent autocrine loop driving pancreatic cancer 
growth, as it has been reported previously that in vivo injection of FGF7 led to 
enhanced pancreatic ductal cell proliferation (Yi et al., 1994). In fact increased 
expression of FGFR2 and FGF7 was detected in ~41% and 34% of examined 
human pancreatic cancer samples, and their co-expression was detected in ~25% 
of the samples. There also was a significant correlation between the presence of 
FGF7, or the co-expression of FGFR2 and FGF7, and poor prognosis. 
Interestingly FGFR2 expression alone in pancreatic cancer cells was not 
associated with a poor prognosis (Cho et al., 2007).  
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FGFR2 as a tumour suppressor FGFR2 as an oncogene 
Skin  
Tumour protective role against squamous 
cell carcinomas (Grose et al., 2007). 
Receptor loss of function mutations in 
melanoma (Gartside et al., 2009). 
Uterine adenocarcinomas  
 Upregulated expression associated with 
tumour progression plus receptor gain of 
function mutations (Pollock et al., 2007).  
Bladder tumours  
Decreased expression associated with a 
poor prognosis (Diez de Medina et al., 
1997).  
Breast tumours  
Receptor amplified and overexpressed in 5–
10% of tumours (Adnane et al., 1991). 
SNPs associated with increase risk of 
breast cancer (Easton et al., 2007). 
Prostate cancer 
Decreased expression of tumour protective 
receptor results in overexpression of 
FGFR1, which drives cancer progression 
(Jin et al., 2003).   
Gastric cancer  
Overexpression of receptor correlated with 
poor prognosis (Kunii et al., 2008). 
Activating mutations in the IIIc isoform of 
the receptor identified (Jang et al., 2001). 
Salivary gland tumours  
Abolished expression of the receptor drives 
malignant transformation via FGFR1c and 
FGFR4 activation (Zhang et al., 2001).  
Lung cancer 
Activating mutations found in squamous cell 
cancer (Davies et al., 2005). 
Thyroid carcinoma  
Loss of FGFR2b transcript and upregulation 
of FGFR1 expression in thyroid carcinoma 
(Thompson et al., 1998). 
Pancreatic cancer  
Observed FGFR2 and FGF7 co-expression 
driving cancer growth and associated with 
poor prognosis (Ishiwata et al., 1998).  
 
Table 7 FGFR2 status and cancer.  
 
4.1.4 FGFR2 germline mutations 
  
 Mutations in human FGFRs have been shown to occur in three members 
of the FGFR gene family (Passos-Bueno et al., 1999). Mutations in FGFR1, 
FGFR2 and FGFR3 have been demonstrated in craniosynostosis syndromes, and 
mutations of FGFR3 are found in a variety of skeletal dysplasias. FGFR2 
activating mutations cause craniosynostosis syndromes including Crouzon, 
Jackson-Weiss, Pfeiffer, Apert, and Beare-Stevenson syndromes (Fig 4.1). 
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Affected children show premature fusion of sutures that separate the calvarial and 
facial bones that results in abnormal skull shape, usually recognised as a tall 
forehead, widely spaced and prominent eyes, and mid-face hypoplasia. These 
may be accompanied by limb as well as sporadic visceral and neural 
abnormalities (Hajihosseini, 2008). So far, 95 individual FGFR2 mutations have 
been recognised in craniosynostosis syndromes and some of them have also 
been found in different types of cancer (Table 8). The aforementioned receptor 
mutations have been identified primarily in the extracellular region, involved in 
ligand binding, and the transmembrane domain, but also in the intracellular 
tyrosine kinase domain involved in signalling. For example, Ser252Trp and 
Pro253Arg mutations in the ectodomain of FGFR2 cause Apert’s syndrome by 
enhancing ligand binding affinity and promoting binding of inappropriate ligands 
(Ibrahimi et al., 2001), thus gain of function mutations in FGFR2c allow binding of 
ligands normally specific for FGFR2b. Nevertheless, the most common mutation is 
a missense mutation and most often it is a substitution of a cysteine for another 
amino acid, altering the disulphide bonds formed in ligand binding domain 
(Ingersoll et al., 2001). Mutations in the kinase domain of FGFR2 that cause 
craniosynostosis constitutively activate the receptor by disengaging an 
autoinhibitory molecular brake at the hinge region of the domain (Chen et al., 
2007). On the other hand, kinase domain loss of function mutations in FGFR2 and 
FGFR3 have been identified in autosomal dominant lacrimo-ariculo-dento-digital 
(LADD) syndrome (Rohmann et al., 2006).  
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Mutation: Germline Somatic 
S252W Apert syndrome 
(Wilkie et al., 1995) 
uterine cancer 
(Pollock et al., 2007) 
S267P Crouzon syndrome 
(Oldridge et al., 1995) 
gastric cancer 
(Jang et al., 2001) 
W290C Pfeiffer syndrome 
(Tartaglia et al., 1997) 
squamous lung cancer 
(Davies et al., 2005) 
S372C Beare-Stevenson cutis gyrata syndrome 
(Przylepa et al., 1996) 
uterine cancer 
(Pollock et al., 2007) 
Y375C Beare-Stevenson cutis gyrata syndrome 
(Przylepa et al., 1996) 
uterine cancer 
(Pollock et al., 2007) 
 
 
Table 8 An example of identical FGFR2 germline mutations identified in craniosynostosis 
syndromes and somatic mutations in uterine, gastric and lung cancer. Mutations clustered 
around the hinge region and the third Ig-like domain of FGFR2. 
 
4.1.5 Potential therapeutic approaches 
 
 It is very promising that oral administration of AZD2171 or Ki23057 
inhibited in vivo proliferation of cancer cells with aberrant FGFR2 signalling 
activation in rodents (Katoh, 2009). It is not known if similar FGFR2 inhibitors 
would cause the same effect in humans with malignancies associated with 
activating FGFR2 mutations or FGFR2 gene amplification. FGFR2 inhibitors have 
the potential to disrupt several beneficial homeostatic processes, including 
cytoprotective mechanisms against environmental insults, such as UV irradiation, 
X-ray irradiation, chronic infection, and tobacco smoke. Future studies will 
determine whether the benefits of FGFR2 inhibitors outweigh their risks (Katoh, 
2009) 
 194 
In light of these established data concerning FGFR2, I wanted to broaden 
understanding of the role of this protein in the complex biology of cancer 
development and progression.  
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4.2 Results 
 
 Given that the tumour suppressive role for Fgfr2b in mouse skin (Grose et 
al., 2007) was discovered in our lab, I wanted to check whether the receptor can 
play a similar role in human skin. In collaboration with Karin Purdie and Catherine 
Harwood (ICMS, Barts and The London), I have begun to investigate FGFR2b in 
human skin using histochemical, molecular and cell biological approaches. 
 
4.2.1 FGFR2 genomic sequence in SCC keratinocyte cell lines 
 
As a first approach to investigate FGFR2 in human skin cancer, I obtained 
six cell lines derived from squamous skin carcinoma patients (see above). After 
extracting genomic DNA, I attempted to amplify each of the 18 exons of FGFR2 
using PCR, thus enabling possible detection of any deletions as well as providing 
DNA for subsequent sequence analysis. Initial findings suggested lack of one 
exon in all six SCC cell lines isolated from patient tumours. Exon 11 was 
detectable in DNA isolated from an hTERT immortalised normal human 
keratinocyte, NTERT, but not in the SCC cell lines (Fig 4.2). Performing gradient 
temperature PCR, I established the optimal annealing temperature (66.6°C) for 
generating the exon 11 specific product and, despite the initial findings, 
subsequent PCR amplified the band of interest in all samples, although the 
amplification was highly dependent on DNA quality (Fig 4.3). “Old” DNA samples, 
obtained at the same time as the cell lines, yielded an extremely weak band when 
resolved on a 2% Agarose/TBE gel, whereas “new” freshly prepared DNA 
samples gave a clear single band of the expected size. 
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Figure 4.2 Human FGFR2 PCR analysis. PCR analysis of genomic DNA isolated 
from 6 primary human SCC cell lines (Pt1-6), generated from patient tumours, and 
control normal human keratinocytes transduced with hTERT (NTERT cells). The 
results reveal the absence of the exon 11 of FGFR2 in all 6 SCC samples.  
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Figure 4.3 Human FGFR2 exon 11 analysis. PCR analysis of exon 11, as 
described above, was repeated with a higher annealing temperature (66.6°C), 
which was established after performing a PCR gradient of temperatures for old 
DNA samples – left panel, and new DNA samples – right panel. Results show that 
exon 11 of FGFR2 is present in all 6 SCC samples but that the quality of input 
DNA affects its detection. 
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4.2.2 FGFR2 mutation screening 
 
A single nucleotide change (point mutation) in the coding region of a gene 
can have profound biochemical and physiological consequences on an organism. 
Well characterised examples of such changes are the germline gain of function 
mutations in FGFR1, 2 and 3 causing craniosynostosis and chondrodysplasia 
syndromes (Wilkie, 2005). Mutations in the FGFR2 gene were also reported in 
breast, endometrial and gastric/colorectal cancers (Stephens et al., 2005). Guided 
by these reports, I decided to screen the FGFR2 coding sequence for mutations in 
skin cancer. A PCR based assay was used to identify mutations in genomic DNA 
isolated from SCC cell lines. Initially I concentrated on screening exons that 
already were known to carry mutations in the above pathologies – exons 7, 10, 13 
and 15. The first attempt to perform direct sequencing of a PCR product was 
aborted due to the imprecise electropherograms obtained and thus the very low 
probability of detecting heterozygous mutation. Instead I cloned the PCR product 
using TOPO? vector and then sequenced the cloned PCR products from four 
positive clones per exon (Fig 4.4). In the process of sequence analysis, eleven 
mutations were identified, one of which had been reported previously (Fig 4.5). 
Five identified mutations were localised in exon 7, encoding the IIIa part of the D3 
extracellular domain, one mutation in exon 10, encoding the transmembrane 
domain of the receptor, and a further three in the kinase domains (Fig 4.5). These 
results were encouraging, as it is well known that within exon 7 several different 
regions are recognised as hot spots for germline activating mutations (Kan et al., 
2002). All identified changes were single base pair substitutions resulting in 
missense mutations, with the exception of two synonymous mutations that did not 
affect the amino acid sequence and one single nucleotide deletion causing change 
of reading frame. Four independent mutations were identified in the patient 2 (Pt2) 
cell line and three in patient 5 (Pt5). In both cases, the cell lines were derived from 
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moderately differentiated tumours. Three out of eleven found mutations were 
confirmed by specific restriction enzyme digestion (Fig 4.6). 
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Wild type Mutation Position 
AAGGTTTACAGTGATG AAGGTTCACAGTGATG T841C 
AACGGCAGTAAATACG AACGGCAGCAAATACG T897C 
CGGCAGTAAATACGGG CGGCAGTAGATACGGG A899G 
GGCAGTAAATACGGGC GGCAGTAAGTACGGGC A900G 
AAGAACACGACCAAGA AAGAACGCGACCAAGA A1210G 
ACGTATCCCCCTGCGG ACGTACCCCCCTGCGG T1268C 
CGCTGGTGAGGATAAC CGCTGGTGCGGATAAC A1339C 
TCCTATGACATTAAC TCCTATGGCATTAAC A1769G 
GCAGCCAGAAATGT GCAGCCAGAAATGT A1895G 
GATGAAAATAGCAGA TCCTATG_CATTAAC 1923_1925delA 
 
 
Figure 4.4 Somatic mutations identified in the human FGFR2 sequence. An 
example of sequence electropherograms of mutation (arrowheads) found in 
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human skin squamous cell carcinoma cell line and the corresponding normal 
sequence. Genomic DNA was isolated from 6 SCC cell lines from patient tumours. 
FGFR2 exons from each cell line were amplified by PCR and cloned into TOPO 
vector. Four clones per sample were identified by PCR and the reaction product 
was sequenced. All identified mutations are shown in the table.  
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Figure 4.5 A schematic representation of FGFR2 and the locations of 
identified mutations. FGFR schematic structure of three Ig-like domains (Ig I–III), 
a transmembrane domain (blue box) and a split tyrosine kinase domain (pink 
boxes). Red circles indicate areas where point mutations have been identified. 
The table below gives more detail of identified mutations in human SCC cell lines 
(numbering relative to NM_022970.0 and NP_075259.2). *Crouzon syndrome, 
**Pfeiffer syndrome. 
 
 
Case FGR2b 
nucleotide 
FGFR2b codon Previous reports 
Pt1  T785C L262P no, but P263L yes in CS* 
Pt5 T841C Y281H yes, but Y281C in CS* 
Pt2 T897C S299S no 
Pt4 A899G K300R no, but Y301C yes in CS*  
Pt6 A900G K300R no, but Y301C yes in CS* 
Pt2 A900G K300K no, but Y301C yes in CS* 
Pt2 A1210G T404A no 
Pt1 T1268C I423T no 
Pt5 A1339C R447R no 
Pt2 A1769G D590G no 
Pt5 A1895G N632S no 
Pt6 1923_1925delA I641del+change of 
reading frame 
no, but K641R yes in 
PS** 
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Figure 4.6 Mutation-specific restriction enzyme digestion. PCR products were 
obtained from TOPO vector clones. The identified mutations were analysed by 
specific restriction enzyme digest. The digested PCR products, (U) uncut and (C) 
cut with appropriate enzyme, were analysed by 2% Agarose gels and the DNA 
was visualised by staining with ethidium bromide. Restriction enzymes, cutting 
sites and the expected fragments sizes for the wild type and mutant alleles are 
shown in the table.  
 
Mutation Restriction 
enzyme 
Cutting 
site 
Products size in 
wild type sample 
Product size in 
mutated sample 
T785C 
 
AvaII g/gwcc 271bp 74bp and 197bp 
A900G RsaI gt/ac 15bp and 256bp 15bp, 63bp and 
193bp 
T1268C 
 
AvaII g/gwcc 291bp 71bp and 220bp 
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4.2.3 SCC cell lines express the FGFR2IIIb splice isoform 
 
A switch in splice variant of FGFR2 causes dramatic differences in ligand 
binding specificity, thereby affecting receptor signalling. Thus, the choice of splice 
isoform expressed might be of great importance in cancer development and 
progression. To determine whether the mechanism of isoform switching is relevant 
in skin cancer I wanted to know which FGFR2 splice variant was present in a 
panel of SCC cell lines.  
 
In the first step, cDNA corresponding to the receptor sequence was 
amplified by RT-PCR. Primers for the reaction were designed to span the third Ig-
like extracellular domain and the transmembrane domain of the receptor (cartoon 
in Fig 4.7) and amplify a 290 bp product, in the case of FGFR2IIIb isoform, and 
287 bp, for the IIIc isoform. Since such a small difference in the product size could 
not be resolved by Agarose gel electrophoresis, products were digested with 
specific restriction enzymes to detect the alternative isoforms. Digestion of the 
FGFR2 PCR product with AvaI resulted in cleavage products of 182 and 108 bp, 
indicating the presence of the IIIb isoform. Contrastingly, digestion with HincII 
resulted in products of 119, 115 and 53 bp, indicating the presence of the IIIc 
isoform. Unfortunately, the digestion of RT-PCR products did not reproducibly 
distinguish the splice isoform of the FGFR2 expressed by SCC keratinocytes cell 
lines. Depending whether the primers used for PCR, were based on human or 
mouse sequence (which share 70% homology), specific yet contradictory results 
were obtained. To find out whether cell line passage number influenced the 
results, I went back to the stock of lowest passage number cells but that did not 
clarify the issue. Therefore, I checked whether the results were dependent on the 
level of confluence to which the cells were grown prior to RNA extraction. The 
experiment was repeated with a control human keratinocyte cell line (HaCaT) and 
 205 
two SCC cell lines (Pt1 and Pt2) grown to 1%, 50%, 80% and 110% of confluency, 
only to reprise the previous confusing results (Fig. 4.8 A and B). The results 
indicated that the expressed splice variant depended only on the choice of primers 
used for RT-PCR analysis. Finally, sequencing of the PCR product obtained with 
mouse specific primers revealed that a mouse Fgfr2c sequence was amplified in 
this reaction, suggesting that the human keratinocyte cell lines were contaminated 
with murine fibroblasts. Furthermore, when cells were grown to overconfluence, 
patches of elongated, fibroblastic cells were observed in the culture dish (Fig 4.9). 
In the mean time though, some organotypic experiments were performed with the 
abovementioned cell lines and normal human keratinocytes (HaCaT) grown on top 
of collagen layer enriched with dermal fibroblasts. In organotypic culture 
experiments I wanted to assess cancer invasion and progression. The morphology 
of SCC compared to HaCaT cells in the co-culture appeared to be very different. 
Normal keratinocytes were organised into continuous and compact layers, which 
resembled differentiated epidermis, whereas SCC cells were enlarged, had many 
vacuoles and were scattered with very little cell-cell contact (Fig 4.10). Again, 
altered cell appearance may be due to fibroblast contamination. Since I learned 
about this contamination the organotypic culture experiments were abandoned. 
Had I had more time available I could have used single cell cloning to re-derive a 
pure epithelial cell population prior to re-embarking on these experiments. 
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Figure 4.7 Identification of FGFR2 splice isoform expressed in HaCaT and 
SCC cell lines. RT-PCR was performed on HaCaT and SCC cell line cDNA with 
human sequence specific primers spanning the third Ig-like loop of the 
extracellular domain and the transmembrane domain. The forward primer is 
located in the IIIa domain and the reverse primer in TM domain, as illustrated in 
the cartoon below. PCR products were then digested with HincII (H) and AvaI (A) 
restriction enzymes, which recognise IIIc and IIIb splicing isoforms respectively. 
Digestion reaction products were run on a 2% Agarose/TBE gel alongside full 
length, undigested PCR product (U). Results indicate that all tested SCC cell lines 
expressed epithelial specific IIIb isoform of FGFR2. 
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Figure 4.8 Identification of FGFR2 splice isoform expressed in HaCaT, Pt1 
and Pt2 SCC and HFF2 cell lines, dependent on cell confluence. RT-PCR was 
performed on HaCaT cells and two SCC cell lines grown to 1%, 50%, 80% and 
110% confluence. Human Foreskin Fibroblast cell line (HFF2) cDNA was used as 
a control for FGFR2 expression. Used primers spanning the IIIa and TM domain 
were specific to FGFR2 A) mouse sequence B) human sequence. Contradictory 
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results were obtained in the case of Pt1 cells, where cells expressed either the IIIc 
isoform (arrows in A) or the IIIb isoform (black arrow in B) of FGFR2. (B) At low 
confluence, Pt1 cells expressed the IIIb isoform, whereas at high confluence the 
IIIc isoform was expressed (grey arrows). (C) HPRT primers were used as a 
control for RNA quality and concentration. (U) undigested PCR products were run 
alongside PCR products digested with HincII (H) and AvaI (A) restriction enzymes. 
Blank PCR without cDNA. 
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Figure 4.9 Pt2 cell line. A) Pt2 cells grown to confluence show dense 
cobblestone appearance by phase contrast microscopy. B) In the same culture 
dish, areas of elongated, fibroblastic cells were observed. 
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Figure 4.10 Organotypic culture of skin equivalent. Normal human 
keratinocytes (HaCaT) and human SCC keratinocytes (1 × 106) were plated on top 
of the stroma consisting of collagen and human fibroblasts (5 × 105), as shown in 
the scheme below, and co-cultured for 6 days. Images shown are of 6 day 
cultures, fixed, sectioned and stained with H&E.  
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4.2.4 FGFR2 expression in normal human skin and human squamous cell 
carcinoma 
 
Immunostaining of normal human skin sections showed a strong cell 
membrane staining for FGFR2 in the epithelium (Fig. 4.11 A, B, D). FGFR2 
staining was also visible in normal skin fibroblasts, since the anti-FGFR2 antibody 
was targeted against a C-terminal epitope and thus recognised both epithelial IIIb 
and mesenchymal IIIc receptor isoforms. However, immunoreactivity of FGFR2 
was more intense in the epidermis compared with dermis. In contrast to normal 
skin, FGFR2 is seen throughout the nucleus and cytoplasm in SCC sections (Fig 
4.11 C, E). 
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Figure 4.11 Anti-FGFR2 immunostaining. Immunostaining was performed on 
sections from normal human skin (A, B, D and F) and human SCC (C, E and G). 
Skin sections show expression of FGFR2 in both epidermis (Ep) and dermis (De). 
In normal skin sections, the epidermal staining is localised to the cell surface 
(arrows in D). However, in SCC this pattern is absent, with staining seen 
throughout the nucleus and cytoplasm (arrows in E). Negative controls using the 
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same staining protocol but with an isotype specific control antibody show no 
positive staining (F and G). Scale bars (50 ?m) in all but F (100 ?m). 
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4.3 Discussion 
 
FGFR2 appears to play a paradoxical role in cancer, depending on the 
tissue type and pathology. While some studies have suggested that increased 
expression of FGFR2b raises breast cancer risk, data from our lab and others 
suggest that it also can act protectively, particularly in mouse skin (Grose et al., 
2007). One of the aspects of my project was to verify whether it plays a similar role 
in human skin, by investigating SCC cell lines isolated from patient tumours.  
 
Firstly, the genomic organisation of FGFR2 was examined in a search for 
obvious alterations. Initially, an exciting result was obtained with exon 11 PCR 
product missing in all DNA samples from SCC cell lines (Fig 4.2).  Exon 11 
encodes the juxtamembrane domain of FGFR2, which is a docking site for the 
main downstream signalling molecule FRS2 (Eswarakumar et al., 2005). Lack of 
this docking site could, potentially, block the two main signalling pathways of 
FGFR2 activation and abolish its tumour suppressive character. Unfortunately that 
result later turned out to be an artefact caused by using old DNA as a template 
(Fig 4.3). The quality of DNA is dependent on extraction and storage conditions. 
Some DNA samples’ are highly fragmented or damaged by preservation 
procedures, while others are better preserved and will give different results in a 
PCR-based assay. Several methods are commonly used to assess DNA quality 
like gel electrophoresis, Southern blot or gene-specific PCR. Although these 
methods provide information on the degree of DNA fragmentation, not all can 
predict the samples ability to support PCR (Siwoski et al., 2002). If researchers do 
not pre-screen samples for DNA quality, but rather directly measure the status of a 
gene, screening it for mutations by single or multiplex PCR, the obtained results 
might not be reliable. 
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Secondly, the above PCR products were cloned and screened for 
mutations in the coding sequence of the gene (Fig 4.4). It is well documented that 
mutations in ligand binding domain (D3) of FGFR2 and FGFR3 arise in patients 
with gastric and colorectal cancers (Jang et al., 2001), endometrial cancers 
(Pollock et al., 2007) and melanomas (Gartside et al., 2009). Furthermore, 
activating mutations of FGFR3 occur at a high frequency in bladder carcinoma and 
at a low frequency in B-cell lymphoma and cervical carcinoma (Chaffer et al., 
2007). My screening resulted in identification of eleven different point mutations, 
localised in the ligand binding domain and the transmembrane domain of FGFR2 
(Fig 4.5). One of those mutations, Y281C, was previously reported in Crouzon 
syndrome - a genetic disorder causing craniofacial synostosis (Kan et al., 2002). 
The fact that this mutation was discovered in a developmental disorder and not 
cancer was not discouraging. In endometrial cancer, twelve different mutations 
were identified in FGFR2, seven of which were the same as those associated with 
craniosynostosis and chondrodysplasia syndromes (Pollock et al., 2007). On the 
other hand, over 20 novel mutations having a great impact on FGFR2 receptor 
functionality were identified recently in melanoma tumours (Gartside et al., 2009). 
One of the novel mutations, that I identified in SCC samples, which did not affect 
the reading frame (K300R – A900G), was present in two independent cell lines, 
which was very encouraging. Even though one study suggested that there was no 
association between FGFR2 mutation and patient survival in endometrial cancer 
(Zhao et al., 2008), the prevalence of these mutations provides a rationale for 
using FGFR inhibitors as an adjuvant therapy to treat cancer patients.  
 
Another potentially interesting result obtained concerns the splicing isoform 
of FGFR2 expressed by SCC cell lines. Despite problems with murine fibroblast 
contamination, there was a definite change in splice isoform of FGFR2 depending 
on cell confluence (Fig 4.8). However, it might just be that the observed incidence 
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of exon switching is due to fibroblast cell contamination. It has been reported 
before that when SVK14 human keratinocyte cells, seeded at low density, were 
cultured in the presence of exogenous FGF1 or FGF2, a partial IIIb to IIIc switch of 
FGFR2 was observed, while cells cultured at low density in standard medium 
expressed only IIIb transcripts. In contrast, when the cells were at confluency 
before addition of FGF1 or FGF2, this switch in isoform expression was not seen 
(Scotet and Houssaint, 1998). A very similar result of IIIb to IIIc switch, 
complemented by morphological changes characteristic for EMT (epithelial 
mesenchymal transition), was recorded for the NBT-II carcinoma cell line 
stimulated with FGF1 (Savagner et al., 1994). It is possible therefore, in my 
experiments, that contaminating mouse fibroblasts stimulated human keratinocyte 
SCC cells by secreting FGFs to switch the FGFR2 splice isoform. As described 
before, the change in FGFR2 variant expression modifies cellular response to 
growth factors. Unfortunately, also because of contamination, my organotypic co-
culture experiments did not provide any new information into understanding of 
SCC pathogenesis.   
 
 Discovery of murine fibroblast contamination was very disappointing but, 
on the other hand, it was fortunate that the contamination was discovered quite 
early on in the process of SCC cell line characterisation. That is the opposite to, 
for example, the human thyroid endothelial cell case. The European Collection of 
Cell Cultures (ECACC) after multiplex analysis of the mentioned TEC61 cell line, 
described by Patel et al. in American Journal of Physiology, 2003 (Patel et al., 
2003), proved that the cell line was in fact identical to the JEG3 cell line. The 
JEG3 cell line was derived from a human choriocarcinoma, and the cell-
conditioned medium from this line was used to support the growth of the putative 
endothelial cell line. No early-passage cells exist, so it is not possible to determine 
when cross-contamination occurred. Since the overall premise and conclusions of 
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the paper could no longer be assured, the authors had to retract the paper           
in June 2009.  
 
 In fact, estimates of the incidence of research papers flawed by the use of 
misidentified and cross-contaminated cell cultures approximate 15-20% (Nardone, 
2007). But, there are even more worrying news as, for example, Liscovitch and 
Ravid reported that DNA fingerprinting analysis revealed that the NCI/ADR-RES 
cell line is actually an ovarian tumor cell line, OVCAR-8, rather than a breast 
cancer cell line. NCI/ADR-RES is included in the National Cancer Institute (NCI) 
panel of 60 cell lines distributed for evaluation of potential anti-cancer drugs 
(Liscovitch and Ravid, 2007). The same authors estimate that about 300 papers 
have been published with the incorrect identification. The importance of absolute 
certainty regarding cell line authenticity in biomedical research, cannot be stressed 
strongly enough. 
 
According to the classical theory of signal transduction, the role of a 
membrane-associated growth factor receptor is to transmit signal from the 
extracellular environment to the cytoplasm, where other cytoplasmic proteins and 
kinases serve as second messengers propagating the signal downstream to the 
nucleus. However, nowadays it is well known that this is not the only scenario of 
signal transduction. For example, it was established that cell surface FGFR1 
redistributes to a cytoplasmic-perinuclear location after cell stimulation by 
exogenous ligand (Prudovsky et al., 1994). FGFR1 is also able to traffic to the 
nucleus, where its majority is found in a patchy distribution within the nuclear 
matrix, at which point it remains functional (Stachowiak et al., 1996). Nevertheless 
the question of nuclear FGFR1 function remains unanswered, even though there 
are numerous suggestions that receptor role is associated with specific regions of 
nuclear matrix. It has been speculated that nuclear growth factor receptors may 
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act as weak transcription factors, topoisomerases and/or nuclear kinases. Another 
function of nuclear FGFRs may be phosphorylation of nuclear substrates, as the 
forced nuclear translocation of FGFRs leads to an increase in the phosphorylation 
of nuclear proteins, and some activities of the nuclear receptor are abolished by 
deactivation of the kinase domain (Schmahl et al., 2004). Observed FGFR2 
nucleus translocation (Fig 4.11) is presumably stimulated by demand for increased 
gene transcription, granting advanced keratinocyte proliferation associated with 
SCC progression. 
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4.4 Future directions 
 
 Given more time, I would have liked to have continue my mutation 
screening to identify more FGFR2 mutations in human skin SCC samples, hoping 
to be able to find a link between the frequency and location of their occurrence 
and the nature of skin cancer. Thus far, the Human Gene Mutation Database 
(HGMD) reports 95 independent mutations in the FGFR2 gene, but there is 
nothing to suggest that this list is exhaustive. Through my studies, I hoped to be 
able to add to this catalogue of mutations and to determine the potential roles of 
those mutations associated with skin cancer. Unfortunately the model for my 
research was far from perfect, as the SCC cell lines used for DNA sequencing 
turned out to be contaminated with mouse fibroblasts. Although all the identified 
mutations were true human gene mutations, not homologous with mouse gene 
sequence, the SCC cell lines did not provide a good model for any kind of 
functional assays. A good cell-based assay for the pathogenesis study of SCC 
would involve pure human SCC keratinocytes, which can be characterised by cell 
viability, death, clonogenicity and migration or invasion measurements. None of 
those would bring informative results if keratinocyte growth was stimulated via 
growth factors secreted by fibroblasts. 
 
 In the future it will be important to confirm that the identified mutations are 
of somatic origin and are not germline mutations. I hope that these preliminary 
results are exciting enough to start a high throughput sequencing experiment with 
a large number of human skin SCC samples. 
 
 I would also like to continue work on the change of expression of the 
FGFR2 splicing isoform. I would like to check whether it is dependent purely on 
cell confluency or, perhaps, on the presence of fibroblast contamination. In order 
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to do that I could single cell clone, as mentioned already, or I could try to eliminate 
fibroblast contamination by differential trypsinisation, when the culture is exposed 
to sterile Hank's Buffered Salt Solution containing 0.05% trypsin. The junctions 
formed between the epithelial cells limit access of trypsin, thus the nonepithelial 
fibroblasts detach from the plate first and can be carefully removed. This 
procedure, when repeated several times at 5-7 days intervals, is reported to enrich 
the purity of epithelial cell culture. With the use of antibodies directed against 
epithelial markers, magnetic-activated cell sorting or immunofluorescence cell 
sorting (FACS) also can be used to remove fibroblast contamination. 
 
 The observed differences in immunostaining of skin tumours might have 
their explanation in FGFR2 splice isoform switch, but while In situ hybridisation 
studies with exon specific probes would give useful data, until reliable isoform 
specific antibodies are available this will be hard to determine. 
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CHAPTER 5: Final discussion 
 
 Deregulation of fibroblast growth factor receptor signalling pathways 
increasingly has been recognised to play an important role in the pathobiology of 
many malignancies. Communication between epithelia and mesenchyme/stroma, 
critical for organogenesis and carcinogenesis, is mediated by those pathways. The 
effects of disrupted signalling are wide ranging and involve enhanced proliferation, 
resistance to cell death, increased motility and invasiveness, increased 
angiogenesis, enhanced metastasis and resistance to chemotherapy and radiation 
(Kwabi-Addo et al., 2004). However, the underlying mechanism of how aberrant 
FGF signalling leads to tumour formation and progression is far from clear.  
 
The justification supporting further research into cancer biology is clear. 
There are more than 100 different types of cancer and on average 293,000 newly 
diagnosed cancer cases each year in the UK (from 2004–06), with around 
147,000 cases among males and 146,000 among females. The three most 
common cancers are prostate, lung and colorectal for males, and breast, lung and 
colorectal for females. There were, on average, 154,000 deaths from cancer each 
year in the UK (from 2004–06), with around 80,000 deaths among males and 
74,000 among females (Office for National Statistics, Cancer incidence and 
mortality Statistical Bulletin - August 2009). That is equivalent to the population of 
Peterborough in England disappearing every year. 
 
 In the 35 years since the first FGF was discovered, the FGF family has 
expanded to 22 ligands that signal through tyrosine kinase receptors (Ornitz, 
2000). The list of Fgf and Fgfr knockout mice is almost complete and, coupled with 
data from many other animal model systems, it provides essential knowledge of 
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the wide spectrum of physiological roles played by those growth factors in 
development, disease and repair. For instance, studies on chick embryos 
determined that FGFs are essential for limb bud outgrowth and patterning (Martin, 
1998) as well as neural induction (Streit et al., 2000), whereas the effect of FGFs 
on mesoderm formation was first demonstrated and most extensively studied in 
Xenopus (Isaacs, 1997). Invertebrate model organisms, such as Drosophila 
melanogaster and Caenorhabditis elegans, turned out to be relatively simple and 
genetically tractable systems for studying various aspects of FGF signalling. The 
only known Fgf in Drosophila - branchless is involved, as its name implies, in 
branching morphogenesis and its receptor, breathless, is expressed in the 
developing tracheal system (Reichman-Fried et al., 1994). A second Fgfr in 
Drosophila, heartless, is necessary for heart formation and mesodermal cell 
migration (Shishido et al., 1997), while egl-15, encoding the only Fgf receptor in C. 
elegans, plays a crucial role in gonad development (Huang and Stern, 2005). By 
contrast, the Fgf family in zebrafish, a widely used vertebrate model for studying 
morphogenesis and metabolism, comprises twenty-seven Fgf family members 
(Itoh, 2007). 
 
The main focus of my PhD was to investigate the role of FGF22 in 
development and tissue homeostasis, using a knockout mouse model, and thus 
contribute to a fuller understanding of the broad field of FGF biology. To date, only 
Fgf20 and Fgf22 knockout mice still remain undescribed in the literature but, 
despite this almost complete coverage, it is very likely that additional roles for 
already described FGFs will be identified in the future, as more physiological 
challenges are performed in knockout mouse models. 
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Summary of my principal results: 
 
FGF22 is not essential for normal embryogenesis. 
 
FGF22 is not required for normal postnatal development. 
 
FGF22 is not necessary for skin homeostasis and repair. 
 
 Fgf22 knockout mice exhibit resistance to chemical carcinogenesis.  
 
Fgf22 knockout mice display a significant weight loss phenotype. 
 
 Fgf22 knockout mice show thinning of retinal layers in the eye.  
 
FGF22 is expressed throughout the digestive tract, in particular in the 
oesophagus and stomach. 
 
 These key observations support the conclusion that FGF22 is not essential 
for embryonic and postnatal development, contrary to previous expectations. 
Moreover, despite its up-regulation in the hair follicle (Nakatake et al., 2001) and in 
the healed wound epidermis (Beyer et al., 2003), FGF22 is not required for normal 
hair development, neither is it essential for efficient wound healing. Furthermore, 
FGF22 clearly is not a critical modulator of presynaptic organisation in developing 
brain (Umemori et al., 2004), since knockout mice develop normally and do not 
display any distinctive behavioural defects. However, FGF22 does appear to play 
a potential oncogenic role in skin tumorigenesis - an entirely unexpected 
phenotype given its postulated negative role during epithelial repair (Beyer et al., 
2003).  
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 An additional surprising finding was that FGF22 appears to be involved in 
control of body weight. Discovery of Fgf22 expression through the digestive tract 
further increased my interest in this area. Although it is well established that 
FGFR2b signalling is essential for digestive tract development (Burns et al., 2004), 
the involvement of its ligand FGF22 in the system was unforeseen. It is recognised 
that absence of embryonic expression of Fgfr2b or Fgf10 results in intestinal 
atresia (Fairbanks et al., 2004). Likewise, foetuses lacking Fgfr2b or Fgf10 
develop smaller stomachs than wild type littermates, with a disproportionately 
severe reduction in the development of the glandular stomach (Spencer-Dene et 
al., 2006). Building on these foundations, the pattern of Fgf22 expression in the 
gastro-intestinal tract is illustrated for the first time. Despite relatively high 
expression levels in the oesophagus and stomach, the role for Fgf22 within the 
digestive system remains unclear, since knockout mice do not demonstrate any 
phenotype in the unchallenged state. All the same, the pattern of Fgf22 expression 
is intriguing in the context of regulation of food intake.  
 
 The key feature of the system regulating food intake is that most, if not all, 
of the peptides that influence satiation are made in the digestive tract and are also 
synthesised in the brain (Woods and D'Alessio, 2008). Likewise, Fgf22 is 
expressed in both compartments and its abrogation causes weight loss. In these 
circumstances, one can hypothesise that Fgf22 affects satiation by stimulating 
food intake. There is only one other known gastro-intestinal hormone of similar 
function: ghrelin, a product of specific endocrine cells in the stomach and 
duodeum that relays a message to its receptors localised in the hypothalamus 
(Woods and D'Alessio, 2008). The above findings open a completely new aspect 
of studying the potential involvement of Fgf22 in control of body weight and 
feeding behaviour. 
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 Providing greater understanding into the role of FGF and FGFR 
interactions involved in normal and pathological conditions was a goal of my 
studies. Thus, in a parallel arm of my project, I wanted to investigate the tumour 
suppressive character of Fgfr2 in the skin, focusing on translating earlier mouse 
findings (Grose et al., 2007) into a human model. This investigation was based on 
characterising SCC cell lines, isolated from patient tumours, in terms of their 
expression of FGFR2 and any associated genetic mutations. 
 
Summary of my principal results: 
 
Frequent FGFR2 mutations are detected in SCC cell lines. 
 
FGFR2 splicing is dependent on cell confluency. 
 
FGFR2 shows a specific change in expression pattern in SCC. 
 
The FGFR2 mutations in SCC cell lines that I identified were localised in 
the ligand binding and transmembrane domains of the receptor. However, the 
character of novel mutations was not determined. Further analysis, including 
mapping of identified mutations onto the known crystal structures of FGFR2 
followed by in vitro and in vivo studies would be required to pursue this project. 
However, one can speculate that novel mutations are loss-of-function mutations, 
as essentially that would be consistent with previous findings of the tumour 
suppressive character of Fgfr2 in murine skin (Grose et al., 2007). Moreover, 
these type of mutations recently have been reported in human melanoma, where 
FGFR2 is thought to lose its activity through several distinct mechanisms, 
including loss of ligand binding affinity, impaired receptor dimerisation, 
destabilisation of the extracellular domains and reduced kinase activity (Gartside 
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et al., 2009). Hypothetically, these mutations can also affect FGFR2 splicing, 
causing inappropriate FGFR2c isoform expression in the epidermis, which is in 
keeping with in vitro findings. Consequently that can cause, stimulated via an 
autocrine signalling loop, rapid and uncontrolled keratinocyte proliferation. On the 
other hand, if the identified mutations are of activating character then the receptor 
can drive malignant cell growth in an exclusively ligand independent manner. 
 
 Recent studies have established that Fgfr2b and Fgfr1b are essential for 
maintenance of skin homeostasis and epidermal barrier function. Fgfr2b/Fgfr1b 
receptor double knockout mice show a defective skin barrier and develop 
epidermal hyperthickening with age, as a result of chronic inflammation (Sabine 
Werner - personal communication). Given that Fgf22 knockout mice do not 
phenocopy those changes, Fgf22 clearly is not essential for normal skin 
physiology. Nevertheless, there is an obvious discrepancy in phenotypes that we 
must consider. Fgfr2b null mice show great sensitivity to chemically induced 
carcinogenesis whereas, contrastingly, Fgf22 knockout mice are more resistant to 
carcinogenesis insult than wild type littermates. It is intriguing that, in these 
particular circumstances, the ligand and its receptor appear to have antagonising 
effects, with a putative tumour suppressive receptor appearing to be activated by 
an oncogenic ligand. It is not a groundbreaking theory, since it is recognised that 
at least several members of the FGF family have oncogenic potential and are 
implicated in different cancers such as leukaemia and Kaposi’s sarcoma (Delli 
Bovi et al., 1987). 
 
 Fgf22 expression in the hair follicle in normal skin is most likely involved in 
regulation of FGFR signalling, but redundancy in the system prevents occurrence 
of an overt phenotype in knockout mouse. During wound healing, in contrast to 
FGF7 and FGF10, which appear to drive the healing process, FGF22 expression 
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is up-regulated towards the end of repair (Beyer et al., 2003). Thus my hypothesis 
was that it acts as a negative regulator of FGFR2 signalling, either by decreasing 
proliferation or increasing differentiation. However, since Fgf22 knockout mice do 
not present a wound healing phenotype, it is possible simply that natural decrease 
in expression of pro-mitogenic ligands is sufficient to turn off the epithelial healing 
process. Therefore once again there is redundancy within the system. 
 
 
 
 
Figure 5.1 Graph representing changes in Fgfs expression during in vivo wound healing.  
 
 
Decreased sensitivity to chemically induced carcinogenesis in Fgf22 
knockout mice implies that basal expression of Fgf22 is conferring sensitivity to 
skin carcinogenesis. If we assume the presence of the above control mechanism, 
then lack of FGF22 may cause increased signalling via FGF7 and FGF10. It is well 
documented that FGF7 and FGF10 hold a potent cytoprotective signal for 
keratinocytes, and FGF7 is already in use in the clinic for oral mucositis. 
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Figure 5.2 Cartoon illustrating a potential mechanistic insight into the phenotype seen in 
Fgfr2b knockout mice. Lack of downstream cytoprotective signalling mediated via FGF7 
promotes a more pro-tumorigenic phenotype. 
 
 
FGF7 has the potential to regulate genes that are mediators of the 
cytoprotective effect, like peroxiredoxin VI or Nrf2 (Braun et al., 2004). 
Peroxiredoxin VI is a cytoplasmic enzyme that detoxifies hydrogen peroxide and 
organic peroxides, whereas Nrf2 is a transcription factor responsible for the 
activation of various cytoprotective genes, which encode ROS-detoxifying 
enzymes and other anti-oxidative proteins (Braun et al., 2004). In Fgfr2b knockout 
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mice this cytoprotective mechanism is inactive due to lack of signalling receptor, 
which is a likely contribution to the huge numbers of papillomas forming in 
response to chemically induced carcinogenesis. In Fgf22 knockout mice on the 
other hand, FGF7 does not have to compete with FGF22 for receptor binding 
which allows strong FGF7 signalling yielding increased cytoprotective effect and, 
in consequence, reduced papilloma formation. 
 
 
 
Figure 5.2 Cartoon illustrating difference in response of Fgf22 wild type and knockout mice 
to chemically induced tumorigenesis.  
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Taken together outlined above results provide first insight into the 
unanticipated character of Fgf22 in vivo using knockout mouse model and function 
of FGFR2 in human skin. Data obtained during my PhD project provide a unifying 
framework for future research. 
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